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ABSTRACT 
 
Japanese encephalitis virus (JEV) and West Nile virus (WNV) are closely 
related Flaviviruses that are important arthropod-borne human pathogens. Both 
of these viruses can cause encephalitis with significant morbidity and mortality 
after infection. Flaviviruses co-circulate in many areas of the world, which raises 
the risk for sequential infection between heterologous viruses. Sequential 
infection between dengue virus serotypes can lead to cross-protection, but in 
some cases, it leads to a severe outcome, dengue hemorrhagic fever. Previous 
work in hamsters and non-human primates demonstrated that prior JEV immunity 
protects against a lethal WNV infection. However, the ability of prior WNV 
immunity to protect against a lethal JEV infection has been inconclusive. WNV-
immune hamsters were fully protected from JEV viremia, but in non-human 
primates, prior WNV-immunity only reduced disease severity, with symptoms of 
encephalitis still observed. These differences in cross-protection led to further 
investigation on the directionality as well as the underlying mechanisms for this 
phenomenon.  
Previous work in our lab found that JEV-immune C57BL/6J (B6) mice 
were fully protected against a lethal WNV infection, and JEV-immune CD4+ and 
CD8+ T cells were required for this cross-protection. In other mouse models, 
memory cross-reactive CD4+ and CD8+ T cell responses may induce protection 
or immunopathology upon secondary heterologous viral challenge. We 
 vii 
hypothesize that JEV/WNV cross-reactive CD4+ and CD8+ T cells preferentially 
expand upon 2o infection and contribute to cross-protection. To elucidate the 
potential role of T cells in sequential flavivirus infection, we identified and 
characterized cross-reactive CD4+ and CD8+ T cell responses between JEV and 
WNV. A previously reported WNV NS4b CD8+ T cell epitope and its JEV variant 
elicited CD8+ T cell responses in both JEV- and WNV-infected mice. Despite 
similarities in viral burden for pathogenic JEV and WNV viruses, CD8+ T cells 
from pathogenic JEV-infected mice exhibited functional and phenotypic profiles 
similar to those seen for the attenuated JEV strain. We believe the differences in 
the CD8+ T cell responses during primary JEV and WNV infection are due at 
least in part to the low levels of peripheral replication seen in JEV-infected mice 
compared to WNV-infected mice.  
We also found that WNV-immune B6 mice were protected against a lethal 
JEV infection. Cross-reactive CD8+ T cells in JEV-immune mice rapidly 
expanded after WNV infection. Even though WNV-immune mice had higher 
frequencies of memory CD8+ T cells, cross-reactive CD8+ T cells did not expand 
after secondary JEV infection. Neutralizing antibodies to JEV were detected in 
WNV-immune mice; however, cross-reactive CD8+ T cells did not expand even in 
the absence of these cross-reactive neutralizing antibodies. We did not detect 
any differences in the CD8+ T cell repertoires between JEV- and WNV-infected 
mice nor were WNV-immune CD8+ T cells functionally exhausted. In fact, 
proliferation of memory CD8+ T cells did not correlate with the ability of WNV-
 viii 
immune CD8+ T cells to restrict recombinant vaccinia viruses expressing the 
cross-reactive epitope or lyse peptide-coated targets. These data suggest that 
the higher frequency of memory CD8+ T cells and cross-reactive antibodies in 
WNV-immune mice are better able to prevent neuroinvasion following 2o JEV 
infection. 
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CHAPTER I 
INTRODUCTION 
 
 West Nile virus (WNV) and Japanese encephalitis virus (JEV) are 
arthropod-borne viruses of the Flaviviridae family. Flaviviruses are medically 
important viruses that co-circulate in many areas of the world (1). WNV and JEV 
are members of the JEV serocomplex along with Murray Valley encephalitis virus 
(MVEV), and St. Louis encephalitis virus (SLEV). Dengue viruses, yellow fever 
virus (YFV) and the tick-borne encephalitis viruses (TBEV) are other medically 
important members of the Flaviviridae family (2). This dissertation will focus on 
cross-protection within the JEV serocomplex, specifically JEV and WNV, and 
cross-reactive CD8+ T cell responses during sequential JEV and WNV infections.  
 
A. West Nile virus 
 WNV was first isolated in 1937 in Uganda and is endemic to regions in 
Africa, Middle East and Asia (1, 3). WNV was first identified in the United States 
(US) in 1999 during a cluster of encephalitis cases in New York City. (4-7). Since 
then, WNV has spread across the continental US, Canada and Mexico (8). 
Analysis of the amino acid sequence suggests that the US emergent WNV strain 
originated in Israel, and shares sequence similarities with lineage I WNV strains 
(4, 5, 9). Interestingly, WNV strains in the US were found to be more virulent in 
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mice and hamsters than previous isolates due to added glycosylation of the 
envelope (E) protein (10, 11). 
 Kunjin virus, isolated in Australia in 1960, is a subtype of lineage I WNV 
(12, 13).  Kunjin and WNV share 93% amino acid homology, but Kunjin is highly 
attenuated in both mice and humans (9, 14, 15). A recent survey found 13 
human cases of Kunjin virus between 1992 and 2010, and only six of these 
cases resulted in neuroinvasive disease (15). The co-circulation of MVEV and to 
a lesser extent JEV, may be limiting Kunjin virus infections and the severity of 
disease symptoms in Australia (1, 16).  
WNV is an enzootic virus that is transmitted by the Culex pipiens complex 
of mosquitoes, and is maintained in nature through a bird-mosquito-bird cycle 
(17, 18). Humans and horses can become infected with WNV, but are generally 
thought of as dead end hosts (18). Human-to-human spread of WNV can occur 
via breast milk, blood transfusions and organ transplantation, necessitating the 
screening of the blood supply and organs (19-22). Clinical manifestations of 
WNV range from asymptomatic disease to mild symptoms or to encephalitis, with 
elderly patients being more prone to encephalitis (6, 7). In humans, the rate of 
neuroinvasive disease in New York in 1999 was found to be 1 in 140 infected 
individuals, and approximately 80% of WNV infections are asymptomatic (7). By 
2008, 11,821 cases of WNV neuroinvasive disease were reported in the US (23). 
WNV has been shown to persist in mice, hamsters, non-human primates 
(NHP), and possibly in humans. WNV antigen and infectious virus can be found 
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in mice up to 4 months post infection, and up to even longer time points in 
hamsters (24-27). In NHPs, WNV can persist in both asymptomatic and 
symptomatic monkeys, suggesting neurovinvasion is not the sole determinant for 
persistence (28). However, the ability of WNV to persist in humans is 
controversial. In a subset of WNV-infected individuals, WNV RNA was found in 
the urine of 5 of 25 of these subjects up to 6 years after the initial onset of 
symptoms (29). However, in a different cohort of 40 patients, WNV RNA was not 
detected in any urine samples tested >6 years after initial presentation (30). 
Therefore, the detection of WNV RNA in human samples may depend upon the 
cohort of patients being tested, the time after initial viral infection, as well as the 
method for detection of WNV RNA.  
 
B. Japanese encephalitis virus 
 JEV was first isolated in Japan in 1934, and is endemic to East and 
Southeast Asia (16, 31). Similar to WNV, JEV is transmitted primarily by Culex 
tritaeniorhynchus mosquitoes, but is maintained through a bird-mosquito-pig 
cycle with humans and horses again serving as dead end hosts (16, 32). 
Annually, 30,000-50,000 cases of JEV occur, with a 30% mortality rate (33). 
Clinical manifestations are similar to those seen in WNV and range from 
asymptomatic cases to encephalitis, with young children and the elderly at the 
greatest risk for neuroinvasive disease. A majority of patients experience 
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headache, fever, and myalgia, and up to 50% of survivors of JEV neuroinvasive 
disease have long-term/permanent neurological sequelae (33, 34).   
 JEV is genetically divided into 5 genotypes (G1, GII, GIII, GIV, GV) based 
on the amino acid sequences of the envelope (E) protein (35). Genotypes can 
predominate in specific regions, but genotype replacement and/or the emergence 
of new genotypes can and does occur (31, 35-37). The JEV strains currently 
used in vaccines (Nakayama, Beijing-1, and SA14-14-2) are GIII viruses (38). 
Recently, it was demonstrated that these vaccines were protective against viral 
strains from other genotypes in mice, suggesting they may be beneficial if 
genotypes replacement occurs (36). JEV is currently not endemic to North 
America, and has been declared a Select Agent by the Animal and Plant Health 
Inspection Service (APHIS) of the United States Department of Agriculture 
(USDA). A report in 2009 described California as a likely site of introduction into 
the US due to proximity to Asia and the availability of susceptible mosquitoes and 
hosts (39). Travelers and military personnel traveling or residing in endemic JEV 
regions and laboratory workers are encouraged to receive the JEV vaccine (40).    
  
C. Characteristics of the JEV and WNV genome 
 WNV and JEV are comprised of a single stranded positive sense ~11kb 
genome that encodes a single polypeptide (4, 35). Host and viral proteases 
cleave the WNV polypeptide into 3 structural proteins (E, pre-Membrane (prM), 
and capsid (C)) and 7 nonstructural (NS) proteins (NS1, NS2a, NS2b, NS3, 
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NS4a, NS4b, and NS5).  The E protein is the major surface protein, and contains 
the putative receptor-binding site (41). The nonstructural proteins have 
independent, but multiple roles during the life cycle of WNV. For example, the 
NS1 protein has roles in viral replication, inhibition of the complement system, 
inhibition of the toll-like receptor 3 pathways and in neuroinvasion (42, 43).  NS2b 
and NS4a are cofactors for NS3, which together have helicase and protease 
functions (44-48). Multiple proteins (NS2a, NS4b, NS5) are also involved in 
inhibiting components of the IFN signaling pathway (49-55). Finally, the NS5 
protein contains the RNA-dependent polymerase and methyltransferase required 
for viral replication (56, 57).  
   
D. JEV and WNV vaccines 
 First and second generation vaccines against JEV are currently licensed 
for use in the US. JE-VAX, a mouse brain derived inactivated JEV Nakayama 
vaccine, in 1992 became the first JEV vaccine licensed in the US (40). JE-VAX 
has an efficacy rate of >90% in children, but serious adverse effects have been 
documented in patients receiving this vaccine (33, 40, 58, 59). Manufacture of 
JE-VAX has recently been discontinued, and remaining stockpiles are currently 
used to vaccinate children under the age of 17 (40).   
 A live attenuated vaccine, JEV SA14-14-2, made via serial passage of the 
virulent SA strain, was first licensed in China in 1989 (60). Two doses of the 
vaccine were found to have an efficacy of >97% in preventing JEV encephalitis in 
 6 
rural China (61). SA14-14-2 is highly attenuated compared to the parental SA14 
strain, and very little replication occurs in the mice (62). There are only 8 amino 
acid mutations in the E protein between the parent SA14 strain and the SA14-14-
2 vaccine strain, and 4 of these amino acid mutations are important for 
attenuation and the lack of neuroinvasion of the vaccine (63, 64). The live 
attenuated SA14-14-2 vaccine is not licensed for use in the US, but is currently 
licensed in China, Nepal, and South Korea (65).   
 A second generation formalin inactivated JEV vaccine based on the SA14-
14-2 virus was developed by the Walter Reed Army Institute for Research and 
grown in Vero cells (66). The vaccine was licensed in the US in 2009 under the 
trade name IXIARO, and is currently approved for adults over 17 years old. 
Immune sera from patients receiving IXIARO have been shown to be effective 
in neutralizing multiple strains of JEV, suggesting IXIARO may protect against 
multiple genotypes (40). IXIARO is given in two doses (day 0 and day 28), and 
protective neutralizing titers can be detected in 83% of individuals 6 months after 
immunization (67).  
 A chimeric virus containing the prM/E proteins of JEV (Ch-JEV) and the 
nonstructural proteins of the YFV 17D vaccine (YF17D) has also been developed 
as a vaccine candidate (68). Interestingly, the viral source of the prM/E proteins 
(Nakayama or SA14-14-2) determined the neurovirulence of the vaccine in mice 
(64, 68). A recent Phase III clinical trial demonstrated that the Ch-JEV vaccine 
has similar immunogenicity and fewer adverse events compared to JE-VAX, 
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while also requiring fewer doses (69, 70). Ch-JEV was recently approved in 
Australia under the trade name IMOJEV (71).  
There are currently no vaccines or therapies approved against a WNV 
virus infection in humans although multiple vaccines have been approved for use 
in horses (18). Several vaccine candidates have been developed for humans 
with a few already in Phase II clinical trials. Immunization with a recombinant 
WNV E protein has been shown to protect against a lethal WNV infection in mice 
(72-75). Similarly, a DNA vaccine encoding the prM/E proteins of WNV elicited 
neutralizing antibody responses and T cells responses in young and elderly 
subjects (76).  
A chimeric WNV (Ch-WNV) vaccine was developed with a similar strategy 
as Ch-JEV. Three amino acid changes were engineered into the original Ch-
WNV strain (NY-99) to mimic the amino acid differences between Ch-JEV SA14-
14-2 and Ch-JEV Nakayama in order to further attenuate the virus (77). Ch-WNV 
has been shown to induce both neutralizing antibodies and T cell responses in 
Phase I and Phase II clinical trials (78, 79). In addition, a WNV virus lacking the 
C protein (RepliVAX), which lacks the ability to make infectious progeny, has 
been shown to be protective in murine, hamster and NHP models (80-82).  
 
E. JEV and WNV mouse models 
Inbred and wild mouse strains have different susceptibilities to WNV 
infection due to a truncation in the 2’-5’ oligoadenylate synthetase gene, a 
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component of the antiviral pathway, in inbred mice (83). Interestingly, susceptible 
mouse strains can even have different mortality rates after WNV infection, 
although there is no difference in viral tropism (84). Neither the route of infection 
nor propagation history (vertebrate or mosquito cell line) changes the mortality 
rate of WNV in mice; however, the propagation history can influence the innate 
immune response to WNV (85-87).  
C57BL/6 (B6) mice are one mouse strain used to study WNV 
pathogenesis. In B6 mice, viremia develops and replication occurs in multiple 
peripheral tissues prior to viral dissemination into the CNS (84, 88). Infection of 
B6 mice can lead to weight loss, hunchback posture, ruffled fur, limb paralysis, 
and mortality (88). On the other hand, Kunjin virus, a subtype of WNV, is highly 
sensitive to type I IFN, and therefore very low levels of viremia and peripheral 
replication occur in B6 mice (14). Susceptibility to Kunjin virus increases in mice 
lacking the interferon α receptor (IFNαR-/-), and can be used as a lethal model for 
WNV infection (14, 89). Similarly, some lineage II WNV strains are more 
susceptible to type I IFN and have an attenuated phenotype in mice compared to 
lineage I WNV strains (90). 
Previous JEV mouse models have utilized intracranial inoculation of 
weanling mice or adult BALB/c mice to study JEV pathogenesis (91-94). Larena 
et al. recently established a JEV model using the JEV Nakayama strain in B6 
mice. Low dose infection via a subcutaneous (sc) inoculation leads to similar 
clinical manifestations as WNV, and resulted in a 60% mortality rate. Only low 
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levels of viral RNA were detected in the serum and spleen early after infection, 
with viral dissemination into the CNS occurring during later stages of the infection 
(95). The ability of JEV to replicate in myeloid cells may influence the 
susceptibility of mouse strains to JEV infection (96). We developed a lethal 
model of an intraperitoneal (ip) infection of JEV Beijing in B6 mice, and this will 
be discussed in Chapter IV.  
Multiple components of the innate immune system are required for 
protection against both JEV and WNV infection.  Retinoic acid inducible gene-I 
(RIG-I) and melanoma differentiation antigen 5 (MDA5) are required for 
intracellular recognition of JEV and WNV and maintenance of the interferon (IFN) 
signaling cascade via interferon-beta promoter stimulator 1 (IPS-1) (97-101). 
Interferon regulatory factor (IRF) 3 and 7, downstream effectors of IPS-1, are 
essential for the initiation of type I IFN, with IRF3/IRF7-/- mice being highly 
susceptible to infection (102-105). Toll-like receptor (TLR) 3 and 7 recognition of 
WNV leads to type I IFN production and also helps in the trafficking of 
lymphocytes to the CNS (85, 106, 107).  
 
F. Adaptive immune responses to JEV and WNV 
i. T cell responses in mice 
During JEV and WNV infection, the adaptive immune response is 
essential for preventing viral dissemination, clearance of virally infected cells, and 
survival. RAG-/- mice, which lack both B and T cells, are highly susceptible to low 
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doses of WNV (88). In mice deficient of CD8+ T cells, higher levels of WNV are 
found in the CNS, which can persist weeks after the initial infection, ultimately 
leading to death (108-111). CD8+ T cells require both perforin and Fas ligand 
effector mechanisms to clear virally infected cells in the periphery and the CNS 
(110, 111). Trafficking of T cells to the CNS is also required for protection from 
WNV as mice lacking chemokines or chemokine receptors have low numbers of 
lymphocytes in the CNS and uniformly succumb to infection (112-114).  
WNV specific CD8+ T cell epitopes have been identified in both mice and 
humans (115-118). In mice, the immunodominant CD8+ T cell epitope 
(SSVWNATTA) is H-2Db restricted and is located in the NS4b protein (115, 116). 
The maturation and expansion of WNV specific CD8+ T cells is linked to type I 
IFN production, demonstrating how the innate immune response to WNV 
influences the adaptive immune response (119, 120). Adoptive transfer of CD8+ 
T cells specific for immunodominant and subdominant epitopes can confer 
protection against WNV infection in mice (115, 116). Interestingly, epitope-
specific CD8+ T cells persist in the CNS weeks after infection, which may reflect 
the ability of WNV to persist in the CNS (24, 121). 
Older mice (18-22 months of age) have been found to be more 
susceptible to mortality from WNV than younger mice (4-6 months old). Similarly, 
T cells from older mice were unable to protect naïve mice against lethal WNV 
infection when compared with T cells from younger mice. This decline in 
protection was found to be due to defects in epitope-specific CD8+ T cell 
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generation, cytokine production, cytolytic activity, and trafficking of CD8+ T cells 
to the CNS (122). However, decreased antibody and T cell responses in older 
mice after RepliVax vaccination did not reduce subsequent protection from a 
WNV infection (123).  
CD4+ T cells also play an important role during WNV infection. WNV 
specific IgG responses are blunted in mice lacking CD4+ T cells, thereby 
resulting in lower neutralizing antibody responses compared to WT mice. CD4+ T 
cells also help sustain primary CD8+ T cell responses to WNV and the retention 
of CD8+ T cells in the CNS. Mice lacking CD4+ T cells have persistent levels of 
virus in the CNS and eventually succumb to the infection (124). WNV-specific 
CD4+ T cells secrete effector cytokines and also have in vivo cytolytic activity 
utilizing both Fas and perforin pathways. In fact, immunization with two WNV 
specific CD4+ T cell epitopes protected mice from WNV mortality (125). 
Therefore, both CD4+ and CD8+ T cells contribute independent functions in 
protecting mice from WNV infection. 
Lower frequencies of CD4+ CD25+ FoxP3+ T regulatory cells (Tregs) were 
found in symptomatic mice compared to asymptomatic mice. Mice succumbing to 
WNV infection had lower frequencies of Tregs, but higher CD8+ T cell responses, 
than surviving mice. Mice completely devoid of Tregs have increased 
susceptibility compared to wild type (WT) mice, suggesting that dampening of the 
immune response to WNV is needed for survival (126). These results suggest 
that the frequencies of CD8+ T cells during the course of the infection may impact 
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the outcome of a WNV infection, which has been suggested previously (108). 
Non-classical γδ T cells secrete IFN−γ early during infection, thereby helping to 
control viral replication and dissemination, and mice lacking γδ T cells have an 
increased susceptibility to WNV (127). A defect in memory CD8+ T cell 
generation was also seen in absence of γδ T cells, due to the lack of CD4+ T cell 
priming by dendritic cells in mice deficient of γδ T cells (128, 129).  
To date, only a single CD8+ T cell epitope in the NS3 protein has been 
identified in BALB/c mice after JEV infection (93). However, CD4+ T cells, 
through induction of antibody responses, may be more important than CD8+ T 
cells in controlling JEV infection. In BALB/c mice, JEV-immune CD4+ T cells were 
better able to protect weaning mice from lethal infection compared to JEV-
immune CD8+ T cells (92). Low neutralizing antibody responses during JEV 
infection of major histocompatibility complex (MHC) II-/- mice resulted in 
increased levels of virus in the CNS during later stages of the infection. Adoptive 
transfer of both JEV-immune CD4+ and CD8+ T cells were required to confer 
protection from JEV infection in naïve mice. JEV-specific CD8+ T cells are 
required for viral clearance from the CNS, but susceptibility to JEV did not 
change if CD8+ T cells were depleted prior to infection (95). Similarly, only 
antibody responses after E protein vaccination could protect against JEV 
infection, whereas CD8+ T cell responses to the E protein alone could not protect 
(130). Mice lacking T cell effector functions (Fas, and perforin) were no more 
susceptible than WT mice (95). This is in contrast to a WNV infection in which 
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mice lacking both Fas and perforin were highly susceptible to infection (110, 
111). Therefore, the requirement of T cells may be different for recovery from 
JEV infection than for recovery from WNV infection.   
Of note, there are differences in the ability of mice to recover from JEV 
and WNV infection. Mice infected with WNV may demonstrate clinical symptoms 
yet recover from infection (unpublished observations) (88). In contrast, JEV-
infected mice that exhibit clinical symptoms uniformly succumb to infection 
(unpublished observations) (95). It appears that once JEV gains access to the 
CNS compartment, there is no recovery from infection regardless of CD8+ T cells 
in the CNS. This is in contrast to WNV infection, in which CD8+ T cells help clear 
virus from the CNS (108-110). Viral dissemination, therefore, may be the most 
important factor contributing to JEV lethality.  
 
 ii. T cell responses in humans 
In humans, CD8+ T cell responses during natural WNV infection are 
directed against a limited number of epitopes that cover multiple WNV proteins 
(117, 118, 131). An immunodominant HLA-A2 restricted epitope, SVG9 
(SVGGVFTSV), was identified and has been shown to confer protection in HLA-
A2 transgenic mice (131, 132). Interestingly in patients with neuroinvasive 
disease, a higher percentage of terminally differentiated WNV-specific CD8+ T 
cells were found in patients with neuroinvasive disease compared to 
asymptomatic individuals, with little difference in overall WNV-specific CD8+ T 
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cell frequencies (133). These results suggest that in humans, the severity of 
primary infection can alter the phenotype of the CD8+ T cell population, without 
altering the magnitude of the response (117, 133). In addition, symptomatic WNV 
individuals have lower Treg frequencies compared to those who are 
asymptomatic, with similar findings in mice (126). Taken together, qualitative 
rather than quantitative epitope-specific CD8+ T cell responses may play a role 
for the increased susceptibility to WNV neuroinvasive disease in elderly patients, 
although it is likely that additional deficiencies in components of the innate and 
humoral immune response play a role as well.   
 Few studies have described epitope-specific CD4+ and CD8+ T cells in 
JEV-infected humans. JEV-specific CD4+ and CD8+ T cell immune responses to 
the NS3 protein have been detected after infection (134-136). Interestingly, NS3 
specific CD8+ T cells from patients experiencing neurological symptoms due to 
JEV infection produced lower levels of IFN−γ than those from asymptomatic JEV 
patients, suggesting a possible role for IFN−γ production by T cells in the 
recovery from JEV infection (134).  These results suggest that the immune 
response during a JEV infection in humans may be an important factor in 
determining resolution of disease or immunopathology. 
 
iii. Antibody responses 
 Antibodies also play an important role during both JEV and WNV 
infections. Mice lacking mature B cells (µMT-/-) are highly susceptible to JEV and 
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WNV infection, exhibiting higher viral burdens and increased mortality compared 
to WT mice (88, 95). During the course of a WNV infection, WNV specific IgM is 
detected by day 4, while WNV specific IgG is detected by day 8 after infection 
(88).  Interestingly, during the early stages of infection, WNV specific IgM 
antibodies have low levels of neutralizing activity, which is actually required for 
survival. However by day 10, a majority of the neutralizing antibodies are of the 
IgG subclass (88, 137). Similar to WNV, anti-JEV antibodies help reduce 
peripheral replication and viral dissemination into the CNS during infection, and 
passive transfer of monoclonal antibodies protects mice against a lethal JEV 
challenge (95, 138, 139). Human gamma globulin from WNV-immune blood 
donors can protect WT mice from WNV-induced lethality, but in immunodeficient 
mice, this protection was not sustained, suggesting that host adaptive immune 
response along with antibodies are required for protection (140).  
Poorly neutralizing WNV antibodies can also protect against lethal WNV 
infection. The ability of non-neutralizing antibodies to protect against lethal 
infection has been seen previously during YFV infections and Sindbis virus 
infections (141, 142).  In WNV, these non-neutralizing antibodies are primarily 
directed against an epitope in the fusion loop in domain II of the E protein (DII-
FL) (143, 144). This epitope is normally hidden on the mature virus particle, but it 
may be briefly exposed during the type II fusion step, which could allow for 
attachment of the antibody to the virus (41). Adoptive transfer of the DII-FL 
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antibody mediates protection against WNV through both FcγR and complement 
mechanisms (144).  
Interestingly, DII-FL antibodies are thought to be more cross-reactive to 
other flaviviruses than neutralizing antibodies specific for the domain III lateral 
ridge (DIII-LR) of the E protein, due to highly conserved sequences of the fusion 
loop (145). The DIII epitope, on the other hand, is structurally conserved but 
highly variable at the amino acid level (41). Recently, a broadly cross-reactive 
neutralizing antibody directed against the DII-FL was identified in mice 
suggesting that antibodies directed against the fusion loop can also have 
neutralizing activity (146). Antibodies have also been detected against the 
nonstructural proteins. Anti-NS1 antibodies recognize expression of NS1 on the 
cell surface of virally infected cells and trigger phagocytosis of infected cells 
through FcγR mediated processes, ultimately leading to clearance of infected 
cells, and protection from WNV infection (147, 148).  
 Natural infection of humans with WNV generates an antibody repertoire 
that is predominantly specific for DII-FL rather than the DIII-LR (149). In mice, 
antibodies against all three domains, DI, DII, and DIII have been detected, with 
the most potent neutralizing antibodies directed against the DIII-LR (41). A WNV 
specific IgG recognizing the DIII-LR, E16, has been developed as a potential 
therapeutic antibody (150). E16 strongly neutralizes WNV and inhibits viral fusion 
with endosomes, thus preventing viral entry into the cell (150, 151). However, the 
timing of antibody administration in mice was important for protection against 
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WNV (150). Therefore, depending at what stage of infection individual presents 
with WNV symptoms, there may be no clinical benefits from this antibody.  
  
G. JEV cross-protection against WNV 
 Studies on the effect of prior flavivirus infection upon secondary infection 
in animals have a long history, with hamsters, bonnet macaques, birds and mice 
all being used to study cross-protection between flaviviruses. In 1972, Price and 
Thind demonstrated that hamsters immunized with any of the four dengue virus 
serotypes were partially protected against WNV infection. However, dengue-2 
isolates demonstrated the greatest protection, and this protection was strain 
dependent. It was believed that this cross-protection was due to neutralizing 
antibody responses, but neutralizing antibodies to WNV were not detected. This 
conclusion was based upon the higher neutralizing antibody responses seen in 
dengue-2 immune hamsters after WNV infection compared to control hamsters 
(152).  
More recently, hamsters immunized with either a live attenuated JEV 
strain or SLEV were protected from viremia, clinical illness and mortality following 
a lethal WNV challenge (summarized in Table 1.1.). However, hamsters 
immunized with YF17D, a distantly related flavivirus, had detectable levels of 
viremia and were only partially protected against a lethal WNV challenge (153). 
Therefore, closely related flaviviruses may be better able to protect against 2o 
heterologous infection compared to distantly related flaviviruses. Bonnet  
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Table 1.1. Examples of cross-protection within the Japanese encephalitis 
serocomplex 
Animal 1
o 
Immunization 
2o 
Infection 
% 
Survival 
% 
Viremia Reference 
Hamster 
JEV WNV 100% N.T.a 
(153) SLEV WNV 100% N.T. 
YF17D WNV 87% N.T. 
Ch-WNV JEV N.T. 0% 
(154) 
Canarypox-
WNV JEV N.T. 75% 
SLEV JEV N.T. 0% 
YF17D JEV N.T. 87.5% 
Bonnet 
Macaques 
JEV WNV 100% 33% (155) WNV JEV 100%b 0% 
Red-
winged 
blackbirds 
WNV JEV 100% 6.3% (156) 
Mice 
JEV WNV 87.5% N.T. (Trobaugh 
et al., in 
preparation) 
Ch-JEV WNV 52.5% N.T. 
YF17D WNV 25.0% N.T. 
Ch-JEV MVEV >90% N.T. 
(89) 
JE-VAX MVEV >90% N.T. 
JE-VAX MVEV 30%c N.T. 
Ch-JEV WNV 100%c N.T. 
JE-VAX  (one 
dose) WNV 14% N.T. (157) 
JE-VAX (two 
doses) WNV 80% N.T. (158) 
JEV DIII E 
protein (three 
doses) 
WNV 40% N.T. (159) 
WNV DIII E 
protein (three 
doses) 
JEV 60%-83% N.T. (73, 74) 
a Not Tested 
b 2 out of 5 macaques demonstrated symptoms of encephalitis  
c Interferon alpha receptor -/- mice (IFNαR-/-) 
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macaques immunized with an intranasally adapted inactivated JEV strain were 
also protected from mortality against WNV, with low levels of WNV viremia 
detected in only one JEV-immune macaque compared to higher levels in two out 
of three macaques of the control group. Also, only the control macaques 
exhibited any signs of encephalitis, suggesting JEV immunization elicited 
complete protection against WNV illness (155).   
B6 mice immunized with the live attenuated JEV SA14-14-2 vaccine strain 
were fully protected against mortality from a lethal WNV challenge. In contrast 
with previous reports in type I IFN deficient mice, we found that immunization 
with Ch-JEV only partially protected against WNV in B6 mice (Trobaugh et al., in 
preparation) (89). In addition to protection from mortality, protection from 
peripheral replication was seen in JEV SA14-14-2-immune mice, but not in Ch-
JEV-immune mice. However, Ch-JEV-immunization led to lower levels of WNV in 
the spleen compared to PBS controls following WNV challenge. Prior 
immunization with either Ch-JEV or JEV SA14-14-2 led to a reduction in WNV 
titers in the CNS, with significantly lower titers in JEV SA14-14-2 immune mice 
(Trobaugh et al., in preparation). These results suggests that prior immunization 
with JEV can protect against both peripheral replication and viral entry into the 
CNS, while Ch-JEV can only restrict peripheral replication of WNV, and thereby 
partially limit WNV dissemination to the CNS. Since Ch-JEV contains only the 
prM and E proteins of JEV, these results also suggest that the nonstructural 
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components of JEV SA14-14-2 were required for complete protection from 
mortality and peripheral replication (68).   
Interestingly, repeated immunizations with inactivated vaccines or proteins 
may increase the chances of flavivirus cross-protection. One immunization with a 
diluted JE-VAX could not protect mice against a lethal WNV challenge; however, 
two immunizations with the same JE-VAX conferred partial protection (157, 158). 
Similarly, three booster immunizations of recombinant JEV E DIII protein partially 
protected against a WNV infection (159). These results suggest that when JEV E 
protein alone is used as the immunogen, repeated immunizations are required to 
generate adequate adaptive immune responses capable of eliciting cross-
protection between JEV and WNV. 
JEV SA14-14-2 is highly attenuated in mice, yet induces both T and B cell 
responses (Trobaugh et al., in preparation) (36, 62, 160). Antibody depletion of 
both JEV-immune CD4+ and CD8+ T cells completely abrogated protection 
against WNV, while depletion of only CD4+ or CD8+ T cells resulted in only a 
slight increase in mortality compared to JEV-immune mice (Trobaugh et al., in 
preparation). These results suggest that prior JEV immunity can protect against 
WNV infection, and both JEV-immune CD4+ and CD8+ T cells are required for 
this cross-protection.  
 
 
 
 21 
H. WNV cross-protection against JEV 
Few reports exist that have examined flavivirus cross-protection against 
JEV (summarized in Table 1.1.). Bonnet macaques immunized with WNV were 
protected from mortality, but 2 of 5 macaques demonstrated signs of 
encephalitis, suggesting that WNV infection only reduced disease severity, rather 
than providing complete protection (155). Recently, Bosco-Lauth et al., 
demonstrated that WNV- and SLEV-immunization of hamsters prevented viremia 
upon a JEV infection (154). However, as hamsters are not susceptible to 
symptomatic JEV infection, protection from mortality could not be addressed. 
Similarly, WNV-immune red-winged blackbirds were protected against JEV 
infection (156). These results demonstrate that cross-protection between JEV 
and WNV may be bidirectional, but that species-specific differences in this 
protection may exist.  
Similar to JEV cross-protection against WNV, the context of the primary 
immunization may influence cross-protection against JEV. Hamsters immunized 
with Ch-WNV were protected against JEV viremia, but canarypox-WNV 
immunized hamsters were not protected (154, 161). Immunization with WNV E 
protein partially protected against a lethal JEV infection (73, 74). Similarly, 
immunization with a recombinant vaccinia virus (rVV) expressing the prM/E 
proteins of MVEV could protect against a JEV infection (162). Therefore, the 
context of the primary immunization may influence cross-protection between JEV 
and WNV.  
 22 
 
I. Heterologous immunity and cross-reactive T cells and antibodies 
 Immunity to a prior viral infection can lead to protection or 
immunopathology due to a 2o related or unrelated viral infection, called 
heterologous immunity (163). Memory cross-reactive CD4+ and CD8+ T cells are 
thought to be the principal mediators of heterologous immunity (164). The ability 
of the T cell receptor (TCR) to recognize multiple epitopes is an important 
component of the immune system allowing finite numbers of TCRs to be able to 
recognize an even larger pool of epitopes (165). TCR cross-reactivity can be due 
to either amino acid sequence homology of the epitopes or similarities in peptide-
MHC structure between epitopes with little sequence homology (166-169). 
 
 i. Cross-reactive T cell responses between unrelated pathogens 
Cross-reactive T cells have been identified for both human and murine 
infections (163). The sequence of infection can dictate the outcome of cross-
reactive responses that might occur during two viral infections. For example, viral 
titers of both Pichinde virus (PV) and VV were decreased in lymphocytic 
choriomeningitis virus (LCMV) immune mice. Also, immunization with murine 
cytomegalovirus (MCMV) resulted in the reduction of LCMV, PV, and VV viral 
titers (164, 170, 171). In cases when viral restriction was detected, a shift in the 
hierarchy of CD8+ T cell epitopes occurred in which CD8+ T cells specific for the 
cross-reactive NP205 epitope rapidly expanded to become the dominant CD8+ T 
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cell population after 2o infection (166). However, prior VV immunity did not restrict 
either LCMV or PV viral replication, and LCMV infection of VV-immune mice did 
not result in the proliferation of VV-specific CD8+ T cells (164, 170, 171). 
Immunopathology can also develop after sequential viral infections 
depending on the viruses involved and the sequence of infection. IFN−γ 
production by T cells in LCMV-immune mice upon VV-infection resulted in 
immunopathology in multiple tissues, which was not seen in PV or MCMV-
immune mice (164, 171-173). Private specificities of an individual mouse TCR 
repertoire also can determine the magnitude and immunopathology of cross-
reactive T cell responses upon a 2o infection (173-175). The TCR Vβ repertoire 
may narrow after 2o infection, but TCR Vβ repertoires are still highly variable and 
dependent on the individual mouse (176). Cross-reactive T cells have also been 
identified between hepatitis C virus (HCV) and influenza, EBV and influenza, 
human immunodeficiency virus (HIV) and HCV, influenza serotypes, and dengue 
serotypes in humans (175, 177-183). In humans, cross-reactive T cells between 
Epstein Barr virus (EBV) and influenza have been suggested to contribute to 
disease severity in infectious mononucleosis due to EBV infection (167). 
 
ii. Cross-reactive T cells during influenza virus infections 
Cross-reactive T cells during influenza infection can lead to cross-
protection or reduction in disease severity upon a 2o infection with a different 
influenza subtype, termed heterosubtypic immunity (184-187). Single amino acid 
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mutations in cross-reactive epitopes can lead to significant differences in cross-
reactive CD8+ T cell responses and viral clearance during the second viral 
infection (185, 188, 189). Therefore, sequence variation in the cross-reactive 
epitope between two influenza viral infections leads to CD8+ T cells that have 
reduced functional avidities for the heterologous epitope. The CD8+ T cells are 
not as effective in clearing a subsequent viral infection, but may help contribute 
to protection (185).  
 
iii. Cross-reactive T cells during sequential flavivirus infections 
 Expansion of memory cross-reactive CD4+ and CD8+ T cells occurs in 
dengue immune mice following 2o heterologous infection, and is required for 
cross-protection between dengue virus serotypes (190-192). In humans, altered 
cytokine profiles and activation states of cross-reactive T cells after a primary 
dengue virus infection are thought to contribute to the increase in the frequency 
of plasma leakage seen in dengue hemorrhagic fever (DHF), after a 2o infection 
(183, 193-196).  
In the JEV serocomplex, cross-reactive T cells have been identified in 
both mice and humans, but the contribution of T cells to cross-protection has not 
been fully addressed. JEV-immunized individuals were found to have cross-
reactive CD4+ T cells that responded to WNV antigen (197, 198). Cross-reactive 
CD8+ T cells against WNV were also identified after vaccination with Ch-JEV; 
therefore it is likely that natural infection with JEV would also generate cross-
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reactive T cells against WNV (198). Previously, our group had found that 
depletion of both JEV-immune CD4+ and CD8+ T cells prior to WNV infection 
resulted in an increased susceptibility to WNV, whereas depletion of only one 
subset did not significantly alter susceptibility (Trobaugh et al., in preparation). 
Although, these data suggest that JEV-immune CD4+ and CD8+ T cells are 
required for cross-protection, it does not address whether JEV immune CD4+ and 
CD8+ T cells are sufficient to protect against WNV challenge.  
 
iv. Cross-reactive antibodies during sequential flavivirus infections 
 Cross-reactive antibody responses against secondary flaviviruses can be 
protective, but they can also lead to immunopathology to the second viral 
infection. One theory attributes the increase in immunopathology in sequential 
dengue virus infections to antibody-dependent enhancement (ADE) (199). ADE 
occurs when antibodies in the sera do not reach the stoichiometric threshold 
required for neutralization of the virus. The antibodies and virus are then taken 
up into FcγR-expressing cells, thus enhancing the infection (200). ADE has been 
demonstrated in some in vivo mouse models of both dengue virus and WNV 
infections, and both complement and FcγR mechanisms are required for ADE 
(201, 202).  
The detection of cross-reactive neutralizing antibodies in humans after 
natural infection or vaccination is highly variable. In Mexico, the presence of 
dengue antibodies in the human population may be preventing infections, or at 
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least overt disease, from WNV, and seroconversion (203). The presence of WNV 
neutralizing antibodies in JEV vaccinated individuals depends on the patient 
cohort studied and the number of immunizations (204-206). Repeated 
vaccinations or infection with multiple flaviviruses increases the likelihood of 
detecting cross-reactive neutralizing antibodies (205, 207-209).  
Similarly, in mice, repeated vaccinations of inactivated JE-VAX or JEV E 
protein induced low levels of neutralizing titers to WNV (74, 158, 159). Also, 
higher levels of virus during the primary infection may increase the frequency of 
cross-reactive neutralizing antibodies, as cross-reactive neutralizing antibodies to 
MVEV were detected after infection of IFNαR-/- mice with Ch-JEV, but not in WT 
mice infected with Ch-JEV. This increase was not seen after immunization with 
the inactivated JE-VAX, suggesting that replication of Ch-JEV in IFNαR-/- mice 
contributed to the increase in neutralizing antibody titers (89). Cross-reactive 
antibodies to nonstructural proteins can also contribute to cross-protection 
between WNV and JEV. Recently, a WNV anti-NS1 antibody recognized cell-
surface expression of the JEV NS1 protein and protected against lethal infection 
if administered prior to infection (210). These results suggest that after 
vaccination or infection, low levels of cross-reactive neutralizing antibodies may 
be present that are boosted upon a second infection (209).  
Adoptive transfer of JEV SA14-14-2-immune serum partially protected 
against WNV infection, but cross-reactive neutralizing antibodies were not 
detected (Trobaugh et al., in preparation). This does not rule out the presence of 
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low levels of cross-reactive neutralizing antibodies that could not be detected or 
the presence of non-neutralizing antibodies. However, as stated earlier, non-
neutralizing antibodies can protect against a WNV infection in vivo (144). The 
transfer of low doses of dengue immune antibodies can result in ADE upon a 
dengue infection in mice, thus increasing disease severity (202). However, in 
other flavivirus mouse models, ADE was not detected, and did not enhance T cell 
responses after 2o infection (190, 198).  
 
J. T cell responses during secondary infections 
 The presence of pre-existing cross-reactive T cells and antibodies may 
influence secondary immune responses during heterologous infections. Factors 
influencing secondary immune responses are complex and diverse, and are 
initiated during the primary immune response. TCR engagement, costimulatory 
signaling, and more recently, cytokine signaling are three signals required for 
generation of epitope-specific CD8+ T cells from naïve T cells (211). Inflammation 
during the early stages of the immune response, specifically type I IFN and IL-12, 
help dictate the expansion of epitope specific CD8+ T cells, but the requirements 
for these cytokines may be pathogen dependent (212-217). Recently, IL-21, 
produced by CD4+ T cells during the primary immune response has also been 
shown to be important for CD8+ T cells survival and memory formation (218-221). 
Also, the initial antigen dose can influence both the magnitude of expansion of 
CD8+ T cells and the generation of memory CD8+ T cells (222-224). Therefore, 
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multiple components of the primary immune response lead to the development of 
antigen-specific CD8+ T cells, with not all viral infections having the same 
requirements.  
CD8+ T cells generated during the primary immune response have been 
subdivided into two populations that are influenced by IL-12, type I IFN, and IL-2 
levels: short-lived effector cells (SLECs) and memory precursor effector cells 
(MPECs) (217, 225-229). SLECs are effector CD8+ T cells that are highly 
functional, and are thought to die during the contraction phase of the immune 
response (230). SLECs are defined as expressing high levels of killer cell lectin-
like receptor G1 (KLRG1+) and low levels of IL-7Rα (CD127low) (212). KLRG1 is 
actually indispensable for the generation of antigen specific CD8+ T cells and is 
mainly used as a marker for the identification of SLECs (231). MPECs, defined 
as KLRG1- CD127hi, are thought to survive the contraction phase and represent 
a high proportion of the memory CD8+ T cells, and are capable of proliferating 
multiple times after antigen restimulation compared to SLECs which have very 
little replicative potential (230, 232). Cytokine driven expression of the 
transcription factors, T-bet, eomesodermin, and B lymphocyte-induced 
maturation protein-1 (Blimp-1), help to promote SLEC differentiation over MPEC 
differentiation (212, 233-236).  
CD4+ T cells are instrumental in the generation of CD8+ T cell memory. IL-
2 and IL-21 are two important cytokines that contribute to “CD4+ T cell help”, and 
mice lacking either cytokine have defects in sustaining primary CD8+ T cell 
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responses, memory CD8+ T cell generation, and/or recall responses during 2o 
infection (124, 237-240). Also, the trafficking and maintenance of effector CD8+ T 
cells into peripheral tissues is reduced in mice lacking CD4+ T cells (124, 240, 
241). Inflammation can also affect the contraction phase of the immune 
response. Low levels of both inflammation and chemokines during the primary 
immune response lead to reduced contraction and an increased frequency of 
memory T cells (121, 242, 243).  
There is a theory that states that during a 2o heterologous viral infection, 
memory cross-reactive T cells preferentially expand upon infection, called 
original antigen sin. This phenomenon has been observed during influenza, 
LCMV, and dengue viral infections. Low avidity cross-reactive T cells are thought 
to be one of the principle mediators of this so-called original antigen sin (244-
246). However, recently it was demonstrated that high avidity naïve T cells can 
expand upon secondary heterologous infection even in the presence of low 
avidity memory CD8+ T cells, suggesting that the process of original antigen sin 
may not occur in all sequential viral infections (247).  
A higher number of memory CD8+ T cells does not always necessitate 
improved proliferation upon a 2o infection. Whether frequencies are low or high, 
memory CD8+ T cells will proliferate until a threshold is reached; however this 
threshold can actually change over time (224, 248, 249). Therefore, memory 
CD8+ T cells at lower frequencies may proliferate more than memory CD8+ T 
cells that start at higher frequencies (222, 224).  
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Higher levels of inflammation during a 2o infection can lead to a greater 
expansion of memory CD8+ T cells compared to instances where there is limited 
inflammation. Similar to the primary immune response, the type of Inflammation 
induced during a 2o infection is dictated by the pathogen and influenced by the 
dose of the infecting pathogen (250). Repeated antigenic stimulations can lead to 
better memory CD8+ T cell responses and better protection (217, 248, 251-253).  
As a result of all these variables, there is really no universal standard for 
the generation of “optimal” antigen specific CD8+ T cells. While, there are 
underlying principles that are useful to study CD8+ T cells, some of these 
principles cannot be broadly applied. Animal hosts have adapted immune 
responses specific to each pathogen, and the resultant CD8+ T cell responses 
are highly specific, and may vary greatly from pathogen to pathogen. Many of 
these differences may be due to the different roles CD8+ T cells play in different 
infections.  
 
K. Thesis Objectives 
Sequential infections with flaviviruses can lead to either cross-protection 
or immunopathology. This thesis sought to characterize cross-reactive CD8+ T 
cell responses during primary and secondary JEV and WNV infections, in order 
to better understand the mechanisms of cross-protection between the two 
viruses. This work characterized the differences in primary cross-reactive CD8+ T 
cells generated by WNV and JEV infections, and the role the specific primary 
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infection takes in shaping secondary immune responses to heterologous viral 
infections.  
 
We initially hypothesized that: 
a) JEV/WNV cross-reactive CD4+ and CD8+ T cell in JEV-infected mice 
preferentially expand during secondary WNV infection 
b) Lack of expansion of cross-reactive CD4+ and CD8+ T cells in WNV-
immune mice leads to limited protection upon secondary JEV infection 
 
During the course of the dissertation, the hypotheses were modified to the 
following: 
a) JEV and WNV infections induce qualitatively and quantitatively 
different cross-reactive CD8+ T cells during the primary immune 
response 
b) The greater number of memory CD8+ T cells and cross-reactive 
antibodies following WNV infection contributes to protection upon 2o 
JEV infection 
c) Greater inflammation during the WNV immune response alters both 
generation and contraction of CD8+ T cells as well as antibody 
responses 
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This work is presented in two parts: 
 
CHAPTER III: Altered effector functions of virus-specific and –cross-
reactive CD4+ and CD8+ T cells in mice immunized with related flaviviruses 
 
 Questions: 
a) Do cross-reactive CD8+ T cell frequencies, cytokine profiles, and 
phenotypes differ between WNV and JEV? 
b) Does the pathogenicity and infecting dose of JEV alter cross-reactive 
CD8+ T cell responses? 
c) Do differences in tissue tropism between JEV and WNV exit? 
 
CHAPTER IV: Sequence of infection determines cross-reactive CD8+ T cell 
responses during secondary heterologous flavivirus infection 
 
Questions: 
a) Does pre-existing WNV immunity protect against a lethal JEV 
infection? 
b) Do cross-reactive CD8+ T cells proliferate during secondary infection, 
and what factors contribute to or inhibit proliferation?  
c) Do WNV and JEV infections induce cross-reactive neutralizing 
antibodies? 
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CHAPTER II 
 
Materials and Methods 
 
 
A. Viruses  
JEV strain SA14-14-2 and chimeric-WNV (Ch-WN) was provided by Dr. 
Thomas Monath (Acambis, Inc.). Ch-WNV contains the prM/E proteins of WNV 
and the nonstructural proteins of the yellow fever (YFV) 17D virus (77). JEV 
strains Nakayama and Beijing were provided by Dr. Alan Barrett (University of 
Texas Medical Branch, Galveston, TX). WNV strain 3356 was provided by Dr. 
Kristen Bernard (Wadsworth Center, Albany, NY) (254). Kunjin virus was 
provided by Dr. Robert Tesh (University of Texas Medical Branch, Galveston, 
TX).  Vaccinia virus (VV) WR was provided by Dr. Girish J. Kotwal (Sullivan 
University, Louisville, KY) and Dr. William Marshall (University of Massachusetts 
Medical School, Worcester MA).  
 
B. Generation of recombinant vaccinia viruses (rVV) 
 The JEV S9 and WNV S9 epitope was fused to green fluorescent protein 
(GFP) at its N- (NJEV and NWNV) or C- (CJEV and CWNV) terminus. GFP 
protein cDNA from the pIRES-AcGFP1 plasmid was modified by polymerase 
chain reaction (PCR) using the GeneAmp XL PCR Kit (Applied Biosystems) and 
the primers shown in Table 2.1. The primers contain the JEV S9 and WNV S9 
peptide sequences along with either SalI or HindIII restriction enzyme recognition 
sequences for cloning into a vaccinia virus transfer vector, pMJ601, which  
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Table 2.1. Sequence of primers used to clone the JEV S9 and WNV S9 
epitopes onto GFP 
Name Sequence 
GFPsa gtcgaccATGGTGAGCAAGGGCGb, c, d 
WNVs gtcgaccatgagctctgtttggaacgcaacaactgccATGGTGAGCAAGGGCG 
JEVs gtcgaccatgagtgccgtttggaattccaccactgccATGGTGAGCAAGGGCG 
GFPas aagctTCACTTGTACAGCTCATCCATGCCGT 
WNVas aagcttcaggcagttgttgcgttccaaacagagctCTTGTACAGCTCATCCATGCCGT 
JEVas aagcttcaggcagtggtggaattccaaacggcactCTTGTACAGCTCATCCATGCCGT 
a GFPs (sense) was used with WNVas (antisense) and JEVas to generate N-
terminal rVVs. WNVs and JEVs was used with GFPas to generate C-terminal 
rVVs. 
b Underline and lower case letters identify restriction enzyme sequences SalI (s) 
and HindIII (as). 
c Upper case letters represent start (s) or end (as) of the GFP sequence. Lower 
case letters represent JEV S9 and WNV S9 epitope sequences. 
d Bold letters represent start and stop codons. 
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contains the thymidine kinase (TK) gene (Bernard Moss, National Institute of 
Allergy and Infectious Diseases, Bethesda MD). Following sequence 
confirmation, the PCR products were cloned into pCR2.1 using the TOPO TA 
cloning kit (Invitrogen). βgal negative colonies were screened for the PCR insert 
and the DNA was digested with HindIII and SalI restriction enzymes (New 
England BioLabs), for ligation into pMJ601, also digested with SalI and HindIII, 
using the Fast-Link DNA ligation kit (Epicentre, Madison, WI). Restriction 
digestion using SalI and HindIII was used to confirm ligation of PCR product into 
pMJ601, and the plasmid was prepared for transfection and homologous 
recombination into VV.  
 VV-WR (1.2 x 107 pfu) was added to equal volume of 0.25% Trypsin and 
incubated for 30 min at 37oC. The inoculum was sonicated and added to 50% 
confluent CV-1 cells in T-25 cm2 flask for 2 hrs at 37oC. Purified plasmid DNA (5 
µg) was incubated with Qiagen Superfect at room temperature for 10 min.  MEM 
w/10% FBS was added to the DNA-Superfect mixture and was added to VV-WR 
infected CV-1 cells. After 2 hrs at 37oC, the cells were washed with PBS and 
cultured in MEM-10% FBS for two days. The cells were then harvested, 
suspended in 0.5ml MEM-2.5% FBS, transferred into eppendorf tubes, freeze-
thawed three times, and stored at -80oC. 
 Next, the cell lysate (110 µl) and 0.25% Trypsin (110 µl) were incubated 
for 30 min at 37oC, followed by sonication for 10 sec. Serial dilutions were added 
in duplicate to HuTK- 143B cells (TK-) (ATCC) and incubated for 2 hrs at 37oC. 
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The media was removed, and 2 ml of MEM-10% FBS supplemented with 25 
µg/ml Bromodeoxyuridine (BrdU) was added for 2 days. On day 2, an agarose 
overlay containing 2% low melting point agarose (20ml), 2X MEM (20ml), 0.33% 
Neutral red (0.4ml, Sigma-Aldrich), 4% X-gal (0.33ml) and BrdU (5mg/ml; 0.2ml) 
was added overnight. Blue plaques (5-6) were collected via a Pasteur pipette and 
placed into tubes with 0.5ml MEM-2.5% FBS and freeze-thawed three times. 
GFP expression of each blue plaque was confirmed using a fluorescent 
microscope (Figure 2.1.A).  Three additional rounds of plaque purification were 
performed with 2 additional plaques selected from each purification step.  
 After the final purification, five plaques were sonicated and 250 µl of cell 
lysate plus 750 µl of MEM-2.5% was added to one well of TK- cells in a 12 well 
plate amplify the plaque. After 2 hrs at 37oC, the media was removed, and MEM-
2.5% FBS + BrdU was added for 2 days. The cells were collected and freeze-
thawed three times in MEM-2.5% FBS.  This amplification step was repeated 
using the 12-well plate lysate (250 µl) to inoculate TK- cells in a T-25 cm2 flask, 
and using the T-25 cm2 lysate (250 µl) to inoculate TK- cells in a T-175 cm2 flask. 
Mice were then inoculated with the viral lysates (1 x 106 pfu) to determine 
whether the recombinant vaccinia viruses (rVV) induced a CD8+ T cell response 
to the inserted epitope. Only the rVVs expressing the epitopes at the C-terminal 
of GFP induced epitope-specific CD8+ T cells that responded to both JEV S9 and 
WNV S9 peptides. The immunodominant VV epitope, B8R, was used to confirm 
functionality of the rVV (Figure 2.1.B.). 
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Figure 2.1. Confirmation of GFP expression and epitope insertion into rVVs. 
(A) GFP expression of rVVs. TK- cells were infected with each of the rVVs and, 
GFP expression was determined on day 2 after infection. (B) CD8+ T cell 
responses to the JEV S9, WNV S9, and VV B8R epitopes. B6 mice were infected 
with 1x 106 pfu of the rVVs ip, and on day 7 after infection, splenocytes were 
analyzed for IFN−γ and TNF-α production following stimulation with 1 µg/ml JEV 
S9, WNV S9 or B8R peptide or media alone. 
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 One virus was then selected to be propagated using CV-1 cells to make 
viral stocks. Ten CV-1 T-175 cm2 flasks were infected with 5 ml of viral inoculum 
(100 µl virus + 50 ml MEM w/o FBS) for 2 hrs at 37oC. The supernatant was 
aspirated and 20 ml of MEM-2.5% FBS was added overnight. The cells were 
harvested the following day due to high levels of CPE. Cells from all the flasks 
were combined, freeze-thawed three times and sonicated. Following an 
additional round of centrifugation, aliquots of the supernatant were stored at -
80oC.  
 
C. Propagation of virus stocks 
 Mycoplasma free Vero cells (flaviviruses) or CV-1 cells (rVV) were grown 
to confluency in T-175 cm2 flask in minimal essential media (MEM) supplemented 
with 10% fetal bovine serum (FBS), 1% Penicillin/Streptomycin (Pen/Strep) and 
1% L-Glutamine. Prior to infection, media was removed and cells were washed 
with phosphate buffered saline (PBS). Virus (500 µl, flaviviruses; 100 µl rVV) was 
added to 5 ml of MEM without (w/o) FBS and added to the cells for 1.5 hrs at 
37oC w/5% CO2. After infection, the inoculum was aspirated and 20 ml of MEM 
supplemented with 2.5% FBS, 1% Pen/Strep, and 1% L-Glutamine was added. 
Cells were monitored daily until 30-50% of the cells exhibited cytopathic effects 
(CPE), consisting of rounding of the cells and disruption of the cell monolayer. 
CPE occurred 2-3 days after infection for WNV and Kunjin, 4-5 days for JEV 
SA14-14-2 and Beijing strains, and 1 day for the rVVs. For flavivirus propagation, 
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the cells and media were collected and spun at 2000 rpm for 10 min at 4oC. The 
supernatant was then aliquoted and stored at -80oC. For the rVVs, the cells and 
media were freeze-thawed 3x, and sonicated for 10 seconds twice. The cells and 
media were then spun at 2000 rpm for 10 min at 4oC, and aliquoted for storage at 
-80oC. All viruses were titrated on Vero cells using a standard plaque assay as 
described later. 
 
D. Peptides 
Peptide (15-19mer) arrays corresponding to the entire proteome of WNV 
were obtained through the Biodefense and Emerging Infections Research 
Resources Repository, National Institute for Allergy and Infectious Diseases 
(NIAID), National Institute of Health (NIH) (BEI Resources, Manassas, VA). 
Peptide truncations (>70% or >90% purity) were obtained from AnaSpec, Inc. 
(San Jose, CA) and 21st Century Biochemicals (Marlborough, MA).  
 
E. Mice and Immunizations 
Male or female C57BL/6J (B6) (Ly5.2+), B6.SJL-Ptprc Pep3/BoyJ (Ly5.1+) 
mice aged 6-14 weeks (Jackson Laboratories, Bar Harbor, ME), C57BL/6Ji-
Kbtm1 N12 (H2-Kb-/-), C57BL/6Ji-Dbtm1 N12 (H2-Db-/-) mice (Taconic Farms, 
Germantown, NY) were housed in specific pathogen-free conditions in the 
University of Massachusetts Medical School Biocontainment facility and were 
cared for according to guidelines approved by the University of Massachusetts 
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Medical School’s Institute Animal Care and Use Committee. All mice were 
infected via an intraperitoneal (ip) injection with varying doses of virus.  Mice 
were weighed and monitored daily for clinical symptoms, and euthanized once 
weight loss exceeded 25%. Clinical symptoms for both JEV and WNV include 
weight loss, hunched posture, ruffled fur, and hind limb paralysis.  
 
F. Isolation of Lymphocytes 
 i: Splenocytes 
 Spleens were harvested and placed in Roswell Park Memorial Institute-
1640 (RPMI) media supplemented with 10% FBS. The spleens were transferred 
onto a 70 µm cell strainer and mashed with the blunt end of a 3 ml syringe, 
washed with RMPI-10% FBS, and spun at 1500 rpm for 5 min. The supernatant 
was decanted and red blood cell lysis buffer (1 ml; Sigma-Aldrich) was added for 
5 min. The cells were washed, and resuspended in RPMI-10% FBS at the 
desired concentration.  
 
ii. Central Nervous System (CNS) T cells  
 Lymphocytes were obtained from brains of WNV infected mice on day 10 
or 4-5 weeks post infection. Mice were perfused with PBS via a cardiac puncture 
to eliminate circulating T cells in the blood, and brains were harvested and 
placed in RPMI-10% FBS. Brains were homogenized on a 100 µm cell strainer 
and washed with RPMI. Cells were then resuspended in RMPI-10%FBS and 
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Collagenase D (Roche; 100 µg/ml; final concentration 500 ng/ml) was added for 
45 min at 37oC.  Lymphocytes were isolated by density centrifugation in a 
30%/70% Percoll gradient at 800g for 30 min at 4oC. Lymphocytes at the 
interface of the two layers were collected, washed, and counted for use.  
 
G. Generation of bulk culture cell lines 
Splenocytes were harvested one week following JEV boost, and 
stimulated with 10 µg/ml JEV NS4b C peptide (GASSVWNATTAIGL) in RPMI 
containing 10% FBS, 1% Pen/Strep, 5x10-5 M β-mercaptoethanol and 
recombinant human IL-2 (rhIL-2; BD Biosciences) (25 U/ml) at 37° C. At day 14 
and every 14 days thereafter, γ-irradiated naïve B6 splenocytes were pulsed with 
10 µg/ml peptide, washed, and added to the bulk cultures at a stimulator-to-
responder ratio of 5:1.    
 
H. 51Chromium release assay 
51Chromium release assay were performed as previously described (255). 
In brief, 51Cr-labelled EL4 cells (ATCC) were incubated with peptide or media 
alone. Effector cells were added in triplicate and incubated for 4 hours at 37oC. 
Renex or media alone were added to target cells for determination of maximum 
target cell lysis and spontaneous lysis, respectively. Supernatants were 
harvested and counted on an automated gamma counter. Percent specific lysis 
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was calculated as [(sample 51Cr release – spontaneous 51Cr release)/(maximum 
51Cr release – spontaneous 51Cr release)] x 100.  
 
I. IFN-γ ELISPOT 
ELISPOT assays were performed as described previously (255). Freshly 
isolated day 7 splenocytes from 2 naïve or JEV-infected mice were pooled and 
plated on anti-mouse IFN-γ coated 96-well plates in duplicate or triplicate (2.5 x 
105 per well) and stimulated with WNV or JEV peptides (2 µg/ml), Con A (2.5 
µg/ml), or media overnight at 37oC. After PBS wash, anti-mouse IFN-γ 
biotinylated antibody was added for 2 hours followed by streptavidin-HR. Spots 
were developed with NovaRed substrate kit (Vector Laboratories, Burlingame, 
CA) and counted with a C.T.L. reader (Cellular Technology Limited). The number 
of spot forming cells per million was calculated as [(mean spots in experimental 
wells – mean spots in medium control) x 4] x 106. The average number of spot 
forming cells per million in media alone was 21 ± 22. A positive response was ≥2 
times media background. 
 
J. Intracellular cytokine staining (ICS) 
i. Splenocytes 
Splenocytes (1-2x106 cells) were stimulated either with peptide (10-6 – 10-
13 µg/ml), peptide pools (5 µg/ml), phorbol 12-myristate 13-acetate (PMA) (50 
ng/ml) and ionomycin (250 ng/ml) (positive control) or without peptide (negative 
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control) in the presence of brefeldin A (BD GolgiPlug) for 5 hours. For some 
experiments, cells were washed with PBS and stained with Live/Dead Aqua 
(Invitrogen), a viability marker, for 20 min at RT for exclusion of dead cells during 
analysis. Cells were then washed in PBS supplemented with 2% FBS and 0.05% 
Sodium azide (FACS WB) and incubated with 1 µg anti-CD16/32 (2.4G2). Cells 
were surface stained with anti-CD3 (clone 145-2C11), -CD4 (L3T4), -CD8 (Ly-2) 
-Ly5.1 (A20), or -Ly5.2 (104). Antibodies were conjugated to APC, PE, PerCP-
Cy5.5, PerCP, Pacific Blue, Alexa 700, or FITC. After permeabilization with BD 
CytoFix/CytoPerm, cells were stained with anti-IFN−γ (XMG1.2), -TNF-α (MP6-
X522) and fixed in 1% paraformaldehyde or 1:3 dilution of BD Stabilizing fixative. 
Samples were acquired on a FACSCalibur or FACSAria (BD Biosciences) and 
data were analyzed using FloJo software (Tree Star, Inc.). EC50 values were 
calculated using GraphPad Prism. The percentage of CD4+ or CD8+ T cells 
producing IFN-γ in response to media was subtracted from peptide-stimulated 
cells. Antibodies were obtained from either BD Bioscience or eBiosciences.  
 
ii. TCR Vβ expression 
Splenocytes were stimulated with either 1 µg/ml JEV S9 or WNV S9 
peptide as described above. Following incubation, cells were stained with anti-
CD3-Pacific Blue, anti-CD8-APC-H7, and a mouse TCR Vβ screening panel (BD 
Biosciences) according to manufacture guidelines. An IgG-FITC isotype control 
(BD Biosciences) was used to determine background staining. Following 
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permeabilization, cells were stained with anti-IFN−γ APC. Cells were gated on 
CD3+ CD8+ IFN−γ+ TCR Vβ+. The background level of staining with the isotype 
control was subtracted from each sample. Since the TCR Vβ panel did not 
include the entire mouse TCR Vβs, the total percentage of TCR Vβ in the 
population was subtracted from 100% to give the percentage of the TCR Vβs in 
population not included in the panel (labeled other in graph). 
 
K. In vivo cytotoxicity experiments 
i. Primary infection experiments: 
In vivo cytotoxicity experiments were performed as described with 
modifications (256). Naive splenocytes (target cells) were pulsed with 1, 0.1 or 
0.01 mg/ml of JEV S9, WNV S9 peptide or control influenza NP 366-374 peptide 
(1 mg/ml) for 45 min at 37oC. Cells were stained with 1 µM Cell Trace Far Red 
DDAO-SE (Invitrogen, Carlsbad, CA) and serial dilutions of 5(6)-
Carboxyfluorescein diacetate N-succinimidyl ester (CFSE) (5 µM, 1.5 µM, 0.4 
mM, 0.1 mM; Invitrogen). Target cells in PBS (2 x 107 cells in 200 µl) were 
injected intravenously (iv) into JEV-infected or naïve mice 8 days post infection. 
Splenocytes were harvested 2 hours later and analyzed using a FACS Aria. 
DDAO+ donor cells were analyzed for CFSE expression.   
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ii. Memory experiments: 
Naïve Ly5.1+ splenocytes were pulsed with 1 µg/ml JEV S9, WNV S9, or 
Flu NP 366-374 for 1.5 hrs at 37oC and stained with CFSE as described above. 
Target cells (1-2 x 107 cells in 200 µl) were injected iv into WNV-immune (4-5 
weeks post infection), JEV-immune (4-5 weeks post infection), or naïve B6 mice. 
Splenocytes were harvested 19 hrs later and stained with anti-Ly5.1-Alexa700, 
and  -Ly5.2-PE antibodies. Ly5.1+ donor cells were analyzed for CFSE 
expression. Percent specific lysis was calculated by the formula 1-(Ratio 
Immune/Ratio Naïve) x 100, where Ratio=(# events of JEV or WNV peptide/# 
events of control influenza peptide).  
 
L. Phenotype analysis of epitope-specific CD8+ T cells 
CD8+ T cells were stained with either peptide-loaded MHC dimer or 
tetramer. To generate peptide-loaded MHC dimers, recombinant H-2Db:Ig fusion 
protein (4µg; BD Biosciences) was loaded with peptide (>90% purity) at 640 
molar excess peptide in PBS (pH=7.2) at 37oC overnight according to 
manufacturers guidelines.  Peptide-loaded dimer was then incubated with 2.4 µg 
APC-anti-mouse IgG (BD Biosciences, mAb A85-1) followed by incubation with 
purified mouse IgG isotype control (4µg; BD Biosciences; mAb A111-3). APC 
labeled JEV S9 and WNV S9 tetramer was obtained from the NIH Tetramer Core 
Facility.  
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Splenocytes were resuspended in PBS, stained with Live/Dead Aqua, and 
incubated with anti-CD16/32 (2.4G2; BD Bioscience). For staining of peripheral 
blood lymphocytes (PBL), red blood cells were lysed with Sigma Lysis buffer 
(Sigma) or BD PharmLyse (BD Biosciences), followed by incubation with anti-
CD16/32 (2.4G2). Cells were then stained with optimal amounts of tetramer (0.5 
µl or 0.75 µl), or 20 µl of peptide-loaded dimer for 30 min at 4oC. Cells were 
surface stained with anti-CD44, -CD62L, -KLRG1, -CD127, -PD-1 (CD279, 
RMP1-14 clone, eBioscience), or -CD43 (1B11, BioLegend) conjugated with 
FITC, PE-Cy7, PerCP-Cy5.5, or PE, washed and resuspended in BD Stabilizing 
Buffer. Peptide-loaded dimer and tetramer staining levels in naïve mice were 
subtracted from experimental values in infected mice. For CD8+ T cells in the 
CNS, anti-CD45-eFluor 450 (30-F11, eBioscience) was also used to help 
distinguish CD3+ CD8+ T cells.  
 
M. Plaque assay of infected tissues 
i. Flaviviruses 
On days 3 and 7 post JEV or WNV infection, spleen, brain and serum 
were obtained and frozen on dry ice and stored at -80°C. Tissues were 
resuspended in MEM w/o FBS to give a 10% (spleen) or 20% (brain) 
homogenate based on tissue weight, and homogenized using a Qiagen mixer 
mill. Serial dilutions were made in MEM and titers were determined on Vero cells 
as described (84). Plates were incubated for 2 (WNV) or 4 days (JEV Beijing and 
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SA14-14-2) prior to second agar overlay containing neutral red (Sigma). The limit 
of detection was 50 pfu/ml for serum, 250 pfu/g for brain and 500 pfu/g for 
spleen.   
 
ii. Recombinant vaccinia viruses 
Ovaries were harvested on day 5 or 6 post infection, weighed, frozen on 
dry ice, and stored at -80oC until use. MEM w/o FBS was added to the ovaries to 
make a 10% homogenate, and ovaries were freeze-thawed three times. Ovaries 
were then homogenized using a Qiagen Mixer-Mill, and serial dilutions were 
made in MEM w/o FBS. Titers were determined on Vero cells using 100 µl of 
virus inoculum in duplicate. After 2 hours of incubation, MEM w/2.5%FBS was 
added for two days, followed by the addition of crystal violet in 10% ethanol to fix 
the cells. The cells were then washed with tap water, and allowed to air dry prior 
to counting the plaques. The limit of detection was 500 pfu/g for the ovaries.  
 
N: Adoptive transfer experiments 
 i. JEV-immune CD4+ and CD8+ T cell cross-protection experiment 
B6 mice (5-6 weeks old) were immunized with 1 x 106 PFU JEV SA14-14-
2 or were unimmunized. Six weeks later, splenocytes were processed, and 
separated into JEV-immune or naïve CD4+ and CD8+ T cell subsets by negative 
selection using AutoMACS according to the manufacturer’s recommendations 
(Miltenyi Biotech). After isolation of CD4+ and CD8+ T cell subsets, 1 x 106 cells 
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of each fraction were combined and administered iv into 9-10 week old mice 
using the following combinations: naïve CD4+ and JEV-immune CD8+; JEV-
immune CD4+ and naïve CD8+; JEV-immune CD4+ and JEV-immune CD8+, and 
naïve CD4+ and naïve CD8+. In addition, groups of mice that were immunized 4 
weeks previously with JEV, Ch-WN or PBS were used as positive and negative 
controls, respectively. Twenty-four hours after cell transfer, mice were infected 
with 1.26 x 106 pfu (100LD50) of WNV and monitored for survival. 
 
ii. CFSE proliferation 
Splenocytes from JEV and WNV immune mice (Ly5.2+), 4-5 weeks post 
infection, were washed with PBS and stained with 1 µM CFSE for 15-20 min at 
37oC. An aliquot of cells was taken prior to staining with CFSE for ICS or 
tetramer analysis to determine frequency of JEV S9 and WNV S9 CD8+ T cells 
prior to adoptive transfer. Following incubation, splenocytes were washed and 
resuspended in PBS to a concentration of 1-2 x 107 cells per 200 µl. The CFSE 
labeled splenocytes were transferred iv via the lateral tail vein into three naïve 
B6.SJL (Ly5.1+) mice per donor mouse. The next day, the mice were infected ip 
with either 1 x 103 pfu JEV Beijing, 1 x 103 pfu WNV or PBS (control). Five days 
later, splenocytes were harvested for ICS to measure CFSE dilution. 
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O: MHC stabilization assay 
RMA-S cells were cultured in suspension with RPMI supplemented with 
10% FBS, 1% Pen/Strep and 1% L-Glutamine at a density of 1 x 106 cells/ml. 
Cells (4 x 105) were plated in 96-well V-bottom plates on day of assay. JEV S9, 
JEV P6A, WNV S9 and WNV P6S peptides or no peptide (media alone) were 
added to the cells at a final concentration of 10-4 g/ml – 10-8 g/ml, and incubated 
overnight at 28oC. The following day, the cells were transferred to 37oC for 3 
hours. The cells were then stained with anti-H-2Db-PE antibody, and fixed with 
BD Cytofix (BD Biosciences).  Background H-2Db expression (no peptide) was 
subtracted from the experimental samples. 
 
P: Generation of bone marrow derived dendritic cells (BMDCs)  
 Tibia and femur from B6.SJL male mice were flushed with a 25 gauge 
needle to remove the bone marrow. The bone marrow was then filtered using a 
70 µm cell strainer and resuspended in 9 ml/mouse (3 ml/well) of RPMI-10% 
FBS, 1% Pen/Strep, 1% L-glutamine, 50 µM 2-mercaptoethanol, 20 ng/ml 
interleukin-2 (IL-2) (Perprotech) and 20 ng/ml granulocyte macrophage colony-
stimulating factor (GM-CSF) (Perprotech). Half of the media was exchanged 
every two days with fresh media. On day 6, 100 ng/ml of lipopolysaccharide 
(LPS) was added to mature the dendritic cells overnight. The supernatants were 
collected and the wells were washed with cold PBS to recover any residual 
BMDCs. The BMDCs were then washed with PBS to remove any LPS. A small 
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aliquot was stained with anti-CD11b, anti-CD11c, anti-CD80 and anti-CD86 to 
check for successful generation and maturation of the BMDCs.  
 
Q: Peptide-pulse and DC immunization 
 On day 7 after BMDCs maturation, 10 µg/ml of peptide was added for 1.5 
hrs at 37oC. The cells were washed with PBS, counted, and resuspended in cold 
PBS to achieve a concentration between 0.5 – 1 x 106 cells/ 200 µl. BMDCs were 
transferred iv (200 µl) into male B6.SJL recipients. On day 7 or 4-6 weeks after 
DC immunization, PBL were stained and analyzed for JEV S9-specific and WNV 
S9-specific CD8+ T cell frequencies as described above. Mice were then infected 
with 1 x 103 pfu JEV Beijing or 1 x 103 pfu WNV, and 5 days later, the PBL was 
analyzed for JEV S9-specific and WNV S9-specific CD8+ T cell frequencies. 
 
R: Statistics 
Means, medians and standard errors were calculated using GraphPad 
Prism (GraphPad Software, Inc., LaJolla, CA). Comparisons of variables 
between JEV and WNV infection groups were performed with log transformed 
data using the Mann-Whitney U test on STATA software (StataCorp, College 
Station, TX) or GraphPad Prism. P < 0.05 was considered significant.  
 51 
CHAPTER III 
ALTERED EFFECTOR FUNCTIONS OF VIRUS-SPECIFIC AND –CROSS-
REACTIVE CD4+ AND CD8+ T CELLS IN MICE IMMUNIZED WITH RELATED 
FLAVIVIRUSES 
 
Previous reports have demonstrated that JEV-immunized bonnet 
macaques and hamsters were fully protected against a lethal WNV challenge 
(153, 155). WNV-immune macaques, on the other hand, were only partially 
protected against a lethal JEV challenge, suggesting a one-way direction in 
cross-protection between JEV and WNV (155). Recently, Bosco-Lauth et al. 
demonstrated that WNV immunization of hamsters could protect them from JEV 
viremia, suggesting WNV immunity may protect from JEV infection in certain 
animal models (154). While these studies demonstrate that prior JEV or WNV 
immunity can protect against a second heterologous infection, underlying 
mechanisms for this cross-protection were not addressed. 
Previous work in our group has demonstrated that JEV-specific CD4+ and 
CD8+ T cells are required for cross-protection against WNV (Trobaugh et al., in 
preparation). Cross-reactive CD4+ and CD8+ T cell epitopes between JEV and 
WNV in BALB/c mice and humans have been identified (91, 197, 257). However, 
very little work had been done to understand cross-reactive T cell responses 
between JEV and WNV in B6 mice. Therefore, the focus of this chapter is on the 
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identification and characterization of JEV-WNV cross-reactive CD4+ and CD8+ T 
cell responses during primary JEV and WNV infections in B6 mice.  
 
A. Identification of JEV-WNV cross-reactive CD4+ and CD8+ T cell epitopes. 
To determine the overall JEV-WNV cross-reactive response, day 7 
splenocytes from JEV SA14-14-2 infected mice were stimulated with overlapping 
peptide pools corresponding to each of the 10 WNV proteins. We found that the 
total JEV-WNV cross-reactive CD4+ T cell IFN−γ responses were mainly directed 
at peptides in the NS4b, NS2a, and E proteins (Table 3.1 and Figure 3.1). In 
contrast, the majority of the JEV-WNV cross-reactive IFN−γ producing CD8+ T 
cells were induced by a single peptide pool corresponding to the WNV NS4b 
protein. These results suggest that the overall cross-reactive CD4+ T cell 
response is broad due to responses in multiple proteins, while the overall cross-
reactive CD8+ T cell response is limited due to a single protein inducing a 
majority of the IFN−γ response.  
 We next deconvoluted the positive peptide pools to identify the specific 
peptides that induced an IFN−γ response by ELISPOT.  We consistently found 
that three peptides, WNV NS1 A, WNV NS3 B and WNV NS4b209-226, induced the 
highest IFN−γ response from splenocytes harvested from JEV-infected mice 
(Table 3.2). Both WNV NS3 B and WNV NS4b209-226 contain previously identified 
CD4+ and CD8+ T cell epitopes in WNV-infected B6 mice, respectively (115, 116, 
125). To identify the optimal cross-reactive epitopes, we generated truncations of  
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Table 3.1. Frequency of IFN−γ+ CD4+ and CD8+ T cells in response to 
stimulation with WNV peptide pools corresponding to the entire WNV 
proteome. Splenocytes from JEV-infected mice were stimulated with pools of 
overlapping peptides corresponding to each of 10 WNV proteins in the presence 
of brefeldin A for 5 hours, permeabilized and stained for surface markers and 
intracellular IFN−γ production by CD4+ and CD8+ T cells as described in 
Materials and Methods 
 
% IFN-γ producing CD8+ T cells % IFN-γ producing CD4+ T cells 
Protein Exp 1 Exp 2 Exp 3 Protein Exp 1 Exp 2 Exp 3 
C 0.16a 0.13 0.66 C 0.04 0.00 0.42 
PreM, M 0.02 0.06 0.37 PreM, M 0.00 0.02 0.00 
E 0.24 0.45 0.72 E 0.06 0.94 0.25 
NS1 0.08 0.10 0.08 NS1 0.09 0.07 0.06 
NS2a 0.19 0.27 0.54 NS2a 0.07 0.89 1.91 
NS2b 0.01 0.00 0.12 NS2b 0.02 0.01 0.05 
NS3 0.47 0.21 0.51 NS3 0.25 0.33 0.34 
NS4a 0.00 0.00 0.09 NS4a 0.00 0.00 0.00 
NS4b 2.75 1.62 3.77 NS4b 0.02 0.60 3.50 
NS5 2.15 0.07 0.80 NS5 0.16 0.06 0.08 
Total 6.07b 2.91 7.66 Total 0.71 2.92 6.61 
a % IFN−γ+ CD4+ or CD8+ T cells. Background staining was subtracted from each 
peptide pool, and % IFN−γ from each peptide pool was added together. 
b Total % IFN−γ+ from all the peptides combined. 
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Figure 3.1. Global JEV/WNV cross-reactive CD4+ and CD8+ T cell response 
in JEV SA14-14-2 infected mice in response to WNV peptide pools. 
Splenocytes were harvested 7 days post-infection and IFN-γ production was 
measured in 3 separate experiments. Mean values for percentages of CD3+ 
CD4+ (left) or CD3+ CD8+ (right) T cells producing IFN-γ in response to peptides 
from a single protein were calculated and are represented as the percent of the 
total IFN-γ response calculated as follows: (mean CD4+ or CD8+ IFN-γ+ percent 
per protein/total CD4+ or CD8+ IFN-γ+ response to all 10 WNV proteins) x 100. 
Raw experimental values from each experiment are displayed in Table 3.1. C= 
capsid, prM/M = pre-membrane, membrane, E = envelope, NS=nonstructural. 
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each potential cross-reactive peptide. The sequences of each WNV truncation 
and the corresponding sequences in JEV are shown in Table 3.2.   
 To determine the MHC restriction of the potential cross-reactive epitopes, 
mice lacking the MHC molecules H-2Db or H-2Kb were infected with JEV SA14-
14-2, and IFN−γ responses to each of the truncations were determined by 
ELISPOT.  WNV NS1 A and WNV NS3 B and their corresponding truncations 
induced IFN−γ production by splenocytes from both H-2Db-/- and H-2Kb-/- mice 
(Table 3.2), with WNV NS1 A-1 and WNV NS3 B-2 inducing the highest IFN−γ 
response suggesting that these two truncations were the optimal cross-reactive 
epitope. These results also suggested that WNV NS1 A-1 and WNV NS3 B-2 
were not CD8+ T cell epitopes, but perhaps CD4+ T cell epitopes due to similar 
IFN−γ responses in B6, H-2Db-/- and H-2Kb-/- mice, demonstrating that IFN−γ 
responses were not reduced in mice lacking the MHC required for CD8+ T cell 
activation. To confirm that WNV NS1 A-1 and WNV NS3 B-2 were cross-reactive 
CD4+ T cell epitopes, we performed intracellular cytokine staining (ICS) on 
splenocytes from JEV-infected mice. We detected IFN−γ responses to the cross-
reactive epitopes (WNV NS1 A-1 and WNV NS3 B-2) and their corresponding 
JEV sequences (JEV NS1 A-1 and JEV NS3 B-2) in only CD4+ T cells (Figure 
3.2.). In fact, the JEV NS1 A-1 and NS3 B-2 epitopes are the first JEV-specific 
CD4+ T cell epitopes identified in B6 mice.  
 Stimulation of splenocytes from JEV SA14-14-2 infected mice with WNV 
NS4b209-226 and its truncations induced IFN−γ responses in H-2Kb-/- mice but not  
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Table 3.2. IFN-γ production induced by peptide stimulation of JEV-infected 
splenocytes from B6, H2-Db-/- and H2-Kb-/- mice in ELISPOT assay. Mice were 
infected with JEV SA14-14-2 and splenocytes were prepared on day 7.  
   Mouse strain 
Peptide name Amino Acid # Sequence C57Bl/6 D
b-/- Kb-/- 
WNVa NS1 A 132-149b   TFVVDGPETKECPTQNRA 197c 136 347 
WNV NS1 A-1 132-145 TFVVDGPETKECPT 174 84 309 
JEV NS1 A-1d 132-145 TFVVDGPETKECPD N.T.e N.T. N.T. 
WNV NS1 A-2 134-147      VVDGPETKECPTQN 0 4 35 
WNV NS1 A-3 136-149        DGPETKECPTQNRA 7 5 0 
WNV NS3 B 560-574 DRRWCFDGPRTNTIL 70 139 201 
WNV NS3 B-1 560-571 DRRWCFDGPRTN 52 35 71 
WNV NS3 B-2 563-574    WCFDGPRTNTIL 93 153 408 
JEV NS3 B-2 563-574    WCFDGPRTNAIL N.T. N.T. N.T. 
WNV NS3 B-3 565-575      FDGPRTNTIL 3 4 0 
WNV NS4b 209-226 LWENGASSVWNATTAIGL N.T. N.T. N.T. 
WNV NS4b A 209-221 LWENGASSVWNAT 14 0 0 
WNV NS4b B 211-224   ENGASSVWNATTAI 1835 29 1704 
WNV NS4b C 213-226     GASSVWNATTAIGL 415 7 2028 
WNV NS4b G9f 213-221     GASSVWNAT 498 5 58 
WNV NS4b A9 214-222      ASSVWNATT 2264 0 1934 
WNV NS4b A10 214-223      ASSVWNATTA 2718 9 2020 
WNV NS4b S9 215-223       SSVWNATTA 1403 43 1734 
WNV NS4b S10 215-224       SSVWNATTAI 2063 0 1482 
JEV NS4b C 213-226     GASAVWNSTTATGL N.T. N.T. N.T. 
JEV NS4b A9 214-222      ASAVWNSTT N.T. 1.2 2390 
JEV NS4b S9 215-223       SAVWNSTTA N.T. 5 2412 
a WNV 3356 GenBank Accession number AF404756 
b Numbers represent amino acid position within each protein 
c IFN-γ+ spot forming cells/million splenocytes  
dJEV GenBank Accession number AF315119 (JEV SA14-14-2) and L48961 (JEV Beijing)  
e Not tested 
f G9 represents amino acid in position 1 (G) followed by peptide length (9).  
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Figure 3.2. Identification of cross-reactive CD4+ T cell epitopes in JEV 
SA14-14-2 infected mice. B6 mice were infected ip with 1 x 106 pfu of JEV 
SA14-14-2, and on day 7, splenocytes were harvested and stimulated with 1 
µg/ml of peptide for 5 hours. Cells were gated on CD3+ CD4+ T cells (upper 
panels) or CD3+CD8+ (lower panels) with IFN-γ displayed on the y-axis.  
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from H-2Db-/- mice confirming H-2Db restriction (Table 3.2). The truncations, WNV 
NS4b A10 and WNV NS4b S9, were both previously identified to be the 
proposed optimal WNV immunodominant epitope (115, 116). Therefore, in an 
effort to identify the optimal cross-reactive epitope, bulk cultures from JEV SA14-
14-2 immunized mice were generated using WNV NS4b C as the stimulating 
peptide (Table 3.2). Ex vivo CTL analysis confirmed that WNV NS4b S9 (WNV 
S9) was the optimal cross-reactive epitope due to a higher percent specific lysis 
at the lowest concentration tested (Figure 3.3.A.).  Additionally, only the S9 
variant peptides and not WNV NS4b A10 bound to an unloaded MHC-dimer 
complex and stained CD8+ T cells from JEV and WNV-infected mice (Figure 
3.3.B.).  
In order to determine whether the cross-reactive WNV S9 epitope was 
recognized in vivo, we performed an in vivo cytotoxicity assay during acute JEV 
SA14-14-2 infection. Naïve splenocytes pulsed with decreasing doses of JEV 
NS4b S9 (JEV S9) were all lysed to a similar extent in JEV-infected mice, with a 
mean percent specific lysis 44.3%, 38.5%, and 43.5% for peptide doses 10-6, 10-7 
and 10-8 µg/ml, respectively (Figure 3.4.A-B.). In contrast, the mean percent 
specific lysis of WNV S9-pulsed target cells was consistently lower than that 
seen for the JEV S9 variant at all peptide doses (10-6: 34.0%; 10-7 33.4%; 10-8: 
28.0%). Splenocytes pulsed with an H-2Db restricted influenza NP epitope were 
not lysed in JEV-infected or naïve mice, confirming specificity of the response to 
the JEV and WNV epitopes (Figure 3.4.A.). These findings support that the 
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Figure 3.3. Identification of the optimal JEV-WNV cross-reactive CD8+ T cell 
epitope. (A) Cytotoxic CD8+ T cell lines were generated from JEV-immunized 
splenocytes that were stimulated in vitro with peptide JEV NS4b C. EL-4 targets 
cells were pulsed with indicated concentrations of JEV S9, WNV S9, and WNV 
S10 variant peptides, and added to effector cells at E:T ratio of 15:1. Percent 
specific lysis was calculated as described in Materials and Methods. (B) Peptide-
loaded dimer staining of splenocytes from JEV (left panel) and WNV (right panel) 
-infected mice. Splenocytes were stained with decreasing doses of H-2Db dimer 
loaded with WNV S10, WNV S9 and JEV S9. Percent dimer+ CD3+ CD8+ T cells 
are shown on the y-axis.  
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Figure 3.4. Characterization of CD8+ T cell effector responses to the JEV S9 
and WNV S9 peptides in JEV- and WNV-infected mice. (A) In vivo cytotoxic 
activity was measured in a naïve mouse (left panels) or 8 days after JEV-
infection (right panels). DDAO and CFSE-labeled target cells pulsed with 100-10-2 
μg/ml of JEV S9 (top panels) or WNV S9 (bottom panels) were injected iv and 
spleens were harvested 2 hours later. Target cells pulsed with 1μg/ml of 
influenza NP 366-374 peptide (Flu) serve as a negative control. CFSE is shown 
on x-axis. Percent specific lysis values are indicated on top of each peak and 
were calculated as described in Materials and Methods. (B) Summary of in vivo 
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lysis of peptide-pulsed target cells in JEV-infected mice. JEV S9-pulsed target 
cells (); WNV S9-pulsed target cells (). Horizontal bars represent median 
specific lysis. Flu peptide and unpulsed target cells are not shown. Data are 
compiled from 2 independent experiments (n=2-3 mice per group). (C-E) 
Cytokine profiles of virus-specific and cross-reactive CD8+ T cells during WNV 
and JEV infections.  (C) CD8+ T cells from JEV- and WNV-infected mice were 
analyzed for their ability to produce IFN−γ and TNF-α after stimulation with 1 
μg/ml JEV S9 and WNV S9. Values represent the percentage of IFN−γ+, TNF-α+ 
and IFN−γ+ TNF-α+ CD8+ T cells. Representative data for one mouse per group 
immunized with JEV SA14-14-2 (top row), 1 x 103 pfu JEV Beijing (second row), 
1 x 106 pfu JEV Beijing (third row) or WNV (bottom row). (D) Cumulative data (3 
experiments, 2 spleens pooled per experiment). Bars represent mean ± SEM of 
the percent of CD8+ T cells producing IFN−γ, TNF-α or both IFN−γ and TNF-α 
from mice infected with JEV or WNV following stimulation with JEV S9 (black 
bar) or WNV S9 (white bar). (E) Ratios of IFN−γ+ CD8+ T cells to IFN−γ+ TNF-α+ 
CD8+ T cells from JEV- and WNV-infected mice upon stimulation with JEV S9 
(black bar) and WNV S9 (white bar) peptides. *P<0.05 between WNV-infected 
group and all JEV groups, Mann-Whitney U test. 
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JEV S9 epitope and the cross-reactive WNV S9 variant is a JEV-WNV cross-
reactive CD8+ T cell epitope that is recognized both in vitro and in vivo.  
 
B. CD8+ T cell cytokine profiles depend upon the infecting flavivirus. 
We next examined the frequency of CD8+ T cells that secrete both IFN−γ 
and TNF-α in the context of the specific stimulating variant as well as the 
infecting virus (JEV vs. WNV), in order to determine the contribution of each 
factor to CD8+ T cell cytokine profiles. In both JEV SA-14-14-2 and WNV-infected 
mice, we found that stimulation by either the JEV S9 or WNV S9 variant induced 
both IFN−γ+ and IFN−γ+ TNF-α+ CD8+ T cells, while TNF-α+ CD8+ T cells were 
not detected in either JEV SA14-14-2- or WNV-infected mice (Figure 3.4.C.-D.). 
In JEV SA14-14-2-infected mice, stimulation with the JEV S9 or WNV S9 
peptides induced a higher frequency of single positive IFN−γ+ CD8+ T cells 
compared to double positive IFN−γ+ TNF-α+ CD8+ T cells. In contrast, in WNV-
infected mice, stimulation with either variant induced a higher frequency of 
double positive IFN−γ+ TNF-α+ CD8+ T cells. The ratio of the frequencies of 
IFN−γ+ CD8+ T cells to IFN−γ+ TNF-α+ CD8+ T cells was significantly higher after 
JEV SA14-14-2 infection compared to WNV infection for JEV S9 and WNV S9 
(P<0.05, Mann-Whitney U) (Figure 3.4.E.). No significant difference in this ratio 
was detected between the JEV S9 and WNV S9 variants when compared within 
the same infection. Interestingly, IFN−γ+ TNF-α+ CD8+ T cells from WNV- infected 
mice produced more TNF-α on a per cells basis than those from JEV SA14-14-2 
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infected mice, while levels of IFN−γ in this population were similar for JEV and 
WNV (Table 3.3.).  
 Since JEV SA14-14-2 is an attenuated virus, we next used a pathogenic 
JEV (Beijing strain) to determine if differences in the cytokine profiles between 
JEV and WNV could be explained on the basis of the pathogenicity and dose of 
the infecting virus. We infected mice with a low dose (103 pfu – comparable dose 
to WNV) or a high dose (106 pfu – comparable dose to JEV SA14-14-2) of the 
JEV Beijing. Similar to a JEV S14-14-2 infection, infection with either low or high 
dose JEV Beijing induced a significantly higher frequency of IFN−γ+ CD8+ T cells 
than IFN−γ+ TNF-α+ CD8+ T cells compared to WNV infection (P<0.05, Mann-
Whitney U) (Figure 3.4.C.-E.). Again, no significant difference was detected 
between JEV S9 and WNV S9 peptide variants within the JEV Beijing infections. 
These results suggest that the infecting virus (JEV versus WNV) rather than the 
epitope (JEV S9 versus WNV S9) induced differences in the cytokine profiles of 
epitope-specific CD8+ T cells.  
 
C. Frequency of epitope-specific CD8+ T cells in JEV- and WNV-infected 
mice.  
 To ascertain whether the differences in the cytokine profiles were related 
to different CD8+ T cell kinetics between JEV and WNV infections, we measured 
epitope-specific dimer+ CD8+ T cells 5, 7 and 10 days post-infection in the PBL. 
Rapid expansion of CD44hi dimer+ CD8+ T cells occurred between days 5 and 7
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Table 3.3. Higher TNF-α production on a per cell basis in WNV-infected 
mice compared to JEV-infected mice. Splenocytes from JEV SA14-14-2 or 
WNV infected mice were stimulated with 1 µg/ml of either JEV S9 or WNV S9 for 
5 hours in the presence of brefeldin A. Raw MFI values from 2 experiments (n=2-
3 mice per group) for IFN−γ (left columns) and TNF-α (right columns) using FloJo 
software.  
 
  IFN-γ MFIa TNF-α MFI 
  JEV WNV JEV WNV 
Experiment Mouse 
JEV 
S9 
WNV 
S9 
JEV 
S9 
WNV 
S9 
JEV 
S9 
WNV 
S9 
JEV 
S9 
WNV 
S9 
1 
1 1367b 1190 1317 1402 930 914 1108 1218 
2 1200 1221 1317 1531 836 857 1147 1282 
3 1216 1180 1297 1645 910 869 1115 1222 
2 1 571 587 502 581 425 419 632 669 
2 656 758 634 745 450 427 597 691 
a mean fluorescence intensity (MFI) 
b MFI values were calculated from CD3+ CD8+ T cell expressing IFN−γ or TNF-α  
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with peak levels occurring at day 7 for all infections with the exception of high 
dose JEV Beijing, which peaked at or before day 5 post-infection (Figure 3.5.). 
For JEV SA14-14-2 and low dose JEV Beijing, an approximately 4-8 fold 
contraction in frequency of JEV S9 dimer+ CD8+ T cells occurred between days 7 
and 10, while only a 1-2-fold contraction in frequency of WNV S9 dimer+ CD8+ T 
cells occurred in WNV-infected mice. Similar to the pattern seen for cytokine 
production, infection with JEV induced a higher proportion of cross-reactive WNV 
S9-specific CD8+ T cells than cross-reactive JEV S9-specific CD8+ T cells seen 
after a WNV infection.  Although the peak CD8+ T cell response for high dose 
JEV Beijing occurred earlier, there was no difference in the frequency of IFN-γ+ 
and IFN-γ+ TNF-α+ CD8+ T cells at day 7 for all JEV infections (Figure 3.4.D.). 
These results suggest that the differences in the CD8+ T cell kinetics are not 
related to the altered cytokine profiles that we observe.  
 
D. Phenotype of epitope-specific CD8+ T cells during acute JEV and WNV 
infection.  
Effector CD8+ T cell activation depends on many factors, including antigen 
stimulation and inflammatory conditions (258). To determine whether the 
differences in the cytokine profiles reflect differences in the activation state of 
CD8+ T cells during acute JEV and WNV infections, we examined the phenotype 
of epitope-specific CD8+ T cells over the course of an acute infection. 
Splenocytes from infected mice were harvested on day 5, 7 and 10  
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Figure 3.5. Kinetics of cross-reactive CD8+ T cell expansion and contraction 
during JEV and WNV infection. Mice were infected with (A) JEV SA14-14-2, 
(B) 1 x 103 pfu JEV Beijing, (C) 1 x 106 pfu JEV Beijing, or (D) WNV. Splenocytes 
were harvested on days 5, 7 and 10 post infection and stained with anti-CD3, -
CD8, -CD44 and either JEV S9 () or WNV S9 dimer (). Cells were gated on 
CD3+, CD8+, CD44hi T cells. Percent CD44hi dimer+ CD8+ T cells are shown after 
subtraction of non-specific staining of JEV S9 dimer and WNV S9 dimer in naïve 
mice. Horizontal bars represent mean epitope-specific CD8+ T cell frequency. 
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post-infection, and CD62L, KLRG1 (killer cell lectin-like receptor G1) and CD127 
(IL-7Rα) expression were measured on CD44hi dimer+ CD8+ T cells (Figure 3.6.). 
At day 5, low-level expression of CD62L on dimer+ CD8+ T cells was seen in all 
infections indicating similar levels of CD8+ T cell activation (Figure 3.6.B.). By day 
10, re-expression of CD62L was detected on both JEV and WNV S9 dimer+ 
CD8+ T cells in all JEV groups. However, on day 10 after WNV infection, CD62L 
expression for the cross-reactive JEV S9 population increased while the WNV S9 
dimer+ population had a persistent CD62Llo phenotype (P<0.05, Mann-Whitney 
U).  
KLRG1 and CD127 expression on effector CD8+ T cells are two markers 
used to define CD8+ T cell subsets. KLRG1hi CD127lo CD8+ T cells are defined 
as short-lived effector T cells (SLECs) that die off during the contraction phase 
while KLGR1lo CD127hi CD8+ T cells are memory precursor effector cells 
(MPECs) that survive contraction and differentiate into long-lived memory cells 
(212, 230, 232). KLRG1 expression was upregulated on JEV S9 and WNV S9 
dimer+ CD8+ T cells for all groups as early as day 5, but progressively decreased 
in all of the JEV groups by day 10 (Figures 3.6.B.). In contrast, KLRG1 
expression increased between days 5 and 7 and persisted at high levels through 
day 10 in WNV-infected mice (median day 10 %CD44hi WNV S9 dimer+ KLRG1hi 
= 65.5% in WNV vs. %CD44hi JEV S9 dimer+ KLRG1hi 20.8%, 26.5%, 22.9% for 
1 x 103 pfu, 1 x 106 pfu JEV Beijing, and JEV SA14-14-2, respectively; P<0.05,  
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Figure 3.6. Phenotypes of JEV S9-specific and WNV S9-specific CD8+ T 
cells differ following JEV and WNV infection. (A) Mice were infected with JEV 
SA14-14-2 (top row), 1 x 103 pfu JEV Beijing (second row), 1 x 106 pfu JEV 
Beijing (third row), or WNV (bottom row). Splenocytes were harvested on days 5, 
7 and 10 and expression of CD62L, KLRG1 and CD127 was determined on 
CD3+ CD8+ CD44hi JEV S9 (black line) and WNV S9 (gray line) dimer+ T cells. 
Shaded plot represents expression in naïve mice (representative from 1 naïve 
mouse per day). Each row represents a single representative mouse from each 
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group (n=3-4 infected mice per group per day). (B) Summary of phenotype 
analysis. Percent of CD62Llo (left panels), KLRG1hi (middle panels) and CD127hi 
(right panels) expressing CD44hi CD8+ T cells bound to JEV S9 dimer () or 
WNV S9 dimer (). Median values shown as horizontal line. #P<0.05 between 
WNV and JEV SA14-14-2 or 1x106 pfu JEV Beijing on day 10, P>0.05 between 
WNV and 1x103 pfu JEV Beijing; *P<0.05 between WNV and each JEV group on 
day 7 and day 10, respectively, Mann Whitney U. The mean background level for 
dimer staining was 0.12% for JEV S9 (range: 0.01% to 0.21%) and 0.19% for 
WNV S9 (range: 0.08% to 0.3%). 
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Mann-Whitney U). An inverse pattern was seen for CD127 expression where 
uniform downregulation of CD127 was seen by day 5 in all groups. Re-
expression of CD127 on dimer+ CD8+ T cells occurred by day 10 for both JEV 
SA14-14-2 and JEV Beijing but remained low in WNV-infected mice (median 
%CD44hi CD127hi WNV S9 dimer+ CD8+ T cells = 32.1% in WNV vs. 61.7%, 
62.4%, and 64.8% for 1x103 pfu, 1x106 pfu JEV Beijing, and JEV SA14-14-2, 
respectively; P<0.05, Mann-Whitney U) (Figure 3.6.B.). 
SLEC generation began by day 5 post infection in all groups but peaked 
on different days (Figures 3.7.). For JEV SA14-14-2 and high dose JEV Beijing, 
the highest frequency of SLECs occurred at day 5 (median 25.8% for SA14-14-2 
and 40.2% for 106 Beijing). For low dose JEV Beijing and WNV, the frequency of 
SLECs increased between days 5 and 7. By day 7, 32.2% of dimer+ CD8+ T cells 
were KLRG1hi CD127lo during low dose JEV Beijing infection compared to 58.3% 
of the dimer+ CD8+ T cells after WNV infection (P<0.05 between WNV and all 
JEV groups, Mann Whitney U). At day 5, frequencies of MPECs were low for all 
groups.  At day 7, MPECs increased only in JEV infected mice and by day 10, 
56.0 - 58.0% of the dimer+ CD8+ T cells were KLRG1lo CD127hi (Figure 3.7.B.-
C.). In contrast, during a WNV infection, a majority of the dimer+ CD8+ T cells 
maintained a SLEC phenotype (KLRG1hi CD127lo) with a low frequency of 
MPECs on days 7 and 10 post-infection (P<0.05 between WNV and all JEV 
groups, Mann Whitney U).  
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Figure 3.7. KLRG1 and CD127 expression on JEV S9-specific and WNV S9-
specific dimer+ CD8+ T cells. (A) Mice were infected with JEV or WNV, and 
splenocytes were harvested on the indicated days. Representative data for one 
mouse per group staining for KLRG1 and CD127 are shown. (B-C) Summary 
data for (B) CD44hi dimer+ KLRG1hi CD127lo CD8+ T cells and (C) CD44hi dimer+ 
KLRG1lo CD127hi CD8+ T cells. Data represent the homologous dimer staining 
for each infection from individual spleens (JEV S9 () for JEV infections or WNV 
S9 () for WNV infection). *P<0.05 between WNV and all JEV groups on day 7 
and day 10, respectively, Mann-Whitney U. 
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E. Viral replication of JEV and WNV viruses in tissues. 
We hypothesized that the differences in the cytokine profiles and the 
phenotype of effector CD8+ T cells might be related to differences in viral 
replication. Therefore, we measured viral titers by plaque assay in spleen, serum 
and brain after JEV and WNV infection to determine whether there were 
differences in peripheral (spleen and serum) and CNS replication. On day 3, 
between 6 x 103 -1.3 x 105 pfu/ml and 2 x 104-6 x 104 pfu/g of WNV was detected 
in the serum and spleen, respectively (Figures 3.8.A.-B.). In contrast, we 
detected low titers (500 pfu/g) of JEV in spleens from 1 mouse in each of the low 
and high dose JEV Beijing groups. We were unable to detect virus in the serum 
on day 3 from any of the JEV groups. At day 7 post-infection, we detected high 
titers of virus in brains from mice infected with 106 pfu of JEV Beijing and WNV, 
but not from low dose JEV Beijing or JEV SA14-14-2 infected mice (Figure 
3.8.C). As expected, virus was not detectable in serum on day 7 or in brains on 
day 3 from any group (data not shown).  These results suggest that overall virus 
burden may not be responsible for the altered cytokine profiles and altered 
phenotype responses measured between JEV and WNV but rather reflect 
differences in peripheral replication. 
 
F. Chapter Discussion 
 Altered responses to flavivirus cross-reactive T cell epitopes can affect the 
outcome upon heterologous virus challenge (259). Our model system utilized two  
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Figure 3.8. Virus burden in tissues following JEV and WNV infection. Virus 
titer as assessed by virus plaque assay in (A) serum and (B) spleen at 3 days 
and (C) brain at 7 days post JEV or WNV infection. Each symbol represents a 
single mouse. Horizontal line represents geometric mean titer. 
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viruses in the JEV serogroup, JEV and WNV, which have different clinical 
outcomes on sequential virus infection in NHP (155). Overall, our results 
demonstrate that peptides that are homologous to the immunizing virus induce a 
greater frequency of epitope-specific CD8+ cells and higher levels of cytokine 
production and cytolytic activity than heterologous peptides. However, distinct 
CD8+ T cell functional responses arise depending on the infecting virus (JEV or 
WNV) independent of pathogenicity of the infecting virus or peptide variant.  
We identified a novel immunodominant JEV NS4b H-2Db restricted CD8+ 
T cell epitope that is a variant of a recently published WNV epitope (115, 116). 
We found that both the JEV and WNV variants induced cytokine secretion and 
stimulated lysis of peptide-coated targets in JEV-infected mice. Regardless of the 
infecting virus, we found that the epitope hierarchy was higher for the variant 
peptide corresponding to the infecting virus. In addition, a greater proportion of 
CD8+ T cells were cross-reactive by dimer staining in JEV- versus WNV-infected 
mice. These cross-reactive CD8+ T cells may preferentially expand upon 
secondary heterologous JEV challenge and contribute to virus clearance and 
protection as seen in PV and VV infection of LCMV-immune mice (164, 172).  
We also identified two cross-reactive CD4+ T cell epitopes located in the 
NS1 and NS3 protein. The cross-reactive NS3 epitope is a variant of the WNV 
NS3 epitope previously identified (125). Cross-reactive CD4+ T cells have been 
identified in JEV-immunized individuals and mice, previously (197, 257). CD4+ T 
cells are required for maintenance of antibody responses, sustaining CD8+ T cell 
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responses, and they can also have antiviral properties during a WNV infection 
(115, 124). Interestingly, the cross-reactive epitopes we identified in the NS3 and 
NS1 proteins do not correlate with the total cross-reactive CD4+ T cell response 
in response to the peptide pools (Figure 3.1.). We found that peptides from the 
NS4b, NS2a, and E proteins induced the highest overall IFN−γ+ CD4+ T cell 
response. This difference may be due to multiple peptides in these proteins 
inducing low levels of IFN−γ, which together contribute to a higher response. 
Subdominant T cell epitopes have previously been shown to mediate 
heterologous immunity in the murine LCMV model, but immunodominant 
epitopes may also play a role (166). This has been suggested in human studies 
in which immunodominant HLA-A2-restricted influenza M1-specific CD8+ T cells 
found to be cross-reactive to the Epstein-Barr virus BMLF-1 epitope expand 
during acute infectious mononucleosis (167). Similarly, in our model, CD8+ T 
cells specific for the immunodominant epitope are cross-reactive in both JEV and 
WNV-infected mice. We detected a significantly higher proportion of IFN−γ+ TNF-
α+ -producing CD8+ T cells in mice infected with WNV compared to those 
immunized with both attenuated and pathogenic JEV strains (Figure 3.4.), as well 
as higher TNF-α production on a per cell basis (Table 3.3.). The role of TNF-α in 
WNV infection can be pleiotropic and may lead to resolution of the infection or to 
immunopathology depending on TNF-α levels (106, 260). A higher level of TNF-
α production by CD8+ T cells during acute WNV infection may help contribute to 
their own trafficking into the CNS leading to the control of viral infection in the 
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CNS or increased immunopathology due to the CD8+ T cells. In fact, WNV 
neuroinvasive disease in humans can lead to long term neurological sequelae 
suggesting that virus clearance and immunopathology may not occur 
independently (261).  
The qualitative disparity in cytokine profiles during acute infection with 
closely related viruses may be due to one of several factors: 1) differences in the 
kinetics of the response; 2) differences in the activation state of CD8+ T cells 
during the viral infections; 3) differences in viral burden and/or tissue tropism 
between JEV and WNV. However, the differences in the CD8+ T cell responses 
between JEV and WNV did not correlate with mortality or inoculum dose, 
because all JEV strains, whether attenuated or pathogenic, induced similar CD8+ 
T cell responses. These results suggest that the differences in the cytokine 
profiles of epitope-specific CD8+ T cells are due to intrinsic differences in the 
immune response generated after JEV and WNV infection. 
Kinetic analysis of JEV S9-specific and WNV S9-specific CD8+ T cell 
responses demonstrated that peak CD8+ T cell responses occurred on day 7 
post-infection for all viruses with the exception of infection with high dose JEV 
Beijing (1 x 106 pfu), in which CD8+ T cells peaked on or before day 5. Activation 
state, as demonstrated by downregulation of CD62L, was similar for all groups at 
days 5 and 7 post-infection. However, the increase in SLECs during JEV 
infection was much shorter in duration than what has been reported for acute 
LCMV infection (212). We also found a significantly higher proportion of KLRG1hi 
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CD127lo SLECs after WNV infection on day 7 compared to all JEV virus 
infections, and these differences persisted to day 10 post-infection. These 
findings are in contrast to those reported by Brien et al., in which WNV S9 dimer+ 
CD127hi CD8+ T cells predominated at day 7 after WNV infection (115). That 
study used a different WNV strain, a lower dose of virus (20-600 pfu) and a 
different route of administration (sc), which may have impacted the kinetics of 
virus replication, inflammation derived from this virus replication, and subsequent 
effector CD8+ T cell generation.   
As expected, replication of the attenuated JEV SA14-14-2 strain in 
peripheral tissues was below the level of detection in viral plaque assay (Figure 
3.8) (62). However, unexpectedly, infection with low or high dose JEV Beijing 
also resulted in minimal peripheral virus replication on day 3, whereas high dose 
JEV Beijing infection resulted in very high titers of virus in brains on day 7 post-
infection. This lack of peripheral replication by JEV was also recently seen in 
another B6 mouse model using a different JEV strain (Nakayama) and route of 
infection (sc) (95). In contrast, WNV was easily detectable in serum and spleen 
on day 3 as well as in brains at day 7. The ability of WNV to replicate in the 
peripheral lymphoid tissues early during infection may alter the inflammatory 
milieu and programming of the CD8+ T cell response. IL-12, type I IFN, and IL-2 
are inflammatory cytokines known to influence the generation of CD8+ T cells 
and SLECs, and the levels of these cytokines may differ during a JEV and WNV 
infection (212, 217, 225, 227-229). The persistence of KLRG1hi CD127lo SLECs 
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and a higher frequency of epitope-specific CD8+ T cells in a WNV infection may 
reflect prolonged antigenic stimulation or increased inflammatory responses due 
to persistent WNV as has been described in B6 mice and other WNV animal 
models (24, 25, 28).  
 
G. Chapter Summary 
We have identified JEV and WNV cross-reactive CD4+ and CD8+ T cell 
epitopes in B6 mice. In our model, the immunodominant CD8+ T cell epitope was 
found to be cross-reactive, however primary infections with JEV and WNV give 
rise to quantitatively and qualitatively distinct CD8+ T cell responses.  These 
differences in the primary immune response to JEV and WNV may contribute to 
differences in secondary immune responses to sequential flavivirus infection. The 
next chapter will focus on the kinetics of the JEV-WNV cross-reactive CD8+ T cell 
epitope during secondary heterologous infections. 
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CHAPTER IV 
 
SEQUENCE OF INFECTION DETERMINES CROSS-REACTIVE CD8+ T CELL 
RESPONSES DURING SECONDARY HETEROLOGOUS FLAVIVIRUS 
INFECTION 
 
Cross-protection between JEV and WNV has been established in multiple 
models, but the contributions of memory CD8+ T cells to this cross-protection has 
not been established (Trobaugh et al., in preparation) (153-155, 157-159). 
Previous work has implicated that prior immunity to WNV will only partially 
protect against JEV (155). It is known that memory cross-reactive CD8+ T cells 
proliferate upon 2o heterologous infection and can contribute to either protection 
or immunopathology (164, 166, 171, 172). Therefore, in order to better 
understand cross-protection between JEV and WNV, we focused on cross-
reactive CD8+ T cell responses during secondary infections.  
In the previous chapter, we identified a cross-reactive CD8+ T cell epitope, 
JEV S9 and WNV S9, which is immunodominant during their respective primary 
infections. This chapter will focus on the kinetics of cross-reactive CD8+ T cell 
expansion during 2o heterologous infection, and possible explanations for the 
differences in proliferation seen in JEV- and WNV- immune mice upon 2o 
heterologous infection. 
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A. Establishing lethal and non-lethal JEV models in B6 mice. 
 Previous JEV models used weaning mice, intracranial inoculation, and 
outbred mice to study JEV pathogenesis (91-94, 262). However, these models 
are not conducive for studying the adaptive immune responses to JEV, and the 
subsequent mechanisms behind cross-protection between JEV and WNV. 
Therefore, we wanted to establish both a non-lethal (primary infection) and a 
lethal (secondary infection) model of JEV in B6 mice. B6 mice were initially 
infected at 5-6 weeks of age, and the surviving mice were rested 4-6 weeks to 
generate memory CD4+ and CD8+ T cells. At 9-11 weeks old, mice were 
administered a secondary infection with a lethal dose of the heterologous virus.  
  We initially tested two different pathogenic JEV strains, Nakayama and 
Beijing, for their ability to induce mortality in B6 mice. B6 mice (6-7 weeks old) 
were infected with 1 x 106 pfu of JEV Nakayama or 5 x 106 pfu of JEV Beijing and 
monitored for survival. Even though different titers were used, both JEV 
Nakayama and JEV Beijing induced similar mortality rates (80% mortality, 4/5 
mice) suggesting that both strains could be used for our lethal model (Figure 
4.1.A.). We ultimately chose to use JEV Beijing in our model of lethal infection 
due to the higher titers of the viral stocks. For the cross-protection model, in 
which JEV was the primary infecting virus, we needed a dose of JEV Beijing that 
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Figure 4.1. Establishing lethal and non-lethal JEV models in B6 mice. 
(A) Identification of JEV strain. B6 mice (6-7 weeks old) were infected with JEV 
Nakayama (1 x 106 pfu) or JEV Beijing (5 x 106 pfu) ip, and monitored for 
survival, n=5 mice/group. (B) B6 mouse susceptibility to low and high dose JEV 
Beijing infection. B6 mice (5-6 weeks old) were infected with a low dose (1 x 103 
pfu, N=67 mice) or high dose (1 x 106 pfu, N=20 mice) of JEV Beijing ip. 
**P<0.001, Log-Rank Test (C) Age-specific differences in JEV susceptibility. B6 
mice were infected with 1 x 106 pfu (n=5 mice/age group) or 1 x 107 pfu (11 
weeks old; N=15 mice). 
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would increase the likelihood of survival, but would still induce a potent immune 
response. When B6 (5-6 weeks old) mice were infected with a low dose of JEV 
Beijing (1 x 103 pfu), we saw a 25.4% mortality rate, while a high dose (1 x 106 
pfu) increased the mortality to 60% (Figure 4.1.B). This is in contrast to a recent 
report by Larena et al. that demonstrated no such dose dependence upon the 
mortality rate for JEV.  However, differences between out study and theirs, such 
as virus strains (Nakayama versus Beijing) and different routes of infection (sc 
versus ip) may contribute to these disparate findings (95). As seen in Figure 3.4. 
and Figure 3.5., infection with either low dose or high dose JEV Beijing induced 
similar epitope-specific CD8+ T cell responses. Therefore, due to the lower 
mortality rate, we chose to use the low dose infection to generate our primary 
JEV-immune responses. 
Figure 4.1.C. also demonstrates the difficulties that we had in using JEV 
as a lethal model, as the susceptibility to JEV varied from experiment to 
experiment. B6 mice (7 weeks old) only had a 10% mortality rate compared to 5-
6 week old mice, which had a 60% mortality rate, when given the same dose of 1 
x 106 pfu of JEV. In fact, susceptibility to JEV Beijing infection actually increased 
as the mice increased in age from 7-week old mice (10% mortality) to 10-week 
old mice (60% mortality), which is contrary to the dogma that resistance to 
flavivirus infection in mice increases with age (unpublished observations) (263). 
When we increased the dose of virus to 1 x 107 pfu and infected the oldest mice 
(11-weeks old), we saw an increase in mortality to 73.3% (Figure 3.1.C.). These 
 83 
results demonstrated that JEV Beijing induced mortality when administered ip in 
10-11 week old mice, and could be used in our cross-protection model as a 
secondary challenge virus. 
  
B. Cross-protection after sequential WNV and JEV infections.  
Prior work in our group has demonstrated that a live attenuated JEV 
SA14-14-2 infection could protect against a lethal WNV challenge (Trobaugh et 
al., in preparation). We wanted to extend these results to determine whether prior 
WNV immunity would protect against a lethal JEV challenge in B6 mice. B6 mice 
(5-6 weeks old) were infected with WNV (1 x 103 pfu) or PBS (control) and 
monitored daily for survival.  Mice that survived the primary infection were 
allowed to rest for 5 weeks to generate a memory response. Thirty-five days after 
the primary infection, the mice were infected with a lethal dose of JEV Beijing (1 
x 107 pfu).  We found that WNV-immune mice were significantly protected 
against a lethal JEV challenge (87.5% survival) compared to PBS controls 
(42.1% survival, P<0.01, Log Rank Test) (Figure 4.2.A).  
To determine whether the pathogenicity of JEV (SA14-14-2 versus 
Beijing) altered cross-protection to WNV, JEV Beijing-immune mice were infected 
with a lethal dose of WNV. Similar to JEV SA14-14-2-immune mice, JEV Beijing 
immune mice were significantly protected against a lethal WNV infection (100% 
survival) compared to PBS controls (66.7% survival; P<0.05, Log- Rank Test), 
suggesting the pathogenicity of the primary infection does not alter cross-  
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Figure 4.2. Cross-protection during sequential JEV and WNV infections. (A) 
WNV-immune mice are protected against lethal JEV infection. WNV-immune 
(n=16 mice, blue square) or PBS control (N=19 mice, black triangle) mice were 
infected with 1 x 107 pfu JEV Beijing and monitored for survival. The ratio 
indicates the number of mice succumbing to the infection in each group. *P<0.01, 
Log-Rank Test. (B) JEV Beijing-immune mice are protected against WNV 
infection. JEV immune mice (N=14 mice, red square) or PBS (N=12 mice, black 
triangle) were infected with 1 x 106 pfu WNV and monitored for survival. *P<0.05, 
Log-Rank Test. 
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protection to WNV (Figure 4.2.B). These results suggest that, in contrast to 
NHPs, there is bidirectional cross-protection between JEV and WNV in mice, and 
further work to understand the mechanisms of this cross-protection is warranted 
(155).  
 
C. Can cross-reactive CD4+ and/or CD8+ T cells protect against a WNV 
infection? 
 Our group has shown that depletion of CD4+ and CD8+ T cells in JEV-
immune mice abrogated cross-protection against WNV (Trobaugh et al., in 
preparation). CD8+ T cells are required for survival against a primary WNV 
infection due to inefficient clearance of virus from peripheral tissues (109). 
Adoptive transfer of a WNV S9-specific CD8+ T cell line protected 
immunodeficient mice from mortality after a low dose WNV infection; however, 
adoptive transfer of two WNV CD8+ T cell lines was required to fully protect 
immunocompetent mice (115, 116). These results demonstrate that CD8+ T cells 
can protect against a lethal WNV infection. Therefore, we wanted to determine 1) 
whether JEV-immune CD4+ and CD8+ T cells are sufficient to protect against a 
WNV infection and/or 2) whether JEV S9-specific and WNV S9-specific CD8+ T 
cells can restrict WNV viremia.  
 JEV SA14-14-2-immune CD4+ and CD8+ T cells were adoptively 
transferred into naïve B6 mice and challenged with a 100LD50 of WNV (1.26 x106 
pfu).  JEV-immune CD4+ and/or CD8+ T cells were transferred in combination 
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with naïve CD4+ and/or CD8+ T cells in order to transfer an equal number of cells 
into naïve mice. Ch-WN- and JEV SA14-14-2-immune mice were protected 
against a lethal WNV infection, similar to previous reports (Figure 4.3.A.) 
(Trobaugh et al., in preparation) (77). Adoptive transfer of JEV-immune CD4+ T 
cells with naïve CD8+ T cells or naïve CD4+ T cells with JEV-immune CD8+ T 
cells resulted in only 12.5% survival. However, mice receiving both JEV-immune 
CD4+ T cells and JEV-immune CD8+ T cells were partially protected from WNV 
infection (37.5% survival rate, P=0.07 compared to PBS, Log-Rank Test). Finally, 
PBS control mice and mice receiving naïve CD4+ and naïve CD8+ T cells were 
100% susceptible to WNV infection by day 10 and day 11, respectively (Figure 
4.3.A). These data suggest that JEV-immune CD4+ and CD8+ T cells are not 
sufficient to fully protect against a high dose WNV infection; however, these 
results do not rule out the possibility that JEV-immune CD4+ and CD8+ T cells 
might protect against a low dose WNV infection.  
Since adoptive transfer of JEV-immune CD4+ and CD8+ T cells partially 
protected against a high dose WNV infection, we wanted to determine whether 
JEV S9-specific and WNV S9-specific CD8+ T cells could reduce levels of WNV 
in the serum and brain after WNV infection. For this experiment, we utilized 
recombinant vaccinia viruses (rVV) expressing the JEV S9 epitope (rVV JEV), 
WNV S9 epitope (rVV WNV) or GFP alone (rVV GFP) to generate epitope-
specific CD8+ T cells. B6 mice were immunized with 5 x 106 pfu of rVV WNV, rVV 
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Figure 4.3. Cross-reactive CD8+ T cells are not sufficient to fully protect 
from WNV mortality. (A) JEV immune CD4+ and CD8+ T cells partially protect 
against WNV infection. CD4+ and CD8+ T cells from JEV-immune or naïve mice 
were adoptively transferred into naïve mice, which were then infected with 1 x 
106 pfu WNV. Ch-WNV and JEV SA14-14-2 immune mice and PBS served as 
positive and negative controls, respectively. N=8 mice/group. (B-C). JEV S9-
specific and WNV S9-specific CD8+ T cells do not restrict WNV replication. B6 
mice were infected with 5 x 106 pfu rVV-WNV, rVV-JEV or rVV-GFP, and 4-5 
weeks later, the mice were challenged with 1 x 103 pfu of WNV.  WNV titers in 
the serum on day 3 (B) and brain on day 7 (C) were measured by plaque assay. 
 88 
JEV, rVV GFP or PBS (control), and after 4-5 weeks, the mice were challenged 
with a low dose (1 x 103 pfu) of WNV. WNV levels were measured on day 3 in the 
serum, and day 7 in the brain by plaque assay. Immunization with rVV WNV and 
rVV JEV did not reduce WNV levels in the serum on day 3 compared to rVV GFP 
immunization and PBS control mice (Figure 4.3.B.). These results are similar to 
those of Shrestha et al., in which CD8+ T cells were not able to reduce levels of 
WNV in the serum (109).  
We next analyzed WNV levels in the brain of these mice to determine 
whether homologous or heterologous memory CD8+ T cells might restrict viral 
dissemination of homologous and heterologous virus into the brain. After the low 
dose WNV infection, only 50% of the PBS control and 40% of rVV GFP 
immunized mice had detectable WNV levels in the brain (Figure 4.3.C.). In the 
rVV WNV-immunized mice, in which virus was detectable, lower levels of WNV 
were seen compared to the PBS controls suggesting that WNV S9-specific CD8+ 
T cells were able to restrict viral dissemination into the CNS. However, rVV GFP-
immunized mice also had lower levels of WNV in the brain similar to rVV WNV 
immunized mice, therefore we cannot conclusively determine that WNV S9-
specific CD8+ T cells restrict WNV entry into the brain. WNV levels in rVV JEV-
immunized mice were similar to those measured in PBS controls suggesting that 
JEV S9-specific CD8+ T cells alone are not able to restrict heterologous WNV 
virus entry into the brain, and JEV-specific CD4+ T cells may also be required to 
prevent WNV entry into the brain. Since JEV viremia is not detectable in our 
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model, we were unable to determine whether JEV S9-specific and WNV S9-
specific CD8+ T cells were able to restrict JEV in the serum. In addition, a very 
high dose of JEV is required for efficient viral entry into the brain (Figure 3.8.C.), 
which may preclude the ability to detect a role for CD8+ T cells in restricting viral 
dissemination. Taken together, these results suggest that cross-reactive JEV S9-
specific CD8+ T cells alone are not sufficient to protect against peripheral 
replication and dissemination of WNV.  
 
D. Cross-reactive CD8+ T cell responses during sequential JEV and WNV 
infections. 
Next, we wanted to understand the kinetics of the cross-reactive CD8+ T 
cell response during sequential JEV and WNV infection. B6 mice were infected 
with JEV or WNV and allowed to generate a memory response for 5 weeks. The 
mice were then infected with a lethal dose of the corresponding heterologous 
flavivirus (JEV-immune: 1 x 106 pfu WNV; WNV-immune: 1 x 107 pfu JEV). JEV 
S9-specific and WNV S9-specific CD8+ T cells were measured in the peripheral 
blood lymphocytes (PBL) by H-2Db dimer staining over the course of the 
infection. At the memory time point prior to 2o infection, WNV-immune mice had a 
significantly higher mean starting frequency of JEV S9-specific and WNV S9-
specific CD8+ T cells compared to JEV-immune mice (mean ± SEM: WNV-
immune: JEV S9: 1.21% ± 0.25%, WNV S9: 3.53% ± 0.97%; JEV-immune:  
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Figure 4.4. Cross-reactive JEV S9-specific and WNV S9-specific CD8+ T cell 
kinetics during 2o infection. (A) Limited proliferation of WNV-immune CD8+ T 
cells upon 2o JEV infection. JEV-immune (n= 14 mice/time point, red circle) or 
PBS control (n=12 mice, open circle) mice were infected with 1 x 106 pfu, and 
WNV-immune (n=11-12 mice, blue squares) or PBS control (n=11-14 mice, open 
square) mice were infected with 1 x 107 pfu JEV. WNV S9 (left panel) and JEV 
S9 (right panel) dimer+ CD44hi CD8+ T cells were measured in the PBL on day -
1/0, 3, 5, and 7. P<0.001 between 1o JEV immune mice and all other groups, 
Mann-Whitney U. (B) CD43 expression on JEV S9-specific and WNV S9-specific 
CD44hi CD8+ T cells following 2o infection. (C) KLRG1 expression on JEV S9-
specific and WNV S9-specific CD44hi CD8+ T cells following 2o infection. (D). 
CD127 expression on JEV S9-specific and WNV S9-specific CD44 hi CD8+ T cells 
following 2o infection. 
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JEV S9: 0.48% ± 0.04%, WNV S9: 0.22 ± 0.04%; P<0.01, Mann-Whitney U) 
(Figure 4.4.A.). WNV infection of JEV-immune mice resulted in expansion of both 
JEV S9-specific and WNV S9-specific CD8+ T cells by day 5 after infection, 
resulting in significantly higher frequencies of both JEV S9-specific and WNV S9-
specific CD8+ T cells compared to WNV infection of PBS controls (mean ± SEM 
on day 5: JEV-immune: JEV S9: 10.00% ± 0.82%; WNV S9: 12.83% ± 0.97%; 
PBS: JEV S9: 0.51% ± 0.11%; WNV S9: 1.26% ± 0.21%; P<0.001, Mann-
Whitney U) (Figure 4.4.A). By day 7, the frequency of JEV S9-specific and WNV 
S9-specific CD8+ T cells continued to increase in PBS control mice typical of a 
primary immune response (mean ± SEM: JEV S9: 1.60% ± 0.23%; WNV S9: 
6.43% ± 0.61%). In JEV-immune mice, only the frequency of WNV S9-specific 
CD8+ T cells continued to increase on day 7, while the frequency of JEV S9-
specific CD8+ T cells remained constant between day 5 and day 7 (mean ± SEM: 
JEV S9: 10.26% ± 1.11%; WNV S9: 17.60% ± 1.72%).   
In contrast to heterologous infection of JEV-immune mice, there was very 
little proliferation of memory JEV S9-specific and WNV S9-specific CD8+ T cells 
by day 5 after JEV infection of WNV-immune mice (Figure 4.4.A.) The frequency 
of WNV S9-specific CD8+ T cells on day 5 was not significantly different than the 
frequency at day 0 (mean ± SEM: Day 0: 3.53% ± 0.97%; Day 5: 3.93% ± 0.45%; 
P=0.9, Mann-Whitney U). There was a small but significant increase in the 
frequency of JEV S9-specific CD8+ T cells in WNV-immune mice upon JEV 
infection by day 5 (mean ± SEM: Day 0: 1.21% ± 0.25%; Day 5: 1.92% ± 0.18%; 
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P<0.05, Mann-Whitney U), suggesting there may be low levels of proliferation in 
WNV-immune mice by day 5. Interestingly by day 7, the frequency of JEV S9-
specific and WNV S9-specific CD8+ T cells continued to increase in both WNV-
immune and PBS controls (mean ± SEM: WNV-immune: JEV S9: 7.46% ± 
0.87%; WNV S9: 10.99% ± 1.57%; PBS: JEV S9: 6.55% ± 1.11%; WNV S9: 
4.18% ± 0.93%). This pattern of expansion paralleled the epitope-specific CD8+ T 
cell kinetics seen during a primary JEV infection of PBS control mice suggesting 
that JEV infection of WNV-immune mice resulted in a 1o immune response rather 
than a 2o memory response.   
 Expression of CD43 is upregulated during an acute infection on effector 
CD8+ T cells, and is required for trafficking of CD8+ T cells to peripheral tissues 
and downregulation of the immune response (264, 265). Low CD43 expression 
on memory CD8+ T cells corresponds to better recall responses during 2o 
infection (264, 266). We saw similar low levels of CD43 expression on JEV S9-
specific and WNV S9 CD8+ T cells at the memory time point (day 0) in both JEV-
immune and WNV-immune mice (Figure 4.4.B). In JEV-immune mice, CD43 
expression was significantly higher on both JEV S9-specific and WNV S9-
specific CD8+ T cells on day 3 after 2o WNV infection compared to PBS control 
mice (mean ± SEM: JEV-immune: JEV S9: 32.9% ± 1.6%; WNV S9: 38.0% ± 
2.4%; PBS: JEV S9: 15.1% ± 3.1%; WNV S9: 14.9% ± 3.7%; P<0.001, Mann 
Whitney U). CD43 expression peaked earlier in JEV-immune mice (day 5) 
compared to PBS controls (day 7) upon 2o WNV infection. It was found 
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previously that conversion of effector CD8+ T cells to memory CD8+ T cells 
expressing low levels of CD43 occurs earlier in low inflammatory conditions, 
suggesting that inflammation in JEV-immune mice may be lower than in PBS 
controls upon 2o WNV infection (267). 
In WNV-immune mice following 2o JEV infection, expression of CD43 on 
JEV S9-specific and WNV S9-specific CD8+ T cells was not detected until day 5, 
two days later than occurred during WNV infection of JEV-immune mice (Figure 
4.4.B). This expression pattern of CD43 was similar to that seen in JEV infection 
of PBS control mice. Therefore, expression of CD43 was seen prior to the 
expansion of epitope-specific CD8+ T cells, in the context of both primary and 
memory responses.  
A significantly higher frequency of both JEV S9-specific and WNV S9-
specific CD8+ T cells in WNV-immune mice expressed KLRG1 compared to JEV-
immune mice at the memory time point (day 0) (mean % KLRG1+ CD8+ T cells ± 
SEM: JEV-immune: JEV S9: 15.1% ± 1.6%; WNV S9: 11.8% ± 2.1%; WNV-
immune: JEV S9: 56.5% ± 7.9%; WNV S9: 62.7% ± 7.4%; JEV S9: P<0.01, WNV 
S9: P<0.001, Mann Whitney U) (Figure 4.4.C). In JEV-immune mice following 2o 
WNV infection, JEV S9-specific and WNV S9-specific CD8+ T cells upregulated 
KLRG1 and downregulated CD127 expression by day 5 after infection, 
suggesting rapid conversion to an SLEC phenotype, KLRG1+ CD127low (Figure 
4.4.C.-D.). In WNV-immune, since a majority of the epitope-specific CD8+ T cells 
already expressed KLRG1, there was only a slight increase in the frequency of 
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KLRG1+ CD8+ T cells by day 7 following 2o JEV infection. However, expression 
of CD127 was downregulated in these mice, which suggests that activation of 
these epitope-specific CD8+ T cells occurred in WNV-immune mice in the 
absence of proliferation. CD8+ T cells in JEV and WNV infection of PBS control 
mice converted to KLRG1+ and CD127low between days 5 and days 7 after 
infection, confirming that the majority of the cells exhibited a SLEC phenotype 
after primary infection.  
Together, these results suggest that activation of JEV S9-specific and 
WNV S9-specific memory CD8+ T cells occurs earlier in JEV-immune mice 
compared to WNV-immune mice following 2o heterologous viral infection. The 
expression patterns of the activation markers CD43, KLRG1, and CD127, 
corresponded with earlier proliferation of memory CD8+ T cells in JEV-immune 
mice. This lack of proliferation, and expression of activation markers in WNV-
immune mice occurred even though a higher frequency of memory CD8+ T cells 
were present when compared to JEV-immune mice prior to 2o infection.   
 
E. WNV infection induces neutralizing antibodies to JEV. 
 Cross-reactive neutralizing antibodies between JEV and WNV can be 
detected after repeated vaccine immunizations and the infection of 
immunodeficient hosts (74, 89, 158, 159). We wanted to determine whether 
infection with pathogenic JEV or WNV would induce cross-reactive neutralizing 
antibodies that might be restricting virus replication and thereby influencing the 
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Figure 4.5. PRNT50 neutralizing antibody titers to JEV and WNV. Each serum 
sample was tested for in vitro neutralizing activity to both WNV and JEV.  Serum 
was collected 1-8 months post (A) 1o WNV (N=15), (B) 1o JEV (N=6), (C) 1o 
WNV 2o JEV (N=7), and (D) 1o JEV 2o WNV (N=7) infection. Black line 
represents geometric mean of PRNT while dashed line represents the limit of 
detection (LOD) tested (1:20 dilution).  
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proliferation of memory CD8+ T cells. Sera from JEV- and WNV-immune mice (1-
8 months after infection) were tested for neutralizing activity to both JEV and 
WNV in vitro. As expected, JEV and WNV infection induced high levels of 
neutralizing antibodies to their homologous virus strains as measured by 50% 
plaque reduction neutralization test (PRNT50) values (Figure 4.5.A.-B.).  
Interestingly in WNV-immune mice, we detected low levels of JEV 
neutralizing antibodies in all but two mice (Figure 4.5.A). This is in contrast to 
JEV-immune mice, in which neutralizing antibodies to WNV were not detectable 
(Figure 4.5.B.). These experiments do not rule out the possible presence of very  
low levels of antibodies to WNV in JEV-immune mice (LOD in our assay was 
1:20).  
Sera were also collected from JEV- and WNV-immune mice 1 to 6 months 
after secondary heterologous infection. After 2o JEV infection of WNV-immune 
mice, we measured only a modest boost in neutralizing antibodies to JEV (Figure 
4.5.C.). This level of neutralizing antibodies was lower than that seen after a 1o 
JEV infection, suggesting that JEV neutralizing antibodies in WNV-immune mice 
may be inducing partial immunity to JEV and restricting virus replication. In 
contrast, WNV infection of JEV-immune mice resulted in the induction of high 
levels of neutralizing antibodies to WNV, similar to levels seen after 1o WNV 
infection (Figure 4.5.D.). These results suggest that 1) low levels of WNV 
neutralizing antibodies in JEV-immune mice were boosted to higher levels after 
WNV infection or 2) WNV infection of JEV-immune mice generated a 1o humoral 
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response. These findings support the notion that the presence of JEV 
neutralizing antibodies in WNV-immune mice leads to virus restriction, and may 
at least partially explain differences in CD8+ T cell proliferation in WNV-immune 
mice upon 2o JEV infection. 
 
F. WNV S9-specific and JEV S9-specific CD8+ T cells do not proliferate in 
WNV-immune mice, even in the absence of cross-reactive neutralizing 
antibodies. 
 Since we detected cross-reactive neutralizing antibodies to JEV in WNV-
immune mice, we next needed to determine whether antibody-dependent 
restriction of virus was the sole mechanism for the lack of proliferation of JEV S9-
specific and WNV S9-specific CD8+ T cells in WNV-immune mice. We 
hypothesized that infection of WNV-immune mice with rVV WNV and rVV JEV, 
which would not be neutralized by WNV, would result in the proliferation of JEV 
S9-specific and WNV S9-specific CD8+ T cells. To test this hypothesis, JEV- and 
WNV-immune mice were infected with a high dose (5 x 106 pfu) of the rVVs, and 
the frequency of JEV S9-specific and WNV S9-specific CD8+ T cells were 
measured in the PBL on day 0 and day 5 after 2o infection.  
We found that infection of JEV-immune mice with the homologous rVV 
JEV resulted in a 29.3 and 25.1 fold expansion of JEV S9-specific and WNV S9-
specific CD8+ T cells, respectively (Figure 4.6.A). A similar fold expansion was 
seen after infection with the heterologous rVV WNV virus (JEV S9: 19.8x; 
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Figure 4.6. Limited proliferation of JEV S9-specific and WNV S9-specific 
CD8+ T cells in WNV-immune mice after 2o rVV infection. (A) Rapid 
proliferation of JEV S9 and WNV S9 CD8+ T cells in JEV-immune mice. JEV-
immune (1o JEV) mice were infected with 5 x 106 pfu rVV JEV (2o rVV JEV, left 
panel), rVV WNV (2o rVV WNV, middle panel), or rVV GFP (2o rVV GFP, right 
panel). JEV S9-specific and WNV S9-specific CD44hi CD8+ T cells were 
measured on day 0 (D0) and day 5 (D5) after infection in the PBL (B) Limited 
proliferation of JEV S9 and WNV S9 CD8+ T cells after 2o rVV infection in WNV-
immune mice. Numbers represent fold expansion from D0 to D5 in the frequency 
of epitope-specific CD8+ T cells. 
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WNV S9: 34.5x). This level of expansion was similar to that seen after WNV 
infection of JEV-immune mice (Figure 4.4.A). 
 If JEV neutralizing antibodies were restricting JEV replication and thereby 
limiting the proliferation of epitope-specific CD8+ T cells in WNV-immune mice, 
we anticipated that rVV JEV infection would result in the proliferation of JEV S9-
specific and WNV S9-specific CD8+ T cells. Interestingly, JEV S9-specific and 
WNV S9-specific CD8+ T cells in WNV-immune mice did not proliferate to the 
same extent as that seen in JEV-immune mice upon rVV WNV infection (Figure 
4.6.B.). We saw only a 2.6 and 1.3 fold expansion in JEV S9-specific and WNV 
S9-specific CD8+ T cells after rVV JEV infection, respectively. A similar fold 
expansion was seen in WNV-immune mice after homologous rVV WNV infection 
(JEV S9: 2.4x; WNV S9: 2.3x). rVV GFP infection of JEV- and WNV-immune 
mice did not result in the expansion of JEV S9-specific and WNV S9-specific 
CD8+ T cells. Therefore, limited proliferation of JEV S9-specific and WNV S9-
specific CD8+ T cells occurred in WNV-immune mice even in the absence of 
neutralizing antibodies. These results suggest that the difference in the 
proliferation of JEV S9-specific and WNV-specific S9 CD8+ T cells upon 2o 
heterologous infection is intrinsic to the CD8+ T cell population in WNV-immune 
mice.   
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G. WNV-immune CD8+ T cells are not functionally exhausted in the spleen. 
 
 Previous reports have demonstrated that WNV virus and/or RNA may 
persist in mice, monkeys and humans (24, 25, 28-30). Antigen persistence can 
lead to the exhaustion of epitope-specific CD8+ T cells and expression of 
programmed death-1 (PD-1) (268). Therefore, we hypothesized that the lack of 
CD8+ T cell proliferation in WNV-immune mice upon 2o JEV infection is due to 
exhaustion of epitope-specific CD8+ T cells.  
To test this hypothesis, we analyzed JEV S9-specific and WNV S9-
specific CD8+ T cells in the spleen and brain for expression of PD-1 in WNV-
immune B6 mice (4-5 weeks post infection). We found a higher percentage of the 
CD8+ T cells in the brain were specific for the JEV S9 and WNV S9 tetramer 
compared to CD8+ T cells in the spleen (mean ± SEM: CNS: JEV S9: 10.36% ± 
1.13%, WNV S9: 24.70% ± 2.63%; Spleen: JEV S9: 0.78% ± 0.11%, WNV S9: 
2.49% ± 0.32%, N=4 mice) (Figure 4.7.A.-B.). Contrary to previously published 
results using the C3H mouse strain, we found cross-reactive CD8+ T cells by 
tetramer analysis in the CNS of WNV-immune mice (269).  
All of the CD8+ T cells in the brain were activated CD8+ T cells expressing 
CD44, however, only a fraction of the CD8+ T cells in the spleen were CD44hi, 
with all of the tetramer positive cells residing in this population (Figure 4.7.A). 
Interestingly, we also saw differences in the expression of KLRG1 between the 
CNS and spleen. In the spleen, 54.4% ± 2.7% (mean ± SEM) of the WNV S9-
specific CD8+ T cells expressed KLRG1 compared to only 13.0% ± 1.6% in the  
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Figure 4.7. WNV-immune CD8+ T cells are not functionally exhausted in the 
spleen. (A-B) Frequency and phenotype of epitope-specific CD8+ T cells in the 
spleen and brain harvested from WNV-immune mice 4-5 weeks post infection. 
JEV S9-specific and WNV S9-specific CD44hi CD8+ T cells in the brains and 
spleen were analyzed for KLRG1, CD127 and PD-1 expression. (A) 
Representative plots from 1 mouse. (B). Summary plots for tetramer frequency 
surface phenotype expression. (C) Memory CD8+ T cells in JEV- and WNV-
immune mice secrete cytokines. Splenocytes from JEV-immune (top row) and 
WNV-immune (bottom row) mice were stimulated with media (left panels), 1 
µg/ml JEV S9 (middle panels) and 1 µg/ml WNV S9 (right panels), and IFN−γ (y-
axis) and TNF-α (x-axis) production was measured. (D). CD8+ T cell responses 
following 2o infection. Splenocytes from 1o JEV 2o WNV (top row) and 1o WNV 2o 
JEV (bottom row) infected mice on day 7 after 2o infection were stimulated with 
media (left panels), 1 µg/ml JEV S9 (middle panels) and 1 µg/ml WNV S9 (right 
panels), and IFN−γ (y-axis) and TNF-α (x-axis) production was measured. 
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CNS (Figure 4.7.B.). Although we saw tissue-specific differences in KLRG1 
expression, JEV S9-specific and WNV S9-specfic CD8+ T cells in both the spleen 
and brain had similar expression levels of CD127. 
We detected low levels of PD-1 expression on JEV S9-specific and WNV 
S9-specficCD8+ T cells in the spleen (Figure 4.7.B.). However, there was an 
increase in the percentage of JEV S9-specficand WNV S9-specficCD8+ T cells 
expressing PD-1 in the brain (mean ± SEM: JEV S9: 22.4% ± 4.8%; WNV S9: 
25.6% ± 4.2%) (Figure 4.7.B.). This modest expression of PD-1 on epitope-
specific CD8+ T cells in the brain is in contrast to that seen in a chronic LCMV 
infection in which a majority of epitope-specific CD8+ T cells in the CNS express 
PD-1 (270). These results demonstrate that CD8+ T cells in the CNS and spleen 
of WNV-immune mice have different phenotypes, and only CD8+ T cells in the 
brain, a site of viral persistence, expressed PD-1, albeit at low levels (24). 
 A hallmark of exhausted CD8+ T cells is their inability to secrete cytokines 
upon peptide stimulation (271). Therefore, we next wanted to determine whether 
WNV-immune CD8+ T cells were functional at memory time points and after 2o 
infection. Similar to our analysis of the PBL (Figure 4.4.A), WNV-immune mice 
exhibited a higher frequency of both JEV S9-specific and WNV S9-specific CD8+ 
T cells that secreted cytokines compared to JEV-immune mice at the memory 
time point (Figure 4.7.C.). JEV-immune CD8+ T cells converted from secreting 
only IFN−γ during the primary immune response (Figure 3.4.), to secreting both 
IFN−γ and TNF-α upon JEV S9 and WNV S9 peptide stimulation. WNV-immune 
 103 
CD8+ T cells were also multifunctional, secreting both IFN−γ and TNF-α at the 
memory time point, confirming that WNV-immune CD8+ T cells in the spleen 
were not functionally exhausted at this time point (Figure 4.7.C.).  
After 2o WNV infection of JEV-immune mice, similar to tetramer analysis of 
the PBL (Figure 4.4.A), there was an increase in the frequency of both JEV S9-
specific and WNV S9-specific CD8+ T cells in the spleen (Figure 4.7.D). The 
cytokine profiles switched from being predominantly IFN−γ+ TNF-α+ CD8+ T cells 
to IFN−γ+ CD8+ T cells. In WNV-immune mice after 2o JEV infection, the 
frequency of cytokine producing JEV S9-specific and WNV S9-specific CD8+ T 
cells did not increase from the memory time point. However, both JEV S9-
specific and WNV S9-specific CD8+ T cells were functional, suggesting again that 
WNV-immune CD8+ T cells in the spleen were not functionally exhausted. These 
results also support the analysis of the PBL in suggesting that very little 
proliferation of WNV-immune CD8+ T cells is seen following 2o JEV infection.  
Since we saw very little proliferation of WNV-immune CD8+ T cells upon 2o 
JEV infection in vivo, we next wanted to determine whether WNV-immune CD8+ 
T cells were capable of proliferating in a naïve environment. This would enable 
us to determine whether the lack of proliferation was intrinsic to WNV-immune T 
cells or due to the in situ environment generated after a WNV infection. CFSE 
labeled JEV-and WNV-immune splenocytes (1-2 x 107 cells) were adoptively 
transferred into naive Ly5.1 congenic mice, and the following day, the mice were 
infected with PBS (control), JEV (1 x 103 pfu), or WNV (1 x 103 pfu). Five days 
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after infection, both CD4+ T cell and CD8+ T cell proliferation were measured by 
dilution of CFSE. We found that for both JEV- and WNV-immune donor CD8+ T 
cells, a higher percentage proliferated upon homologous infection (1o JEV 2o 
JEV; 1o WNV 2o WNV) compared to heterologous infection (1o JEVWNV; 1o 
WNV 2o JEV), but this difference did not reach statistical significance (mean % 
proliferation ± SEM: JEV-immune: 2o JEV: 45.2% ± 11.5%; 2o WNV: 17.3% ± 
6.1%, P=0.2, Mann-Whitney U; WNV-immune: 2o WNV: 29.9% ± 8.9%; 2o JEV: 
9.3% ± 2.5%, P=0.13, Mann-Whitney U) (Figure 4.8.A.-B.). We detected very 
little homoeostatic proliferation of both JEV and WNV-immune donor splenocytes 
upon the injection with PBS (mean % proliferation ± SEM: JEV-immune: 0.8% ± 
0.2%; WNV-immune: 3.7% ± 1.7%). 
A majority, but not all, of the proliferating CD8+ T cells were specific for the 
JEV S9 or WNV S9 epitope after 2o heterologous infection (mean % proliferation 
± SEM: JEV-immune: 2o WNV: JEV S9: 55.8% ± 9.4%, WNV S9: 49.5% ± 
10.8%; WNV-immune: 2o JEV: JEV S9: 24.9% ± 6.4%, WNV S9: 30.4% ± 6.6%) 
(Figure 4.8.C.-D.). Only a small percentage of the proliferating CD8+ T cells were 
specific for the subdominant cross-reactive CD8+ T cell epitope that was recently 
identified, JEV E1 and WNV E1 (mean % proliferation ± SEM: JEV-immune: 2o 
WNV: JEV E1: 0.8% ± 0.8%, WNV E1: 4.1% ± 2.1%; WNV-immune: 2o JEV: JEV 
E1: 8.4% ± 2.4%, WNV E1: 3.3% ± 1.1%) (198). These results confirm that the 
WNV S9 and JEV S9 epitope is the dominant cross-reactive epitope. Since the 
two cross-reactive epitopes that were studied did not account for all for the 
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Figure 4.8. Proliferation of JEV- and WNV-immune T cells after 2o infection 
in naïve hosts. (A) Representative plots of CFSE dilution (x-axis) on CD8+ T 
cells from 1 JEV-immune (top row) or WNV-immune (bottom row) donor mouse 
after 2o PBS (left panels), 1 x 103 pfu JEV (middle panels), or 1 x 103 pfu WNV 
(right panels) infections. (B) Summary of CD8+ T cell proliferation from JEV-
immune (1o JEV) or WNV-immune (1o WNV) mice. Black bar and error bars 
represent mean ± SEM. (C) Frequency of epitope-specific IFN−γ+ CFSElow CD8+ 
T cells from JEV donor mice after 2o JEV (red circles) or WNV (blue squares) 
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infection. Black bar and error bars represent mean ± SEM. (D) Frequency of 
epitope-specific IFN−γ+ CFSElow CD8+ T cells from WNV donor mice after 2o JEV 
(red circles) or WNV (blue squares) infection. Black bar and error bars represent 
mean ± SEM. (E) Representative plot of CFSE dilution (x-axis) on CD4+ T cells 
from one JEV-immune (top row) or WNV-immune (bottom row) donor mouse 
after 2o PBS (left panels), 1 x 103 pfu JEV (middle panels), or 1 x 103 pfu WNV 
(right panels) infections. (F) Summary of CD4+ T cell proliferation from JEV-
immune (1o JEV) or WNV-immune (1o WNV) mice. Black bar and error bars 
represent mean ± SEM. (G) Frequency of epitope-specific IFN−γ+ CFSElow CD4+ 
T cells from JEV donor mice after 2o JEV (red circles) or WNV (blue squares) 
infection. Black bar and error bars represent mean ± SEM. (H) Frequency of 
epitope-specific IFN−γ+ CFSElow CD4+ T cells from WNV donor mice after 2o JEV 
(red circles) or WNV (blue squares) infection. Black bar and error bars represent 
mean ± SEM. 
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proliferating CD8+ T cells, there are likely additional JEV/WNV cross-reactive 
CD8+ T cell epitopes that have yet to be identified. 
As was seen for CD8+ T cells, a higher percentage of CD4+ T cells 
proliferated in responses to homologous infection compared to heterologous 
infection (mean % proliferation ± SEM: JEV-immune: 2o JEV 43.5% ± 1.9%; 2o 
WNV: 17.4% ± 0.7%; WNV-immune: 2o JEV 12.7% ± 2.0%; 2o WNV: 31.7% ± 
2.0%) (Figure 4.8.E.-F.). Interestingly, the cross-reactive epitopes, NS1 and NS3, 
accounted for a only small fraction of the proliferating CD4+ T cells after 
heterologous infection (mean % proliferation ± SEM: JEV-immune: 2o WNV: JEV 
NS1: 9.7% ± 2.1%, WNV NS1: 4.9% ± 1.2%; JEV NS3: 1.4% ± 0.9%, WNV NS3: 
1.6% ± 1.4%; WNV-immune: 2o JEV: JEV NS1: 6.1% ± 2.0%, WNV NS1: 4.9% ± 
1.8% JEV NS3: 2.3% ± 0.7%, WNV NS3: 3.8% ± 1.1%) (Figure 4.8.G.-H.). These 
results suggest that there are additional cross-reactive CD4+ T cell epitopes yet 
to be identified. 
Taken together, these results confirm that CD4+ and CD8+ T cells are not 
functionally exhausted in WNV-immune mice. The lower level of proliferation of T 
cells upon heterologous infection may be due to a limited number of cross-
reactive T cells, and the variability between donor mice may reflect the individual 
private specificities in the T cell repertoire of each donor mouse (174). Since 
exhaustion of WNV-immune CD8+ T cells was not limiting T cell proliferation 
upon 2o JEV infection, additional mechanisms for this lack of expansion needed 
to be explored.   
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H. Analysis of the amino acid differences between the JEV S9 and WNV S9 
peptides. 
The JEV S9 and WNV S9 amino acid sequences differ by only two amino 
acids at the P2 and P6 positions of the epitope. In order to address the possible 
contribution of these residues to the lack of proliferation in WNV-immune mice 
upon 2o JEV infection, the P6 amino acid in JEV S9 was mutated (SA) to 
generate JEV P6A, and the P6 amino acid in WNV S9 was mutated (AS) to 
generate WNV P6S (Table 4.1.).  These mutations also allowed us to compare 
the P2 amino acids because JEV P6A contains the corresponding SA amino 
acid change seen in WNV S9. Likewise, the WNV P6S mutant peptide contains 
the AS amino acid change at the P2 position of JEV S9.  
First, we examined whether the P2 or P6 residues affected the ability of 
the peptides to bind to MHC. To test this, we used RMA-S cells, which lack the 
TAP protein, and therefore are defective in presenting endogenous antigens 
(272, 273). Exogenously added peptides bind and stabilize unloaded MHC on the 
cell surface, and the expression of the MHC on the surface depends upon the 
stability of the peptide-MHC complex (274). RMA-S cells were loaded with 10-4 – 
10-8 µg/ml of each peptide and incubated overnight to allow for surface 
stabilization of the peptide-MHC complex. The cells were then transferred to a 
37oC incubator to allow for internalization of unbound MHC, and H-2Db 
expression on the cell surface was measured. Both JEV S9 and 
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Table 4.1. Amino acid sequences of JEV S9 and WNV S9 mutants 
Peptide Name Amino Acid Sequence 
JEV S9 SAVWNSTTA 
JEV P6A SAVWNATTAa 
WNV S9 SSVWNATTA 
WNV P6S SSVWNSTTA 
aRed letter indicates amino acid change in mutant. 
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JEV P6A, which contains the same P2 amino acid, stabilized H-2Db on the 
surface of RMA-S cells to a significantly higher level compared to WNV S9 and 
WNV P6S at a peptide concentration of 10-6 µg/ml (P<0.05; Mann-Whitney U) 
(Figure 4.9.A.). No significant difference was seen between peptides that differed 
at P6 in their ability to stabilize MHC. These results demonstrate that alanine at 
the P2 position helps the JEV peptides bind to MHC better than the serine in the 
WNV peptides. 
Since the P2 amino acid affects MHC binding, we hypothesized that the 
P6 amino acid would affect binding to the TCR. To test this hypothesis, bone 
marrow derived dendritic cells (BMDCs) were peptide-pulsed with 10 µg/ml of the 
JEV S9, JEV P6A, WNV S9, or WNV P6S peptides and adoptively transferred iv 
into naïve mice. On day 7 after adoptive transfer, PBLs were analyzed by 
tetramer stain for specificity of the CD8+ T cells to either the JEV S9 or WNV S9 
tetramer. After JEV S9 immunization, the ratio of WNV S9-specific to JEV S9-
specific CD8+ T cells was less than 1 (ratio mean ± SEM; 0.85 ± 0.04), 
demonstrating a higher frequency of JEV S9-specific CD8+ T cells than WNV S9-
specific CD8+ T cells in these mice (Figure 4.9.B.).  On the other hand, in WNV 
S9-immunized mice, the ratio was greater than 1 (ratio mean ± SEM; 1.65 ± 
0.07), demonstrating a higher frequency of WNV S9-specific CD8+ T cells 
compared to JEV S9-specific CD8+ T cells.   
After immunization with the mutant peptides, the ratio of CD8+ T cells 
binding to the WNV S9 and JEV S9 tetramers was altered. The CD8+ T cell 
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Figure 4.9. The P2 and P6 amino acids of JEV S9 and WNV S9 affect MHC 
stabilization and tetramer specificity. (A) P2 amino acid affects MHC 
Stabilization. RMA-S cells were loaded with 10-4 – 106 µg/ml of peptide. Percent 
loss of stabilization was calculated using 10-4 µg/ml concentration as the max 
stabilization of H-2Db MHC. * P<0.05 comparing both of the JEV peptides versus 
the two WNV peptides, Mann-Whitney U. N=5 independent experiments. (B) P6 
amino acid affects tetramer binding to CD8+ T cells. Peptide-loaded BMDCs (10 
µg/ml) were adoptively transferred into naïve male B6.SJL mice. JEV S9-specific 
and WNV S9-specific CD44hi CD8+ T cells were analyzed in the PBL on day 7 
after adoptive transfer. N=4 mice/peptide. 
 112 
population in JEV P6A immunized mice switched from being specific to the JEV 
S9 tetramer to becoming more specific to the WNV S9 tetramer (mean ratio ± 
SEM; 1.28 ± 0.03).  Likewise, immunization with WNV P6A changed the 
specificity of the CD8+ T cells from being WNV S9 specific to JEV S9 specific 
(mean ratio ± SEM; 0.93 ± 0.06) (Figure 4.9.B.). Taken together, these data 
confirm that the P2 amino acid affects MHC stability while the P6 amino acid 
helps to determine the specificity of the CD8+ T cell population for the tetramers.  
 
I. Functional avidity of cross-reactive CD8+ T cells in JEV- and WNV-
infected mice. 
 Memory CD8+ T cell proliferation upon secondary heterologous infection 
can be influenced by the functional avidity of CD8+ T cells for the cross-reactive 
epitope. In fact, memory CD8+ T cells specific for the NP366-374 epitope of 
influenza have reduced recall responses and viral clearance upon infection with a 
heterologous influenza viral strain (185). On day 7 after JEV and WNV infection, 
IFN−γ dose responses to the homologous and heterologous epitopes were 
measured, and the concentration of each peptide that elicited 50% of the 
maximal IFN−γ response was calculated (EC50), and compared between each 
infection. A low EC50 concentration means that the CD8+ T cells have a high 
functional avidity for the epitope. 
In both JEV and WNV infections, the homologous epitope, JEV S9 for the 
JEV infection and WNV S9 for the WNV infection, had a higher functional avidity 
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compared to the heterologous epitope (Figure 4.10. and Table 4.2.). Also in both 
infections, there is only a ½ log difference in the EC50 values between the 
homologous JEV S9 and the heterologous WNV S9 epitope. Interestingly, there 
is less than a log difference in the EC50 values for the same epitope regardless of 
the infecting virus. The EC50 values of the CD8+ T cells only increased slightly at 
memory time points (Table 4.2.). These data demonstrate that WNV infection 
induces a CD8+ T cell population with similar functional avidities to the cross-
reactive epitope as a JEV infection. Therefore, a lower functional avidity of the 
WNV S9-specific CD8+ T cells for the JEV S9 epitope compared to JEV S9-
specific CD8+ T cells for the WNV S9 epitope does not account for differences in 
proliferation during 2o infection.  
 
J. TCR Vβ usage of JEV S9-specific and WNV S9-specific CD8+ T cells 
during primary JEV and WNV infection. 
 We next hypothesized that the amino acid differences between JEV S9 
and WNV S9 may be inducing two distinct TCR Vβ repertoires that proliferate 
differently upon 2o heterologous infection. Both JEV S9-specific and WNV S9-
specific IFN−γ+ CD8+ T cells in JEV and WNV-infected mice were analyzed for 
TCR Vβ usage on day 7 after infection. Both JEV and WNV infections induced a 
broad TCR repertoire that utilized multiple Vβs. TCR Vβ 13 was found to be the 
dominant TCR Vβ utilized by epitope-specific CD8+ T cells in both JEV- and 
WNV-infected mice, however the proportions were different (mean % frequency:  
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Figure 4.10. Functional avidity of JEV S9-specific and WNV S9-specific 
CD8+ T cells in JEV- and WNV-immune mice. Splenocytes from JEV (A) or 
WNV (B) infected mice on day 7 after infection were stimulated with either 
varying concentrations (x-axis) of JEV S9 (red circle) or WNV S9 (blue square) 
peptides, and the frequency of IFN−γ+ CD8+ T cells were measured. N=3-
mice/data point. 
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Table 4.2. EC50 values for IFN−γ production by JEV S9-specific and WNV S9-
specific CD8+ T cells.  
Infection Time point Peptide EC50 Value (g/ml)a,b 
JEV 
Day 7 JEV S9 10-10.24  
Day 7 WNV S9 10-9.86 
Day 28 JEV S9 10-10.81 
Day 28 WNV S9 10-10.43 
WNV 
Day 7 JEV S9 10-9.64 
Day 7 WNV S9 10-10.03 
Day 28 JEV S9 10-9.52 
Day 28 WNV S9 10-10.35 
a EC50 values calculated using GraphPad Prism software 
b N=4 mice/group except for JEV on Day 28 where N=2 mice 
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JEV-immune: JEV S9-specific CD8+ T cells: Vβ 13: 26.3%; WNV-immune: WNV 
S9-specific CD8+ T cells: Vβ 13: 33.7%) (Figure 4.11.). Vβ 8.1/8.2 and Vβ 7 were 
two subdominant TCR Vβs found in both JEV and WNV infections.     
We also analyzed the TCR Vβ repertoires after rVV JEV, rVV WNV, and 
Kunjin virus infections to determine if the TCR Vβ repertoires are different 
between virus infections containing the same epitope. The TCR Vβ usage during 
a rVV WNV and Kunjin virus infection was similar to WNV, with Vβ 13 being the 
dominant TCR Vβ and Vβ 8.1/8.2 being subdominant (Figure 4.11.). Likewise, 
the TCR Vβ usage of the CD8+ T cell population after rVV JEV infection was 
similar to the repertories in JEV-infected mice. In conclusion, the same epitope 
induces similar TCR Vβ repertoires regardless of the viral infection, and different 
TCR Vβ usage during the primary infection between JEV and WNV does not 
appear to account for the differences in proliferation upon 2o infection. However, 
TCR Vβ usage after a secondary heterologous infection is highly variable and 
depends upon the private specificities of the host (176). Therefore, the TCR Vβ 
repertoires after 2o infection may differ in JEV- and WNV-immune mice, and will 
need to be investigated further. 
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Figure 4.11. TCR Vβ Usage of JEV S9-specific and WNV S9-specific IFN-γ+ 
CD8+ T cells on day 7 following primary infection. Splenocytes from JEV (A), 
WNV (B), rVV JEV (C), rVV WNV (D), and Kunjin (E) infected mice were harvest 
on day 7 after infection and stimulated with 1 µg/ml JEV S9 (red) and WNV S9 
(blue) for 5 hours. Cells were stained with anti-CD3, -CD8+, -IFN−γ and one TCR 
Vβ. The frequency of CD3+ CD8+ IFN−γ+ T cells for each TCR Vβ is shown on the 
y-axis. 
 119 
K. The proliferation of memory WNV S9-specific CD8+ T cells upon 2o 
homologous and heterologous infection depends on the primary infection. 
 Neither the functional avidity nor the TCR Vβ usage of CD8+ T cells in JEV 
and WNV appear to account for the differences in proliferation upon 2o 
heterologous infection. Therefore, we next determined whether the WNV S9 
epitope was able to induce a memory CD8+ T cell population that could 
proliferate upon 2o JEV infection in the context of a different primary viral 
infection. B6 mice were immunized with rVV JEV, rVV WNV, and rVV GFP and 
4-5 weeks after primary infection, the mice were infected with either JEV or 
WNV. JEV S9-specific and WNV S9-specific CD8+ T cells were analyzed in the 
PBL by tetramer staining on day 0 (memory frequency) and day 5 after 2o 
infection.  
Infection of rVV JEV-immune mice with a low dose WNV infection (1 x 103 
pfu) resulted in a 3.8 and 5.9 fold expansion of JEV S9-specific and WNV S9-
specific CD8+ T cells, respectively (Figure 4.12.A.). This infection scenario is 
similar to infection of JEV-immune mice with WNV, in which we see proliferation 
of both JEV S9-specific and WNV S9-specific CD8+ T cells upon 2o infection. A 
similar fold expansion was seen after homologous infection of rVV WNV-immune 
mice with WNV (JEV S9: 3.9x; WNV S9: 4.6x). In native virus infection, (e.g. 
WNV infection of WNV-immune mice) proliferation of JEV S9-specific and WNV 
S9-specific CD8+ T cells would likely not occur due to the presence of 
neutralizing antibodies. Importantly, infection of rVV GFP immune mice, which  
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Figure 4.12. Primary rVV infection generates memory WNV S9-specific 
CD8+ T cells that proliferate upon 2o JEV infection. rVV JEV (left panels), rVV 
WNV (middle panels), rVV GFP (right panels) immune mice were infected with 
(A) low dose WNV (1 x 103 pfu), (B) high dose WNV (1 x 105 pfu), or (C) high 
dose JEV (1 x 106 pfu). On day 0 (D0) and day 5 (D5) after infection, JEV S9-
specific and WNV S9-specific CD44hi CD8+ T cells were analyzed by tetramer 
stain in the PBL. Numbers represent fold expansion of tetramer positive CD8+ T 
cells between D0 and D5. 
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lack memory JEV S9-specific and WNV S9-specific CD8+ T cells, did not result in 
proliferation of these populations upon 2o WNV infection. Infection of rVV JEV-
immune mice with a high dose WNV infection (1 x 105 pfu) resulted in 11.4 and 
18.7 fold increase in JEV S9-specific and WNV S9-specific CD8+ T cells, 
respectively (Figure 4.12.B.). A similar increase in the fold expansion was seen in 
rVV WNV was seen after the high dose WNV infection (JEV S9: 10.8x, WNV S9: 
13.1x). These results suggest that the dose of the 2o infection can also influence 
the fold expansion of memory CD8+ T cells.  
Although minimal proliferation of JEV S9-specific and WNV S9-specific 
CD8+ T cells was seen after 2o JEV infection of WNV-immune mice, infection of 
rVV WNV-immune mice with JEV (1 x 106 pfu) resulted in an 11.9 and 13.1 fold 
expansion of the frequency of JEV S9-specific and WNV S9-specific CD8+ T 
cells, respectively (Figure 4.12.C.). A similar fold expansion was seen in rVV 
JEV-immune mice (JEV S9: 11.4x and WNV S9: 9.5x). Therefore, the WNV S9 
epitope in the context of a 1o rVV infection induces a memory CD8+ T cell 
population that proliferates upon a 2o heterologous JEV infection. Our findings 
suggest that the type of primary infection dictates the quality of the memory CD8+ 
T cell responses and resultant expansion upon a 2o infection rather than the 
epitope itself.  
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L. An attenuated WNV (Kunjin virus) induces a memory CD8+ T cell 
population that proliferates upon 2o JEV infection. 
 The cytokine milieu during a primary infection can influence the generation 
of memory CD8+ T cells (211). rVV and WNV stimulate different components of 
the innate immune system, which then may lead to the induction of different 
cytokines that could alter the formation of the memory CD8+ T cell compartment 
(275, 276). Therefore, comparing rVV and WNV in their ability to induce a 
memory CD8+ T cell population that proliferates upon 2o infection, may not be an 
adequate comparison. To address this concern, we used Kunjin virus, which has 
a 100% conserved WNV S9 amino acid sequence as WNV. Use of this virus 
permitted us to determine the effects of pathogenicity and sensitivity to type I IFN 
of the infecting 1o WNV strain on memory CD8+ T cell generation and 
subsequent ability of these memory CD8+ T cells to proliferate upon a 2o JEV 
infection.  
B6 mice were infected with 1 x 103 pfu of Kunjin virus, and 5 weeks post 
infection, the mice were challenged with a lethal dose of JEV (1 x 107 pfu) at the 
same time as the WNV-immune mice in Figure 4.2.A. Similar to WNV-immune 
mice, Kunjin immune mice were protected against a lethal JEV challenge 
compared to PBS (Kunjin: 85.7% survival, 2/14 mice; PBS: 50% survival, 7/14 
mice; P=0.059, Log-Rank test) (Figure 4.13.A.). We hypothesized that cross-
reactive CD8+ T cells in Kunjin-immune mice would not proliferate upon 2o JEV 
infection due to the identical epitopes between WNV and Kunjin. Prior to 2o  
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Figure 4.13. Memory WNV S9-specific CD8+ T cells in Kunjin-immune mice 
proliferate after 2o JEV infection. (A) Kunjin-immune mice are protected 
against lethal JEV infection. B6 mice were infected with 1 x 103 pfu Kunjin virus 
(N=14 mice) or PBS (N=14 mice) and 5 weeks later infected with 1 x 107 pfu 
JEV. The mice were monitored daily for survival. P=0.059, Log-Rank Test. (B) 
JEV S9-specific and WNV S9-specific CD8+ T cell frequency in PBL after 2o JEV 
infection. (C-E) Expression of CD43 (C), KLRG1 (D), and CD127 (E) on JEV S9-
specific (red circle) and WNV S9-specific (blue square) CD44hi CD8+ T cells. 
Black bar and error bars represent mean ± SEM.  
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infection, the frequency of JEV S9 and WNV S9 in Kunjin-immune mice (Figure 
4.13.B.) was considerably lower in the PBL compared to WNV-immune mice, but 
comparable to that in JEV-immune mice (Figure 4.4.A.) (mean ± SEM: Kunjin-
immune: JEV S9: 0.22% ± 0.07%, WNV S9: 0.60% ± 0.15%).  
In contrast to WNV-immune mice, 2o JEV infection of Kunjin-immune mice 
resulted in the expansion of JEV S9-specific and WNV S9-specific CD8+ T cells 
by day 5 after infection (mean ± SEM: JEV S9: 3.80% ± 0.36%; WNV S9: 7.18 ± 
0.54%) (Figure.4.13.B.). The frequency of JEV S9-specific and WNV S9-specific 
CD8+ T cells continued to increase on day 7 (mean ± SEM: JEV S9: 11.78% ± 
0.61%, WNV S9: 16.98% ± 0.85%). Even though WNV and Kunjin share the 
same sequence of the WNV S9 epitope, the memory WNV S9 CD8+ T cells in 
Kunjin-immune mice responded differently upon a 2o JEV infection compared to 
WNV-immune mice.   
The upregulation of CD43 on JEV S9-specific and WNV S9-specific CD8+ 
T cells also differed in Kunjin-immune mice compared to WNV-immune mice. 
CD43 upregulation began on day 3, and reached maximal expression by day 5 
after infection (Figure 4.13.C.). Upregulation of KLRG1 and downregulation of 
CD127 began by day 3 and reached its peak on day 7, suggesting a conversion 
from a predominantly MPEC population to a SLEC population by day 7 (Figure 
4.13.D.-E.). This expression pattern of CD43 is similar to a 2o WNV infection of 
JEV-immune mice (Figure 4.4.B.), in which CD43 upregulation preceded 
expansion of JEV S9-specific and WNV S9-specific CD8+ T cells, and by day 7 in 
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all infection, a majority of the CD8+ T cells had a SLEC phenotype. These results 
further support the notion that the context of the primary viral infection dictates 
the ability of memory CD8+ T cells to proliferate upon a 2o infection, rather than 
differences in the epitope sequences (JEV S9 versus WNV S9).   
 
M. Dendritic cell (DC) immunizations also generate a WNV S9-specific CD8+ 
T cell population that proliferates upon 2o JEV infection. 
 After DC immunization with the JEV and WNV peptide mutants, we 
challenged the mice with a low dose of either JEV (1 x 103 pfu) or WNV (1 x 103 
pfu), to determine whether the amino acid differences between JEV S9 and WNV 
S9 had any effect on proliferation during 2o heterologous infection. After 2o JEV 
infection, the frequency of JEV S9-specific and WNV S9-specific CD8+ T cells in 
mice immunized with all 4 peptides increased in the PBL from day 0 to day 5 
(Figure 4.14.A.). Most importantly, JEV S9-specific and WNV S9-specific CD8+ T 
cells in WNV S9-immunized mice expanded upon a 2o JEV infection, 
demonstrating that DC immunization also induces a WNV S9-specific CD8+ T cell 
population that proliferates upon 2o JEV infection.  
Following a low dose WNV infection, we saw rapid proliferation in all of the 
peptide-immunized mice by day 5 after infection (Figure 4.14.B.). In addition, the 
magnitude of expansion was higher after 2o WNV infection compared to a 2o JEV 
infection. In some mice, the frequency of WNV S9-specific CD8+ T cells 
exceeded 40% in the PBS after a 2o WNV infection. We believe this difference in 
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Figure 4.14. DC Immunization generates memory WNV S9-specific CD8+ T 
cells that proliferate upon 2o JEV infection. BMDCs were pulsed with 10 µg/ml 
JEV S9, JEV P6A, WNV S9, or WNV P6S (x-axis) and adoptively transferred into 
naïve mice. 4-6 weeks after transfer, the mice were infected with (A) 1 x 103 pfu 
JEV or (B) 1 x 103 pfu WNV. JEV S9-specific (red circle) and WNV S9-specific 
(blue square) CD44hi CD8+ T cells were measured on day 0 (D0) and day 5 (D5) 
after infection in the PBL. Black bar and error bars represent mean ± SEM. 
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magnitude of expansion is due to the ability of WNV to replicate in the periphery 
compared to JEV at this low dose (1 x 103 pfu). Increasing the dose of the 2o JEV 
infection may increase the expansion of CD8+ T cells similar to that seen in a 2o 
WNV infection. Therefore, DC immunization also induces a WNV S9-specific 
CD8+ T cell population that proliferates upon 2o JEV infection. 
 
N. Restriction of rVVs in the ovaries by JEV and WNV-immune mice.  
Since the context of the primary infection dictates the proliferation of 
memory WNV S9-specific CD8+ T cells upon 2o JEV infection, we next 
determined whether WNV-immune CD8+ T cells were able to restrict virus 
independent of proliferation. WNV-immune, JEV-immune or PBS (control) B6 
mice were infected with a high dose (5 x 106 pfu) or low dose (rVV WNV: 1 x 105 
pfu; rVV JEV and rVV GFP: 5 x 105 pfu) of the rVVs and viral titers in the ovaries 
were measured. This design permitted us to study the role of JEV S9-specific 
and WNV S9-specific CD8+ T cells in restricting virus since WNV antibodies 
should not neutralize the rVVs.  
In WNV-immune mice, we saw a significant reduction in the median viral 
titers after infection with the higher dose of the homologous rVV WNV (median 
titer: 2.4 x 104 pfu) compared to both JEV-immune (2.9 x 106 pfu; P<0.05) and 
PBS control mice (1.7 x 106 pfu, P<0.01; Mann-Whitney U) (Figure 4.15.A.). 
There was no significant reduction in the rVV WNV titers in JEV-immune mice 
compared to PBS controls (P<0.54, Mann-Whitney U). There was a slight 
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Figure 4.15. Restriction of rVVs in the ovaries of JEV- and WNV-immune 
mice. (A) WNV-immune (1o WNV), JEV-immune (1o JEV), or PBS control mice 
were infection with high dose (5 x 106 pfu) rVV WNV (left panel), rVV JEV (middle 
panel) or rVV GFP (right panel). Ovaries were harvested on day 5 after infection. 
(B) Infection of WNV-immune, JEV-immune or PBS mice with low dose rVV WNV 
(1 x 105 pfu), rVV JEV (5 x 105 pfu), or rVV GFP (5 x 105 pfu). Ovaries were 
harvested on day 6 after infection. Each data point represents one mouse, and 
black bar represents median value. *P<0.05, **P<0.01, Mann-Whitney U. 
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reduction in the titers of the heterologous rVV JEV in WNV-immune mice 
compared to JEV-immune and PBS control mice (median titer: WNV-immune: 
1.2 x 104 pfu; JEV-immune: 5.0 x 105 pfu; PBS: 8.6 x 105 pfu; P<0.2, Mann-
Whitney U), but these differences were not statistically significant. Importantly, 
there was no difference in the titers of rVV GFP in WNV-immune, JEV-immune or 
PBS control mice, confirming the specificity of this viral restriction to the JEV S9-
specific and WNV S9-specific CD8+ T cell epitopes.  
Even though we saw rapid proliferation of JEV S9-specific and WNV S9-
specific CD8+ T cells in JEV-immune mice after 2o rVV infection (Figure 4.6.A.), 
we did not observe any restriction of either the homologous or heterologous rVV 
in the ovaries compared to PBS control mice (2o rVV WNV: P=0.5; 2o rVV JEV: 
P=0.7; Mann-Whitney U) On the other hand, significant restriction of rVV WNV, 
and to a lesser degree, rVV JEV, occurred in WNV-immune mice in the absence 
of CD8+ T cell proliferation. We hypothesized that this lack of restriction in JEV-
immune mice was due to a low starting frequency of memory CD8+ T cells prior 
to infection, and/or due to the high dose of rVV used in the infection.  
In order to make the environment more favorable for the CD8+ T cells, we 
lowered the infection dose (rVV WNV; 1 x 105 pfu, rVV JEV and rVV GFP: 5 x 
105 pfu) and harvested the ovaries on day 6 rather than day 5 to allow for a 
greater expansion of epitope-specific memory CD8+ T cells. In WNV-immune 
mice, we detected near complete restriction of the homologous rVV WNV at the 
lower dose and later harvest day compared to PBS control mice (median titer: 
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WNV-immune: 333 pfu, PBS: 2.3 x 106 pfu P<0.01, Mann-Whitney U) (Figure 
4.15.B.). Virus levels of the heterologous rVV JEV were also restricted in WNV-
immune mice compared to PBS control mice (WNV-immune: 1.1 x 105 pfu, PBS: 
4.3 x 106 pfu; P<0.05, Mann-Whitney U). 
In contrast to the high dose infection, there was a slight reduction in the 
median titers of rVV WNV in JEV-immune mice compared to PBS control mice 
upon the low dose infection (JEV-immune: 6.1 x 105 pfu, PBS: 1.7 x 106 pfu; 
P=0.066, Mann-Whitney U), but this reduction was not statistically significant. 
After the lower dose and later harvest time point, a significant reduction in 
homologous rVV JEV titers in JEV-immune mice occurred (median titer: JEV-
immune: 4.5 x 104 pfu, P<0.05, Mann-Whitney U) (Figure 4.15.B.). Again, no 
restriction of virus was seen in mice infected with the control rVV GFP virus. 
Therefore, JEV-immune mice were better able to restrict the rVVs at a lower 
dose and at a later time point. These results also demonstrate that WNV-immune 
mice are better able to restrict both low and high dose of 2o rVVs compared to 
JEV-immune mice, even though there is limited proliferation of memory CD8+ T 
cells during 2o infection.  
  
O. Restriction of low and high doses of the rVVs by Kunjin-immune mice.  
After 2o JEV infection of Kunjin-immune mice, we saw rapid proliferation of 
memory JEV S9-specific and WNV S9-specific CD8+ T cells (Figure 4.13.B.). 
Therefore, we next wanted to determine whether restriction of low and high  
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doses of the rVVs by Kunjin-immune mice was similar to that seen in either JEV-
immune mice or WNV-immune mice. After high dose rVV WNV infection (5 x 106 
pfu), we measured a small but significant reduction in viral titers in Kunjin-
immune mice (median titer: 1.7 x 105 pfu) compared to PBS mice (8.6 x 105 pfu, 
P<0.05, Mann-Whitney U) (Figure 4.16.A.). However, there was no significant 
reduction in the titers of either rVV JEV (median titer: 9.3 x 105 pfu) or rVV GFP 
(median titer: 3.4 x 105 pfu) in Kunjin-immune mice compared to the PBS controls 
(median titer: rVV JEV: 8.6 x 105; P=0.7; rVV GFP: 1.6 x 106 pfu; P=0.4; Mann-
Whitney U). 
After infection with a lower dose of the rVV (5 x 105 pfu), there was no 
significant restriction in rVV WNV, rVV JEV or rVV GFP titers on day 5 after 
infection in Kunjin-immune mice (Figure 4.16.B.) Interestingly, this lack of 
restriction occurred in the context of memory JEV S9-specific and WNV S9-
specific CD8 T cell proliferation similar to what we see after rVV infection of JEV-
immune mice (Figure 4.15.) These data suggest that low frequencies of memory 
CD8+ T cells may not be able to efficiently restrict virus after 2o heterologous 
infection. 
 
P. WNV-immune mice have reduced frequencies of the immunodominant 
VV B8R epitope after 2o rVV infection. 
As a control for rVV viral infection, we also measured the tetramer 
frequency of the immunodominant VV epitope, B8R, in the PBL of JEV-, WNV-,  
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Figure 4.16. Restriction of rVVs in the ovaries of Kunjin-immune mice. (A) 
Kunjin-immune mice (purple circle) and PBS control (black square) mice were 
infected with 5 x 106 pfu rVV WNV (left panel), rVV JEV (middle panel), or rVV-
GFP (right panel). Ovaries were harvested on day 5 after infection. Black bar and 
error bars represents mean ± SEM. *P<0.05, Mann-Whitney U. (B) Kunjin-
immune mice (purple circle) and PBS control (black square) mice were infected 
with 5 x 105 pfu rVV WNV (left panel), rVV JEV (middle panel), or rVV-GFP (right 
panel). Ovaries were harvested on day 5 after infection. Black bar and error bars 
represents mean ± SEM. (C) Proliferation of memory JEV S9-specific (red 
circles) and WNV S9-specific (blue squares) CD44hi CD8+ T cells in Kunjin-
immune mice following 2o rVV (5 x 105 pfu) infection. Black bar and error bars 
represents mean ± SEM. Numbers represent fold expansion of JEV S9-specific 
and WNV S9-specific CD8+ T cells in the PBL from day 0 (D0) to day 5 (D5). 
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Kunjin-immune mice following 2o rVV infection. This allowed us to determine if 
prior flavivirus immunity altered the generation of an epitope-specific CD8+ T cell 
response to VV. After infection with a high dose (5 x 106 pfu) of the rVVs, we saw 
no significant difference in the frequency of B8R-specific CD8+ T cells in the PBL 
on day 5 in JEV- or WNV-immune mice compared to PBS (Figure 4.17.A.), even 
though we measured a significant reduction in the titer of rVV WNV in WNV-
immune mice. However, after a low dose rVV WNV infection of WNV-immune 
mice, we detected a significant reduction in the median frequency of B8R-specific 
CD8+ T cells compared to that seen in JEV-immune mice (median frequency: 
WNV-immune: 2.55%; JEV-immune: 11.5%; P<0.05, Mann-Whitney U), and PBS 
control mice (Median Frequency: PBS: 9.7%; P<0.001, Mann-Whitney U) (Figure 
4.17.B.). No reduction in the B8R frequency in JEV-immune mice following either 
low or high dose rVV infection was seen. These results suggest that almost 
complete abrogation of rVV WNV replication, as seen in WNV-immune mice, is 
required to disrupt the generation of B8R-specific CD8+ T cells following 2o rVV 
infection. 
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Figure 4.17. Frequency of the VV immunodominant B8R epitope in JEV-
immune, WNV-immune, and PBS control mice after 2o rVV infection. (A) 
WNV-immune (1o WNV), JEV-immune (1o JEV) and PBS control mice were 
infected with 5 x 106 pfu rVV JEV (left panel), rVV WNV (middle panel), or rVV 
GFP (right panel). B8R-specific CD44hi CD8+ T cells were measured on day 5 
after infection in the PBL. Black bar represents median value. N=4-6 mice/group. 
(B) WNV-immune (1o WNV), JEV-immune (1o JEV) and PBS control mice were 
infected with 5 x 105 pfu rVV JEV (left panel), 1 x 105 pfu rVV WNV (middle 
panel), or 5 x 105 pfu rVV GFP (right panel). B8R-specific CD44hi CD8+ T cells 
were measured on day 6 after infection in the PBL. Black bar represents median 
value. N=4-9 mice/group. ***P<0.001, *P<0.05, Mann-Whitney U.  
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Q. Higher degree of peptide-coated target cell lysis in WNV-immune mice 
compared to JEV-immune mice  
 We have previously demonstrated that CD8+ T cells during primary JEV 
infection recognize and kill both JEV S9 and WNV S9 peptide-coated targets in 
vivo (Figure 3.2.B.). We have also shown that both low and high doses of rVV 
are restricted more efficiently in WNV-immune mice than JEV-immune mice. One  
possible hypothesis is that the high frequency of memory CD8+ T cells in WNV-
immune mice is killing infected rVV cells before the rVV can replicate and spread 
into peripheral tissues. Memory CD8+ T cells have been shown to rapidly kill 
peptide-coated targets at a similar rate as effector CD8+ T cells (277). Therefore, 
we performed an in vivo CTL assay using JEV- and WNV-immune mice to 
determine whether WNV-immune mice can kill target cells better than JEV-
immune mice. Splenocytes from naïve B6.SJL (Ly5.1+) mice were pulsed with 1 
µg/ml of JEV S9, WNV S9 or the Flu NP366-374 peptide, labeled with serial 
dilutions of CFSE and adoptively transferred into B6 Ly5.2+ naïve or JEV- and 
WNV-immune mice. Splenocytes were then harvested 19 hours later, and Ly5.1+ 
donor cells were analyzed for CFSE levels.  
Figure 4.18.A. is a representative histogram from naïve (top panel), JEV-
immune (middle panel) or WNV-immune (bottom panel) mice. In naïve mice, we 
did not detect any lysis of the peptide-coated targets, as 4 individual peaks were 
seen representing the peptides and unpulsed targets. In JEV-immune mice, 
target cells pulsed with the homologous JEV S9 peptide were lysed to a higher  
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Figure 4.18. Higher degree of peptide-coated target lysis in WNV-immune 
mice compared to JEV-immune mice. Splenocytes from naive B6.SJL (Ly5.1+) 
mice were pulsed with 1 µg/ml of JEV S9, WNV S9 or Flu NP peptides and 
transferred (1-2 x 107 cells) into B6 JEV- and WNV-immune mice. 19 hours later, 
the splenocytes were harvested and CFSE expressing was determined on Ly5.1+ 
cells. (A) Representative histogram from 1 mouse/infection. (B-C) Summary of 
the percent specific lysis of each peptide in JEV-immune mice (B) or WNV-
immune mice (C). N=5 mice/infection, 2 independent experiments. Black line and 
error bar represents mean ± SEM.  ** P<0.01, *P<0.05, Mann-Whitney U.  
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degree (mean ± SEM; 64.9% ± 7.8%) compared to targets pulsed with the 
heterologous WNV S9 peptide (mean ± SEM; 33.9% ± 5.6%; P<0.05, Mann-
Whitney U) (Figure 4.18.B). However, both JEV S9 and WNV S9 targets were 
lysed to a higher degree than the irrelevant peptide, Flu NP366-374, (mean ± SEM; 
2.1% ± 1.8%: P<0.05; Mann-Whitney U).  
In WNV-immune mice, a similar pattern was seen. Targets pulsed with the 
WNV S9 and JEV S9 peptides were lysed to a higher degree compared to 
targets pulsed with Flu NP366-374 peptide (mean ± SEM: WNV S9: 90.4% ± 1.9;  
JEV S9: 78.6 ± 6.4%; Flu NP366-374: 15.7 ± 4.5; P<0.01, Mann-Whitney U) (Figure 
4.18.). However, there was no significant difference in the target cell lysis of 
WNV S9 and JEV S9 peptide-pulsed targets in WNV-immune mice (P=0.1, 
Mann-Whitney U). Interestingly, there was a higher level of lysis of the Flu NP366-
374 peptide-pulsed targets in WNV-immune mice compared to the JEV-immune 
mice suggesting there may be some non-specific target cell lysis in WNV-
immune mice. These data support our findings on restriction of rVV replication, in 
which WNV-immune mice appear to have an enhanced ability to clear both 
homologous and heterologous rVVs compared to JEV-immune mice.  
 
R. Chapter Discussion 
 In the previous chapter, we identified an immunodominant cross-reactive 
CD8+ T cell epitope between JEV and WNV. In this chapter, we explored the 
kinetics of cross-reactive CD8+ T cells during 2o heterologous infection. We found 
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that cross-reactive CD8+ T cells in WNV-immune mice proliferated poorly upon 2o 
JEV infection compared to those in JEV-immune mice infected with WNV. This 
lack of proliferation was not due to exhaustion of CD8+ T cells nor differences in 
the CD8+ T cell repertoire between JEV and WNV. WNV-infection did induce 
neutralizing antibodies to JEV; however the presence of these antibodies did not 
influence the proliferation of memory CD8+ T cells upon 2o infection. We believe 
the higher frequency of memory CD8+ T cells induced by WNV infection 
compared to JEV infection is the most likely influence on the proliferative 
capacity of memory CD8+ T cells during 2o heterologous infection.   
 To understand cross-protection between JEV and WNV, we first had to 
establish a lethal model of JEV. Our model is slightly different than the model 
established by Larena et al., in which they used a sc infection of JEV Nakayama 
(95). A high dose sc infection resulted in 100% mortality by day 6 after infection, 
whereas in our studies, an ip infection resulted in only 60% mortality by day 12-
15 after infection (Figure 4.1.) Different routes of infection (sc versus ip) have not 
been shown to alter B6 susceptibility to WNV infection (85). Therefore, the 
difference in mortality rates and survival times may be due to the different viral 
strains of JEV used in the two model systems (95).  
We also found that prior immunity to WNV protected against a lethal JEV 
infection. Previous work in NHPs suggested that WNV immunity elicited only 
partial protection against JEV, as signs of encephalitis were seen in some 
animals (155). However, in our model, we did not see any signs of encephalitis or 
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weight loss in WNV-immune mice upon 2o JEV infection (data not shown). Two 
WNV-immune mice did succumb to 2o JEV infection, however sera samples were 
not collected to confirm seroconversion after primary WNV infection. Kunjin-
immune mice were also protected against a JEV challenge, suggesting that the 
pathogenicity of the WNV strain did not alter cross-protection against JEV. We 
have similarly seen that the pathogenicity of the JEV strain did not influence 
cross-protection against WNV. 
Despite the high frequency of memory CD8+ T cells in WNV-immune mice 
compared to JEV-immune mice, we saw very little proliferation of JEV S9-specific 
and WNV S9-specific CD8+ T cells after 2o JEV infection compared to 2o WNV 
infection of JEV-immune mice (Figure 4.4.A.). During primary JEV and WNV 
infection, the peak and magnitude of epitope-specific CD8+ T cells are similar at 
day 7 (Figure 3.5.). However at the memory time points, WNV-immune mice 
have a higher frequency of epitope-specific CD8+ T cells compared to JEV-
immune mice, suggesting that the contraction phase of effector CD8+ T cells into 
memory CD8+ T cells is more rapid in JEV-immune mice compared to WNV-
immune mice.  
Closely related viruses in the Togaviridae family have been shown to 
replicate differently in peripheral tissues, similar to what we and others have 
found for JEV and WNV (95, 278). These differences in tissue tropism during the 
primary infection lead to an altered inflammatory cytokine profile (278). In our 
model, we believe JEV and WNV induce different levels of inflammation due to 
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the lack of peripheral replication by JEV compared to WNV. Previous work has 
shown that inflammation during the early stages of infection can modulate the 
contraction phase of CD8+ T cells (222, 242, 279). This difference in 
inflammation may influence the contraction of epitope-specific CD8+ T cells in 
WNV-immune mice. Also, recent work has shown that antigens in the CNS can 
activate CD8+ T cells in periphery to facilitate CD8+ T cell entry into the CNS 
(280, 281). Therefore, it is possible that persistent WNV antigen in the CNS may 
continuously be presented to WNV S9-specific CD8+ T cells in the periphery, 
thereby altering contraction of CD8+ T cells (24, 121). 
We found differential expression of KLRG1 and PD-1 on JEV S9-specific 
and WNV S9-specific CD8+ T cells in the CNS and the spleen (Figure 4.7.C.). 
The higher level of PD-1 expression on CD8+ T cells in the CNS may reflect 
localized CD8+ T cell exhaustion in the CNS. However, the level of PD-1 
expression is lower than seen on CD8+ T cells after a chronic LCMV infection, 
suggesting that all of the CD8+ T cells in the CNS may not be fully exhausted 
(270). In addition, WNV viral persistence in mice has been shown to lead to a 
sustained presence of immune cells in the CNS months after the initial infection 
(121). T regulatory cells (Tregs) in the CNS during WNV infection may regulate 
the microenvironment of the CNS differently than in the spleen, leading to the 
faster conversion of activated CD8+ T cells into memory CD8+ T cells to prevent 
continued immunopathology (121, 126). This faster conversion into memory 
CD8+ T cells in the CNS compared to the spleen during WNV infection may 
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enhance the ability of WNV to persistent in the CNS and needs further 
investigation.  
When analyzing the CD8+ T cell repertoires between JEV and WNV, we 
saw very little difference in the TCR Vβ usage and functional avidities of both 
JEV S9-specific and WNV S9-specific CD8+ T cells. This was also true after rVV 
and Kunjin virus infection; however, rVV and Kunjin virus infection generated a 
memory CD8+ T cell population that proliferated after 2o JEV infection. In fact, 
only after WNV infection did memory WNV S9-specific CD8+ T cells proliferate 
poorly after JEV infection, suggesting a factor intrinsic to WNV-immune mice was 
causing this difference in proliferation.  
WNV antibodies that are poorly neutralizing can protect against a lethal 
WNV infection in mice through complement-mediated mechanisms (144). 
Therefore in JEV-immune mice, antibodies against WNV may be non-
neutralizing, but still able to protect in vivo, as we have seen previously 
(Trobaugh et al., in preparation). During sequential dengue virus infections, low 
levels of cross-reactive neutralizing antibodies between dengue serotypes are 
hypothesized to contribute to severe outcomes (199). In our model, we do not 
see increased immunopathology upon 2o infection but rather protection, which 
has also been seen in mouse models of sequential dengue virus infection (192). 
Pre-existing cross-reactive neutralizing antibodies and antibody dependent cell 
cytotoxicity through non-neutralizing antibodies are two humoral mechanisms 
that have been shown to correlate to reduced disease severity or reduced 
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viremia in humans experiencing secondary dengue-3 infection (282, 283). 
Recently, a WNV anti-NS1 antibody, which mediates protection against WNV 
through non-neutralizing mechanisms, was shown to protect against a lethal JEV 
infection (147, 210). Therefore, the role of non-neutralizing antibodies in cross-
protection also warrants further investigation.  
Even in the absence of cross-reactive neutralizing antibodies, memory 
CD8+ T cells in WNV-immune mice had limited proliferative capacity upon 2o rVV 
JEV infection. A pre-existing high frequency of memory cross-reactive CD8+ T 
cells did not result in a higher magnitude of CD8+ T cells after 2o heterologous 
infection. In contrast, low frequency of cross-reactive memory CD8+ T cells were 
able to proliferate to a greater extent and more rapidly than CD8+ T cells in mice 
with higher frequencies of these CD8+ T cells. However, even in the absence of 
proliferation, memory CD8+ T cells in WNV-immune mice were better able to 
restrict homologous and heterologous virus and lyse peptide-coated targets 
better than those from JEV-immune mice. This difference is not solely due to the 
presence of the WNV S9 sequence in the infecting virus as mice infected with 
Kunjin virus, which has the same WNV S9 amino acid sequence, were not able 
to restrict rVV replication as well as WNV-immune mice. Instead, there seemed 
to be a relationship between the frequency of memory CD8+ T cells and 
restriction of the rVVs. Both JEV-immune and Kunjin-immune mice had lower 
memory CD8+ T cell frequencies, and less viral restriction compared to WNV-
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immune mice, which had higher memory CD8+ T cell frequencies and greater 
viral restriction.  
Adoptive transfer of JEV-immune CD4+ and CD8+ T cells into naïve mice 
partially protected against a high dose WNV infection. Mosquitoes inoculate on 
average 104 pfu of WNV into chick toes during feeding, and longer feeding times 
can result in a higher inoculum in mice (284). This suggests that our challenge 
model may be too stringent, and if we gave a lower dose, as would happen after 
mosquito feeding, we might see better cross-protection. Cross-reactive CD8+ T 
cells are not able to restrict heterologous viruses as efficiently as homologous 
viruses due to a lower functional avidity for the cross-reactive epitope, suggesting 
a lower inoculum dose may be beneficial for the ability of cross-reactive CD8+ T 
cells to restrict virus (185). The dose of the inoculum may be another important 
factor that needs to be taken into consideration when studying cross-protection 
between flaviviruses.   
 The number of memory CD8+ T cells in JEV- and WNV-immune mice 
appears to be an important factor in protection against 2o heterologous infection. 
A higher frequency of memory CD8+ T cells has been shown to correlate to 
better protection upon 2o infection in both viral and bacteria models (248, 253, 
285). Therefore, understanding the factors leading to enhanced memory CD8+ T 
cell frequencies in WNV-immune mice versus JEV-immune mice will help in 
understanding cross-protection between JEV and WNV and may yield important 
information relative to the incorporation of T cell epitopes into vaccines.  
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S. Proposed Model 
 In JEV-immune mice (Figure 4.19.A.), the lack of peripheral replication of 
virus during the primary immune response leads to lower levels of inflammation 
promoting MPEC CD8+ T cell generation. Rapid contraction after the primary 
infection leads to low levels of memory cross-reactive CD4+ and CD8+ T cells. 
Due to low levels of cross-reactive non-neutralizing antibodies and low levels of 
memory cross-reactive CD8+ T cells, WNV infection of JEV-immune mice leads 
to rapid expansion of memory CD4+ and CD8+ T cells. Proliferation of memory 
CD4+ and CD8+ T cells along with cross-reactive non-neutralizing antibodies 
likely contribute to the cross-protection seen in JEV-immune mice after WNV-
infection. Cross-reactive CD4+ T cells may aid in the development and response 
of cross-reactive CD8+ T cells, in sustaining cross-reactive antibody responses, 
and/or may have direct anti-viral activity (cytolysis and effector functions). 
 In WNV-immune mice (Figure 4.19.B.) high levels of virus replication 
during the primary infection lead to higher inflammatory conditions promoting 
SLEC CD8+ T cell generation. Persistent antigen and/or the high inflammatory 
environment delays the contraction of epitope-specific CD8+ T cells leading to an 
increased frequency of memory CD8+ T cells. This higher frequency of memory 
CD8+ T cells along with preexisting neutralizing and non-neutralizing antibodies 
to JEV reduces JEV replication early during stages of the 2o infection leading to a 
reduced expansion of memory CD8+ T cells. Similar to JEV-immune mice,  
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Figure 4.19. Proposed model for 2o infections of JEV-immune (A) and WNV-
immune (B) mice. (A) Low levels of peripheral replication during primary JEV 
infection leads to low levels of inflammation promoting MPEC CD8+ T cell 
generation. Rapid contraction after the primary infection leads to low levels of 
memory cross-reactive CD4+ and CD8+ T cells. Due to low levels of cross-
reactive non-neutralizing antibodies and low levels of memory cross-reactive 
CD8+ T cells, WNV infection of JEV-immune mice leads to rapid expansion of 
memory CD4+ and CD8+ T cells. Proliferation of memory CD4+ and CD8+ T cells 
along with cross-reactive non-neutralizing antibodies likely contributes to the 
cross-protection seen in JEV-immune mice after WNV-infection. Cross-reactive 
CD4+ T cells may aid in the development and response of cross-reactive CD8+ T 
cells, sustaining the cross-reactive antibody response, and/or have direct anti-
viral activity. (B) High levels of WNV replication during the primary infection leads 
to high inflammatory conditions promoting SLEC CD8+ T cell generation. 
Persistent antigen and/or the high inflammatory environment delays the 
contraction of epitope-specific CD8+ T cells leading to an increased frequency of 
memory CD8+ T cells. This higher frequency of memory CD8+ T cells along with 
preexisting neutralizing and non-neutralizing antibodies to JEV reduces JEV 
replication early during early stages of 2o infection leading to a reduced 
expansion of memory CD8+ T cells. Similar to JEV-immune mice, cross-reactive 
CD4+ T cells may aid in the development and response of cross-reactive CD8+ T 
cells, sustaining the cross-reactive antibody response, and/or have direct anti-
viral activity.  
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cross-reactive CD4+ T cells may aid in the development and response of cross-
reactive CD8+ T cells, sustaining the cross-reactive antibody response, and/or 
have direct anti-viral activity.  
 
T. Chapter Summary 
We have found that prior WNV immunity protects against a lethal JEV 
infection. However, WNV memory cross-reactive CD8+ T cell proliferate very little 
upon 2o JEV infection compared to memory CD8+ T cells in JEV-immune mice 
upon 2o WNV infection. High levels of memory CD8+ T cells and JEV neutralizing 
and non-neutralizing antibodies in WNV-immune mice may be contributing to this 
difference in proliferation.  
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Chapter V 
FINAL SUMMARY AND IMPLICATIONS 
 
 Flaviviruses co-circulate in many areas of the world, and this raises the 
risk of an individual experiencing sequential infections between flaviviruses (1). 
Sequential infections between flaviviruses can lead to cross-protection, or in the 
case of dengue virus, lead to more severe outcomes (199). Our interest was to 
study the mechanisms underlying cross-protection, but such studies are 
challenging, if not impossible, to perform in humans. Due to the lack of an 
adequate mouse model to study sequential infections between dengue viruses, 
we used JEV and WNV to study sequential infections between flaviviruses (286). 
Previous work in animal models demonstrated that while cross-protection 
between JEV and WNV existed, that it may not be entirely reciprocal (153, 155). 
These studies suggested that cross-reactive antibody responses were the 
contributing factor to this cross-protection. However, in mice immunized with 
recombinant E protein, only partial cross-protection is seen between JEV and 
WNV, suggesting that cross-reactive T cells that target other viral proteins may 
play a role in cross-protection (74, 153, 158, 159). Our group previously found 
that JEV immune CD4+ and CD8+ T cells were required for complete cross-
protection between JEV and WNV (Trobaugh et al., in preparation). Therefore, 
the goal of this thesis was to further explore and understand the role of cross-
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reactive T cell responses between JEV and WNV during primary and secondary 
infections. 
  
A. Possible impact of innate immune responses on primary immune 
responses.  
We identified JEV-WNV cross-reactive CD4+ and CD8+ T cell epitopes 
during the primary immune response to each virus, but the cross-reactive CD8+ T 
cell responses differed both quantitatively and qualitatively. We hypothesized that 
these differences in the primary immune responses may be due to lower levels of 
peripheral virus replication leading to lower inflammatory responses during a 
primary JEV infection compared to a primary WNV infection. 
JEV and WNV are thought to stimulate similar pattern recognition 
receptors leading to an innate immune response (98, 101, 287). However, a 
major difference between JEV and WNV is the ability to establish viremia and 
replicate in peripheral lymphoid tissues (Figure 3.8.A.-B.) (88, 95). Some reports 
suggest that JEV infection of dendritic cells promotes an anti-inflammatory 
environment compared to WNV, which generates a pro-inflammatory 
environment (86, 100, 104, 105, 288-290). In fact, the ability to replicate in 
myeloid cells actually increased the susceptibility of mice to JEV infection (96). 
Therefore, the differing ability of JEV and WNV to initially infect certain cell types 
or subsets may influence peripheral replication. Although our group and others 
have not been able to detect JEV in the spleen or serum early during infection, 
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virus entry into the CNS does occur at later time points, suggesting there may be 
other sites of viral replication that have yet to be identified as seen after WNV 
infection (84, 95).  
The conversion of effector CD8+ T cells to memory CD8+ T cells in JEV-
infected mice resembles what is seen after DC immunization, in which low levels 
of inflammation results in a CD8+ T cell population that can be rapidly 
restimulated (291). IL-12, type I IFN, and IFN−γ are inflammatory cytokines that 
promote effector CD8+ T cell differentiation into SLEC, and are absent during DC 
immunization (225, 229, 291). Induction of IL-12 and IFN−γ by CpG, a potent 
inducer of inflammation, during DC immunization induces high frequencies of 
SLECs and subsequent slower conversion of effector CD8+ T cells to memory 
CD8+ T cells (225). Therefore, JEV infection may induce lower levels of IL-12 and 
type I IFN compared to WNV infection, thereby altering effector CD8+ T cell 
generation. In comparison, WNV infection may induce high levels of IL-12 and 
type I IFN early during infection leading to the generation of SLECs thereby 
prolonging the time until memory CD8+ T cell formation.  
Inflammation during the primary infection may also be influencing the 
ability to recover from JEV and WNV infection. Neuroinvasion seems to correlate 
highly with mortality after JEV infection, since very few mice showing clinical 
symptoms survive. (95). However, mice that demonstrate clinical signs, including 
signs of neuroinvasion, can recover from WNV illness (88). A similar clinical 
pattern has been described following infection with Venezuelan equine 
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encephalitis virus (VEEV) and eastern equine encephalitis virus (EEEV) in mice. 
It has been hypothesized that peripheral replication and early inflammation 
(possibly due to production of type I IFN or other mediators) results in early 
clinical signs during VEEV infection, which helps to prime the CNS to mount an 
antiviral immune response. On the other hand, EEEV infection induces low levels 
of peripheral replication and type I IFN resulting in later onset of clinical 
symptoms, just prior to death (278). We postulate that the ability of mice to 
recover from WNV infection may be due to the higher levels of inflammation (IL-
12, type I IFN, IFN−γ or other mediators) priming the CNS to limit WNV 
replication and neuronal cell death, which does not occur in JEV-infected mice.  
We found that CD8+ T cells from WNV-infected mice secreted higher 
levels of TNF-α compared to CD8+ T cells from JEV-infected mice (Table 3.3.). 
Non-lymphocyte populations may also produce TNF-α, which could influence the 
levels of systemic TNF-α during JEV and WNV infection (101, 260, 289, 292, 
293). TNF-α has been hypothesized to alter blood-brain barrier permeability 
during WNV infection leading to either a decreased (low levels of TNF-α) or an 
increased (high levels of TNF-α) susceptibility to WNV (106, 260). However, the 
complete absence of TNF-α lead to an increase in mortality, believed to be due 
to impaired trafficking of T cells to the CNS (260). Higher levels of TNF-α 
following WNV infection may alter blood-brain barrier permeability sufficiently to 
permit the trafficking of lymphocytes into the CNS. On the other hand, lower 
systemic TNF-α levels following JEV infection may prevent this alteration and 
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thereby reduce T cell entry into the CNS. The limited T cell entry into the CNS 
following JEV infection may contribute to the impaired ability to recover from 
neuroinvasive JEV infection compared to WNV (88, 95). Understanding the 
differences and similarities in host innate immune responses and the subsequent 
inflammatory response during JEV and WNV infections will be important in 
deciphering how the primary immune response alters the secondary immune 
response between JEV and WNV.    
 
B. Immune responses during sequential JEV and WNV infection. 
In our B6 mouse model, prior WNV immunity protects against a lethal JEV 
infection, similar to prior JEV immunity upon a 2o WNV infection. However, only 
in JEV-immune mice did memory cross-reactive CD8+ T cells expand upon a 2o 
infection. The lack of proliferation in WNV immune mice upon 2o JEV infection 
seems to be due to both cross-reactive neutralizing and non-neutralizing 
antibodies against JEV and a high frequency of memory cross-reactive CD8+ T 
cells.  
 
i. Cross-reactive antibody responses 
Cross-reactive neutralizing antibodies were only detected in WNV-immune 
mice, suggesting the sequence of infection can influence the generation of cross-
reactive antibodies. Repeated vaccinations and infection of immunodeficient 
mice are two conditions in which flavivirus cross-reactive neutralizing antibodies 
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have previously been detected in mice (89, 159, 192, 294). This suggests that 
increased antigen stimulation and viral replication may influence cross-reactive 
neutralizing antibody generation. Therefore, the ability to detect cross-reactive 
neutralizing antibodies in WNV-immune mice may be due to the increased 
peripheral replication of WNV during the primary infection. It is plausible that all 
flavivirus infections develop low levels of cross-reactive neutralizing antibodies, 
and a second infection increases the chances of detecting these antibodies 
(209). However, measurement of cross-reactive antibodies in vitro depends on 
many factors, and the ability of WNV-immune sera to protect against JEV in vivo 
requires further investigation (295). 
In this thesis, we did not address the presence of non-neutralizing cross-
reactive antibodies between JEV and WNV. We have previously shown that 
adoptive transfer of JEV-immune serum, in which anti-WNV neutralizing 
antibodies were not detected, was able to partially protect against mortality from 
a WNV challenge (Trobaugh et al., in preparation). Therefore, the presence of 
non-neutralizing antibodies in JEV- and WNV-immune mice may also be 
impacting the outcomes upon 2o infection. In fact, cross-reactive IgG antibodies 
to WNV can be detected after immunization with recombinant JEV E protein even 
though there are low or non-existent neutralizing antibodies (159). This suggests 
that the type of cross-reactive antibodies in JEV- and WNV-immune may be 
influencing the expansion of memory CD8+ T cells and protection upon a 2o 
heterologous infection.  
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ii. Cross-reactive T cell responses 
During primary JEV and WNV infections, CD8+ T cells are required for the 
clearance of CD8+ T cells in the CNS (95, 108, 109). However, the role of CD8+ T 
cells during 2o heterologous infection was not known. JEV-immune CD4+ and 
CD8+ T cells are required for cross-protection, yet they are not sufficient to fully 
protect against a high dose WNV infection (Figure 4.3.A. and Trobaugh et al., in 
preparation). Recently, a similar pattern was seen in sequential dengue virus 
infections (192). On their own, the ability of cross-reactive CD4+ and CD8+ T cells 
to restrict heterologous virus may be limited and may depend on both the sites of 
viral replication and the particular infecting virus. In other mouse models of 
heterologous immunity, virus levels were reduced only 1-2 logs upon 2o infection 
(164, 171, 172, 185, 294). The low frequency and reduced functional avidity of 
cross-reactive CD8+ T cells may contribute to this low level of viral clearance 
(166, 185). Even though there is only low-level viral restriction at an early time 
point during 2o heterologous infection, these reduced viral levels may lead to 
subclinical infections. One important consideration to note is that T cell entry into 
infected tissue to clear these virally infected cells may not always be beneficial 
and can lead to immunopathology (164, 171-173). 
In dengue virus infections, CD8+ T cell responses to cross-reactive 
epitopes depend on both the sequence of infection and the particular cross-
reactive epitope (182, 183, 196, 296, 297). In our model, we found that the 
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particular viral infections (JEV versus WNV) rather than the cross-reactive 
epitope (JEV S9 versus WNV S9) had greater impact on CD8+ T cell effector 
functions. JEV S9-specific and WNV S9-specific CD8+ T cells had similar 
functional avidities for the cross-reactive epitope, which may explain why we did 
not detect the different cytokine profiles that are seen in CD8+ T cell clones from 
individual dengue-infected patients after stimulation with cross-reactive peptides 
(296). Differences in the functional avidity of cross-reactive CD8+ T cells can lead 
to alerted cytokine profiles upon cross-reactive peptide stimulation (182, 183, 
196, 296, 297). This difference in cytokine profiles is considered to be a 
contributing factor to severe DHF upon 2o dengue infection (259). 
It is likely that the relationship between viral replication, the frequency of 
cross-reactive CD4+ and CD8+ T cells, and the presence of neutralizing and non-
neutralizing antibodies are all determinants of outcome upon 2o heterologous 
infection. Low levels of memory CD4+ and CD8+ T cells in isolation may not be 
sufficient to overcome a high virus inoculum. However, neutralizing and/or non-
neutralizing antibodies may restrict viral levels to a point that allows for cross-
reactive CD4+ and CD8+ T cells to effectively clear the virus. In absence of other 
components of the immune system, high frequencies of memory CD8+ T cells 
were able to restrict both homologous and heterologous viruses to a greater 
extent than lower frequencies of memory CD8+ T cells even in the face of rapid 
expansion and proliferation of those cells. It is possible that low levels of cross-
reactive memory CD8+ T cells may need the help of cross-reactive CD4+ T cells 
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to reduce high viral loads, and may account for why adoptive transfer of both 
JEV-immune CD4+ and CD8+ T cells were required to partially protect mice 
against a high dose WNV challenge. It will be important to determine the 
threshold of memory CD8+ T cells required for protection against both 
homologous and heterologous viral infections, and this may assist in the design 
of viral vaccines (285).  
 
iii. Cross-protection between JEV and WNV 
The goal of our model system was to investigate the cross-protection that 
occurs between JEV and WNV.  In mouse models of sequential dengue virus 
infection, both cross-protection and enhancement of disease have been 
observed depending on the experimental conditions (192, 202, 298, 299). In our 
mouse model, we did not see any severe outcomes upon 2o heterologous 
infections (unpublished data). However, as we did not design our experiments to 
address immunopathology, we cannot rule out that a severe outcome may result 
under certain conditions.  
In humans, cross-protection between JEV/WNV and other flaviviruses is 
likely to occur. JEV and WNV by and large are not endemic to the same 
geographic regions, with the exception of some regions of India, Pakistan, and 
Papa New Guinea (1, 16). Therefore, it is difficult to predict or assess whether 
the outcome of sequential infection in humans with these viruses would lead to 
severe disease or cross-protection.  
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The presence of susceptible mosquito vectors, susceptible hosts, and the 
climate are important factors that could be influencing the spread of JEV and 
WNV into non-endemic regions (8). Culex pipiens, a predominant mosquito 
vector for WNV, and Culex tritaeniorhynchus, a predominant mosquito vector for 
JEV, can become productively infected with heterologous JEV and WNV, 
respectively (300-302). Even though these mosquito vectors are able to transmit 
both JEV and WNV, introduction of JEV into WNV endemic regions, and WNV 
into JEV endemic regions, has been limited (16). 
The level and length of viremia in amplifying hosts may be an important 
factor in the spread of JEV and WNV. Migratory birds with high levels of viremia 
may spread JEV and WNV into non-endemic regions (35, 303). However, WNV-
immune red-winged blackbirds were completely protected from JEV viremia in an 
experimental setting, suggesting that once birds become immune, they are not 
susceptible to a 2o infection (156). JEV, unlike WNV, also uses pigs as amplifying 
hosts since JEV can establish high levels of viremia for up to 4 days (304). 
Therefore, close interactions of humans and pigs can lead to an increase in the 
number of cases of JEV in humans, and this interaction may be important for the 
spread of JEV (16). The likelihood of cross-protection in birds suggests that in 
order for one virus (e.g. JEV) to establish itself into a WNV-endemic region, an 
adequately sized naïve offspring population would be required for amplification of 
the virus and transmission into mosquitoes. 
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Although WNV has spread into dengue endemic areas of Central and 
South America, very few human cases have been reported (8, 203). It is thought 
that prior dengue or YFV immunity may be contributing to this “protection” (203). 
In contrast, prior JEV immunity has been demonstrated to lead to either an 
increased or decreased association with severe DHF depending on the cohort 
studied (305, 306). Therefore, not all sequential infections between flaviviruses 
are created equal, and multiple other factors (e.g. climate, vector 
density/infectivity, and time between sequential infection) contribute to whether 
there will be cross-protection or a severe outcome.  
 
C. The potential development of a cross-reactive flavivirus vaccine. 
 The ideal vaccine candidate would induce life long protective immunity 
after only one immunization, similar to the live attenuated YF17D vaccine, but 
could also induce protective immunity to multiple viruses (307). Based on data 
presented in this thesis, a cross-reactive vaccine between JEV and WNV may be 
feasible. Neutralizing antibody titers are the current standard in determining 
whether a JEV vaccine is a suitable candidate, and presumably, similar 
standards will be used to approve a WNV vaccine (308). However, although we 
detected cross-reactive neutralizing antibodies only after a WNV infection and 
not after a primary JEV infection, we still detected bidirectional cross-protection 
(Figure 4.5.). These findings suggest that the measurement of neutralizing 
antibodies may not be the proper immune correlate for cross-protection and that 
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investigation into assays that measure cross-reactive non-neutralizing antibodies 
or T cell responses may be warranted. In fact, adoptive transfer of JEV SA14-14-
2-immune serum partially protected mice against lethal WNV infection in the 
absence of cross-reactive neutralizing antibodies, suggesting that cross-reactive 
non-neutralizing antibodies are an important correlate of protection that needs to 
be considered (Trobaugh et al., in preparation). 
The context of the viral vector and the number of immunizations can also 
influence cross-protection between JEV and WNV. Ch-WNV, but not the 
canarypox-WNV vaccine, induced protection from JEV viremia in hamsters (154). 
Similarly, repeated vaccinations with recombinant JEV or WNV E protein or 
inactivated JEV vaccines generated cross-reactive neutralizing antibodies that 
induced partial protection (73, 74, 158, 159). These results suggest that low 
levels of cross-reactive neutralizing antibodies may be present after initial 
immunization, and repeated vaccinations are required to increase their 
frequency. A recent report by Purtha et al. sheds light on the possible 
mechanism for these observations. They found that, in the absence of WNV 
neutralizing antibodies secreted by long-lived plasma cells, immunization with 
DIII of the JEV E protein generated JEV-specific memory B cells that were able 
to secrete WNV neutralizing antibodies after heterologous secondary WNV 
infection (309). This result suggests that JEV DIII immunization induced a 
population of cross-reactive memory B cells that were able to expand after 
heterologous infection. Therefore, repeated vaccinations with the same vaccine 
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may increase the frequency of such cross-reactive memory B cells thereby 
increasing the levels of cross-reactive neutralizing antibodies that may contribute 
to cross-protection.  
Complete cross-protection between JEV and WNV requires both cross-
reactive antibodies and T cells (Trobaugh et al., in preparation). This suggests 
that a live, attenuated vaccine, due to the ability to induce both T cell and 
antibody responses, may be the ideal vector to generate a cross-reactive 
vaccine.  Our data suggest that the inclusion of cross-reactive CD4+ and CD8+ T 
cell epitopes into flavivirus vaccines may help in cross-protection. However, the 
threshold of memory CD8+ T cells required for cross-protection is as yet still 
undefined. The value of such cross-reactive memory CD8+ T cells as a correlate 
of cross-protection for vaccine development warrants further investigation.  
 
D. Final Conclusions 
 We found that cross-protection between JEV and WNV occurs in both 
directions; however the mechanisms of this cross-protection may depend upon 
the sequence of infection. A high frequency of memory CD8+ T cells and cross-
reactive antibodies in WNV-immune hosts may limit the expansion of memory 
cross-reactive CD8+ T cells due to low levels of heterologous virus. The rapid 
proliferation of low frequency memory cross-reactive CD8+ T cells in JEV-
immune mice upon 2o WNV infection may be needed to combat the higher viral 
loads. From our studies, it appears that both the humoral and adaptive immune 
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responses are required for complete protection from virus dissemination and 
mortality.  
This research suggests that if WNV spreads to JEV endemic areas, JEV-
immune individuals may be protected from a WNV infection. Similarly, if JEV 
spreads to the US or if a WNV-immune individual travels to a region where JEV 
is endemic, WNV-immune individuals may be protected against a JEV infection. 
Cross-protection is challenging to study in human populations, as silent 
sequential infections remain largely undetected. Mouse models such as we have 
developed are vital for addressing this issue, both from the standpoint of the 
emergence of viral disease into new geographic regions, as well as vaccine 
development.  
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